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Abstract  
Tetrazine-Triggered Bioorthogonal Decaging Reactions for Prodrug Activation 
Sarah H. Davies 
Bioorthogonal decaging reactions have emerged as a promising strategy for the spatially and 
temporally controlled activation of proteins and drugs. The inverse electron-demand Diels-Alder 
(IEDDA) reaction between tetrazines and strained alkenes exhibits high reaction rates and selectivity 
and has been widely applied for the decaging of amine prodrugs. Although amines are common in 
small molecule drugs, decaging methods for other functional groups are required in order to develop 
a broadly applicable prodrug activation strategy that can be applied to a wider range of drugs and 
diseases. This thesis describes the application of the tetrazine-triggered IEDDA reaction to cleave 
protecting groups from carboxylic acid- and alcohol-containing molecules.  
The first project relates to the development of both vinyl and trans-cyclooctene (TCO) protecting 
groups to mask a carboxylic acid-containing anti-inflammatory drug. In each case, the prodrug 
stability, reaction profile and kinetics of decaging were studied with a range of tetrazines. Whilst vinyl 
esters suffered from poor stability and release rates, rapid drug release (< 2 minutes) was achieved 
from a stable TCO prodrug. Importantly, decaging of a non-toxic TCO prodrug in live macrophages was 
demonstrated, resulting in the reinstation of the anti-inflammatory activity.  
The second project describes methods to release alcohol-containing molecules via the TCO-tetrazine 
IEDDA reaction. Work towards three linkers (carbonate, ether and carbamate benzyl ether) is 
described. The carbamate benzyl ether linker was shown to be both synthetically accessible and 
stable, which was not the case for the other linkers. Therefore, the tetrazine-triggered decaging of a 
TCO-carbamate benzyl ether fluorophore was studied in detail. In addition, this reaction was shown 
to be compatible with living organisms through decaging of a prodrug in the presence of live cells. 
Overall, the work presented here offers new methods for masking carboxylic acid and alcohol 
functionality that can be rapidly reinstated through tetrazine-triggered decaging.  
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Introduction 
This chapter contains work from the following publication:  
Bioorthogonal Decaging Reactions for Targeted Drug Activation. Sarah Davies†, Benjamin. J. Stenton† 
and Gonçalo J. L. Bernardes. Chimia, 2018, 72, 771–776. 
† These authors contributed equally. 
 
1.1 Bioorthogonal ligation reactions 
1.1.1 Bioorthogonal chemistry 
Bioorthogonal reactions are chemical reactions that can be carried out in living systems, without 
affecting any native biological processes.[1] Therefore, an essential requirement is that the reaction is 
highly selective and no cross reactivity is observed with biomolecules. In addition, the reaction must 
have a fast rate under physiological conditions (aqueous media, 37 °C, near physiological pH) and at 
the low reactant concentrations (typically ≤ µM) that are required for use in biological systems.[2] The 
reagents and products should be both thermally and metabolically stable to enable accurate study of 
the biomolecule. Furthermore, the reagents and by-products should be non-toxic to cells. However, 
in practice, most reported bioorthogonal reactions do not fulfil all these criteria (often they suffer 
from slow reaction rates, stability or toxicity issues) and more work is required in order for their full 
potential to be realised.  
Bioorthogonal chemistry arose from the need for suitable methods to label and study biomolecules in 
their native biological environment. Previous methods for labelling proteins relied on the use of 
monoclonal antibodies and genetically encoded fluorescent proteins. However, the large size of these 
biological moieties can drastically alter the properties of the molecule being studied. In addition, they 
cannot always be used to study intracellular processes or non-protein biomolecules such as lipids, 
glycans and metabolites.[1,2] The development of bioorthogonal chemistry offers a widely applicable 
strategy for the labelling and studying of biomolecules. It involves incorporating a small, abiotic, 
bioorthogonal handle into a molecule of interest, which can then react with a probe containing the 
2 
Chapter 1: Introduction   
complementary bioorthogonal functional group (Scheme 1).[1,3] Since being first described in 2003 by 
Professor Carolyn Bertozzi,[4] several biorthogonal ligation reactions (in which a bond is formed 
between two reactants) have been reported.[3,5–12]  
 
Scheme 1. Schematic representation of the bioorthogonal labelling strategy. A chemical reporter (dark blue 
circle) is incorporated into the target biomolecule (red rectangle). This is labelled with a probe (green star) 
containing the complementary bioorthogonal handle (light blue circle).  
Bioorthogonal reactions may be initiated using either a photo- or chemical- (metal or small organic 
molecule) trigger. This thesis will primarily focus on the use of small molecule, chemical-triggered 
bioorthogonal reactions that have been applied in mammalian cells or higher organisms. 
 
 
1.1.2 Small molecule-triggered ligation reactions 
The term “bioorthogonal” was first used to describe a Staudinger ligation reaction between a 
glycoprotein containing a metabolically-incorporated azide handle and fluorescent phosphine 
probes.[4,13] The classical Staudinger reduction results in an aza-ylide, which is susceptible to 
hydrolysis.[14,15] However, incorporating an electrophilic methyl ester into the phosphine probe 
prevents hydrolysis of the aza-ylide and instead, intramolecular cyclisation results in the formation a 
stable carbamate bond (Scheme 2).  
 
Scheme 2. Staudinger ligation reaction.  
Disadvantages of this reaction include slow kinetics (k2 = 2.5 x 103 M1 s1) and the oxidation of 
phosphines by air and metabolic enzymes. Unfortunately, attempts to enhance the rate-determining 
step (RDS, nucleophilic attack of the phosphine onto the azide)[16] through using electron-rich 
phosphines, resulted in increased deactivation of the phosphine through oxidation.[5] However, 
despite these drawbacks, the Staudinger ligation was successfully used to label cell surface 
3 
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glycoproteins in living mice.[17] Mice were injected with azide-containing sugars, which were 
metabolically incorporated onto the surface of splenocyte cells. This was followed by injection of a 
phosphine probe and ex vivo analysis which confirmed that the Staudinger ligation had occurred in 
the mice. On the other hand, a pretargeting strategy utilising the Staudinger ligation in tumour-bearing 
mice was unsuccessful.[18] A radiolabelled phosphine probe was administered after accumulation of 
an antibody-azide conjugate at the tumour. No Staudinger reaction occurred in vivo due to the 
formation of a side product, which could not be identified. 
Further developments led to the traceless Staudinger ligation in which the acyl group is connected to 
the phosphine via a cleavable linker.[19,20] Attack of the aza-ylide nitrogen results in linker cleavage and 
removal of the phosphine oxide from the ligation product. This traceless Staudinger reaction has been 
used to install diazirines into a molecule of interest (through incorporation of an azide and reaction 
with a phosphine-diazirine probe),[21] as well as for peptide bond synthesis.[22]  
Azides are appealing handles for bioorthogonal chemistry since they are small, abiotic, non-toxic and 
inert to biological systems (they can be reduced by thiols, however, this does not normally occur under 
physiological conditions).[1] In addition to their electrophilic nature, they are 1,3-dipoles and can 
undergo [3+2] cycloadditions with alkynes to generate stable triazoles.[23] However, activation of the 
alkyne is required in order for the reaction to proceed at physiological temperature. Several activation 
methods exist, including the use of a Cu(I) catalyst, which will be discussed in more detail in section 
1.1.3. Alternatively, a strain-promoted azide-alkyne cycloaddition (SPAAC) utilises ring strain to 
activate the alkyne (Scheme 3).[24]  
 
Scheme 3. Strain-promoted azide-alkyne cycloaddition (SPAAC).  
Although the SPAAC (k2 = 1.2 x 103 M1 s1) is slower than the Staudinger ligation, the rate can be 
enhanced by modifying the cyclooctyne with electron-withdrawing groups (EWGs). Difluorinated 
cyclooctyne (DIFO) exhibits a second order rate constant one order of magnitude higher than 
cyclooctyne (Figure 1).[25] Although DIFO is synthetically challenging,[25,26] it has been utilised for 
imaging glycans in zebrafish embryos.[27] In an alternative strategy, the reaction rate was accelerated 
by increasing ring strain (Figure 1).[28] This was achieved by either fusing additional rings to cyclo-
octyne (dibenzocyclooctyne (DIBO),[29] dibenzo-aza-cyclooctyne (DIBAC),[30] biarylazacyclooctynone 
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(BARAC),[31] bicyclo[6.1.0]nonyne (BCN)[32]) or by decreasing ring size (3,3,6,6-tetramethylthiacyclo-
heptyne, (TMTH, 1)).[33]  
 
Figure 1. Selection of cyclooctyne derivatives and their second order rate constants for SPAAC. 
Cycloaddition reactions constitute a large section of the bioorthogonal repertoire due to their high 
selectivity and their orthogonality to biological systems. The cycloaddition of cyclooctyne derivatives 
with nitrones,[34,35] nitrile oxides[36] and diazo groups[37] have also been reported. However, 
cyclooctyne is not truly bioorthogonal as it can react with biological nucleophiles including thiols.[38,39]  
Azides also react with oxonorbornadiene to give a stable triazole product (Scheme 4).[40] The reaction 
proceeds via a regioselective [3+2] cycloaddition, followed by a retro Diels-Alder reaction and 
elimination of furan (2). Oxonorbornadienes are synthetically accessible, but the reaction suffers from 
slow rates (k2 = 104 M1 s1). 
 
Scheme 4. [3+2] cycloaddition of an azide with oxonorbornadiene.  
The inverse electron-demand Diels-Alder (IEDDA) reaction (Scheme 5) between a strained alkene, 
trans-cyclooctene (TCO), and a tetrazine is one of the fastest reported biorthogonal reactions to 
date.[41] As a result, the reaction has been extensively studied and several dienes and dienophiles have 
been explored. This reaction will be discussed in detail in section 1.2. 
 
Scheme 5. IEDDA reaction between a tetrazine and TCO. Discussed in more detail in section 1.2. 
Tetrazines also undergo [4+1] cycloadditions with tertiary isonitriles (k2 = 0.58 M1 s1), which, after 
retro Diels-Alder reaction, result in stable imine complexes (Scheme 6).[42] Asymmetric tetrazines 
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bearing an EWG and a bulky t-Bu substituent were shown to react preferentially with isonitriles over 
strained alkenes/alkynes, with accelerated reaction rates (k2 = 57 M1 s1).[43] 
 
Scheme 6. [4+1] cycloaddition of tetrazines with tertiary isonitriles. 
Aldehydes and ketones were some of the first bioorthogonal handles to be explored since they can be 
easily incorporated into biomolecules. They are small, mild electrophiles and undergo condensation 
reactions with hydrazines and hydroxylamines to generate Schiff bases that are stabilised by the alpha 
effect (Scheme 7).[44] The reaction of an aldehyde with hydrazine was applied to assemble a drug from 
inactive precursors in live cells several years before the term bioorthogonal had been introduced.[45] 
Typically the second order rate constant is 104 M1 s1 and aniline catalysts have been shown to 
increase the rate up to 170 M1 s1.[46,47] Although reaction with lysine is possible, the equilibrium in 
water favours the carbonyl, meaning negligible formation of the Schiff base occurs.[48] These reactions 
are more suited for extracellular applications where the optimum pH for the reaction (pH 56) can be 
achieved. In addition, the reactive handles are not abiotic and intracellular aldehyde and ketone 
metabolites (e.g. free sugars, pyruvate) may interfere with the reaction.  
 
Scheme 7. Condensation of aldehydes with hydrazines and hydroxylamines under acidic pH. 
An alternative aldehyde condensation based on a Pictet-Spengler reaction has also been 
reported.[49,50] This reaction results in CC bond formation through condensation of an aldehyde with 
a tryptamine, followed by intramolecular cyclisation (Scheme 8).  
 
Scheme 8. Aldehyde condensation based on a Pictet-Spengler reaction.  
6 
Chapter 1: Introduction   
In another example of a condensation reaction, 2-cyanobenzothiazole (CBT, 3) reacts rapidly with 1,2-
aminothiols (k2 = 10 M1 s1, Scheme 9).[51] However, since 1,2-aminothiols form adducts with cellular 
metabolites, the reaction is more suitable for in vitro applications. [52] 
 
Scheme 9. Condensation of CBT (3) with 1,2-aminothiols. 
  
 
1.1.3 Metal-triggered ligation reactions 
Examples of metal-mediated bioorthogonal reactions[53] include palladium-catalysed cross-
couplings,[54] ruthenium-catalysed olefin metatheses[55] and the copper-catalysed azide-alkyne 
cycloaddition (CuAAC),[56,57] commonly referred to as the click reaction (Scheme 10).  
 
Scheme 10. Copper-catalysed azide-alkyne cycloaddition (CuAAC). 
The [3+2] cycloadditon between an azide and terminal alkyne, as mentioned previously, was first 
carried out under physiological conditions through activation of a terminal alkyne with a Cu (I) 
catalyst.[56,57] This CuAAC or click reaction, occurred with high regioselectivity and reaction rate (25 
times faster than the Staudinger ligation and 6 orders of magnitude higher than in the absence of a 
Cu catalyst), making it particularly useful for studying biomolecules that are present in low 
concentrations.[1,56] However, the toxicity of the metal catalyst limits the CuAAC to labelling 
experiments, as harmful effects are often observed even with low concentrations of Cu(I) and short 
exposure times.[5,58] Ligands that stabilise Cu (I) and prevent toxicity through the formation of reactive 
oxygen species have been developed, allowing its use to be extended to glycan labelling in zebra fish 
embryos.[59] Other methods of overcoming the toxicity of the catalyst include the development of 
metal-organic nanoparticles (NPs)[60] and heterogeneous Cu NPs.[61] Non-toxic Cu NPs were used to 
generate a triazole-containing anti-cancer drug in cells from two inactive precursors.[61] 
Despite the toxicity of Cu, the CuAAC is still widely used for labelling and analysis due to its fast 
reaction rate, the small size of both handles and the commercial availability of a wide range of alkynes 
and azides.[8] It is commonly utilised in affinity based protein profiling, in which an azide-modified 
covalent inhibitor is added to cells and covalently binds to the target enzyme.[62,63] This is followed by 
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labelling with an alkyne affinity probe (fluorophore/biotin) and analysis.[64–66] Phosphine affinity 
probes have also been used to label an alkyne via the Staudinger ligation.[67] Photoaffinity labelling can 
be used to extend this approach to non-covalent enzyme inhibitors (Scheme 11).[66] A probe containing 
both an alkyne and a photoreactive group, such as a diazirine, is added to cells and allowed to bind to 
the target protein. UV light then triggers a reaction which covalently links the probe to the target. This 
can then be labelled via CuAAC with an azide affinity probe.  
 
Scheme 11. Affinity based protein profiling. Photocrosslinking is used to stabilise the interaction between a non-
covalent inhibitor and a target protein. CuAAC is then applied to label the protein-inhibitor complex for analysis. 
Ru-catalysed cross metathesis has been reported for CC bond formation on proteins containing S-
allyl-cysteine[55] or Se-allyl-seleno cysteine[68] residues (Scheme 12a). Alternative CC bond forming 
reactions based on Pd cross coupling have also been reported. Using a Pd(II) catalyst, modification of 
proteins in bacterial cells by a Cu-free Sonogashira cross-coupling was demonstrated.[69,70] In addition, 
intracellular assembly of an anti-cancer agent (PP-121 (6)) was achieved through a Pd-catalysed 
Suzuki-Miyaura cross coupling reaction (Scheme 12b).[71] 
 
Scheme 12. Metal catalysed CC bond formation reactions. a. Ruthenium-catalysed olefin metathesis b. 
Example of intracellular formation of anti-cancer drug PP-121 (6) by Pd-catalysed cross coupling.  
Gold(I) chloride complexes have been reported for intramolecular hydroarylation reactions in cells, 
leading to formation of fluorophore 8 (Scheme 13).[72] This reaction was carried out in cells in parallel 
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to Ru catalysed deallylation (discussed in section 1.3.3), representing the first example of two 
orthogonal, metal-triggered bioorthogonal reactions occurring simultaneously.  
 
Scheme 13. Gold-catalysed intramolecular hydroarylation.  
 
 
1.1.4 Photo-triggered ligation reactions 
The tetrazole-alkene photo-catalysed cycloaddition[73] is an example of a photo-triggered reaction. 
Upon treatment with UV light (302 nm), the tetrazole undergoes cycloreversion and elimination of 
nitrogen to produce a nitrile imine that then undergoes spontaneous [3+2] cycloaddition with an 
alkene (Scheme 14). Nitrile imines are highly reactive 1,3-dipoles that must be generated in situ. The 
use of light to trigger the reaction offers a method to spatio-temporally control the initiation of the 
reaction.[74] Additional advantages include the simple synthesis of tetrazoles, the high yield and 
regioselectivity of the reaction and the formation of fluorescent products that enables easy tracking.[3] 
The reaction was applied to modify alkene-containing proteins in mammalian[75] and bacterial cells.[76] 
However, the toxicity associated with the use of UV light limits the application of this reaction. Reports 
of tetrazoles that can be activated with long wave radiation (365 nm) have been described in an effort 
to reduce photo-toxicity.[77] Another disadvantage is that the reaction of tetrazoles with tryptophan 
and thiols has been observed.[78]  
 
Scheme 14. Photo-triggered tetrazole-alkene reaction.  
Photo-induced versions of small molecule-triggered ligation reactions have also been reported. For 
example, photo-triggered dehydration of an o-naphthalene quinone precursor 9 generates reactive 
intermediate 10 that undergoes Diels-Alder reaction with vinyl ethers (Scheme 15a).[79] A photo-
induced SPAAC reaction was also developed by masking the alkyne as cyclopropenone (Scheme 
15b).[80] Upon application of a photo-trigger, the alkyne is generated in situ and reaction with azides 
occurs.  
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Scheme 15. Photo-triggered versions of ligation reactions. a. the Diels-Alder reaction b. the SPAAC. 
 
 
1.1.5 Conclusion 
Second order rate constants of ligation reactions are significantly lower than the formation of an 
antibody-antigen complex (k2 = 0.13 x 106 M1 s1).[81] However, the reaction handles are more cell 
permeable and compatible with biological systems. Despite the discovery of several bioorthogonal 
reactions (Scheme 16), all of them still suffer from limitations meaning that there is not one perfect 
bioorthogonal reaction. Therefore, the ideal reaction depends on the nature of the specific application 
and even those with severe limitations have proved useful in chemical biology. For example, the 
Staudinger reaction, which suffers from slow reaction rates, is often used for in vivo labelling as the 
reaction is highly selective and virtually no background labelling occurs in fluorescent studies.[8]  
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Scheme 16. Overview of some of the most common bioorthogonal ligation reactions and their typical second 
order rate constants. 
Bioorthogonal ligation reactions have also been applied for dual labelling experiments, which utilise 
two orthogonal ligation reactions for the simultaneous labelling of two different biomolecules.[82–84] 
Recently a one-pot triple labelling experiment was performed, in which three proteins, modified with 
either an azide, a non-sterically hindered tetrazine or a t-Bu-tetrazine, underwent selective reaction 
with a corresponding modified-fluorophore (DIBAC, TCO or isonitrile, respectively).[43] No cross-
labelling was observed by in-gel fluorescence, demonstrating the orthogonality of these three 
bioorthogonal reactions. Bioorthogonal ligation reactions have emerged as a useful strategy for 
labelling and studying biomolecules and by combining multiple orthogonal reactions, the power of 
this approach can be further increased. 
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1.2 The IEDDA reaction between tetrazines and alkenes 
1.2.1 Mechanism 
The reaction of tetrazines with alkenes was first reported in 1959[85] and highlights the fact that most 
bioorthogonal reactions existed well before they were used for biological applications.[86] Its fast 
reaction rate (1000 times faster than the Cu click reaction) and high selectivity at low concentrations 
give it potential for in vivo applications.[41,87] On the other hand, the normal electron-demand Diels-
Alder reaction requires dienophiles (for example, maleimides) that are also Michael acceptors. This 
means that the dienophile can react with biological nucleophiles, such as thiols.[88,89]  
The IEDDA reaction is a [4+2] cycloaddition between an electron-poor diene and an electron-rich 
dienophile that forms a highly strained bicyclic intermediate. This then eliminates nitrogen in a retro 
[4+2] cycloaddition to give a 4,5-dihydropyridazine which either isomerises to a 1,4-dihydropyridazine 
or is oxidised to a pyridazine (Scheme 17).[12,90] The kinetics of the reaction depend on several factors 
including electronics, ring strain, stereochemistry and solvent effects.[12]  
 
Scheme 17. IEDDA reaction between a tetrazine and an alkene. 
A faster rate can be achieved by utilising electron-withdrawing substituents on the diene (to lower the 
LUMO energy) and electron-donating groups on the dienophile (to increase the HOMO energy), 
thereby decreasing the HOMO-LUMO energy gap.[12] For this reason, tetrazines are more reactive than 
triazines, which have attracted significantly less attention as bioorthogonal reagents due to their lower 
reaction rates (105 times slower than tetrazines).[91] EWGs on the tetrazine can enhance the rate,[92] 
however there is a balance between reactivity and stability. Several tetrazines bearing strong EWGs 
(12 and 13) are unstable under aqueous conditions.[41] For this reason diaryl tetrazines, such as 14 and 
15, are often used since they offer both moderate reactivity and stability (Figure 2).[41]  
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Figure 2. Electronic effects of the diene. 
Ring strain was shown to have a larger effect on raising the energy of the HOMO than electronic 
effects. Sauer and co-workers showed that smaller, more strained rings exhibited faster rates 
(cyclopropene > cyclobutene > cyclopentene > cyclohexene > cis-cyclooctene (cis-CO)).[93] However, 
TCO (16) adopts a crown conformation[94,95] in which the double bond is twisted (Figure 3), creating a 
highly strained system with a high energy HOMO,[96] making it 7 orders of magnitude more reactive 
than the cis-isomer.[41] In fact, the rate constant for TCO is 28 times that of cyclopropene for the 
reaction with tetrazine 13 in dioxane at 20 °C.[93] The rapid reaction between 3,6-di-2-pyridyl-1,2,4,5-
tetrazine (DiPy-Tz, 15) and TCO (k2 = 1140 M1 s1 in MeOH, 25 °C) proceeds, without catalysis, in both 
organic solvents and water, with a high tolerance to a range of functional groups.[97] Unfortunately the 
ring strain in TCO makes it unstable with respect to isomerisation (t1/2 = 3.26 h in mouse serum).[98]  
 
Figure 3. TCO adopts the lower energy crown conformation. The highly strained double bond makes it very 
reactive.  
Stereochemistry also influences the rate and the axial isomer of functionalised TCO (TCO-OR,                    
k2 = 8.02 x 104 M1 s1 in 100% water) undergoes cycloaddition with tetrazines approximately 4 times 
faster than the equatorial isomer (k2 = 2.26 x 104 M1 s1, Figure 4),[97] possibly due to transannular 
interactions destabilising the axial isomer.[98]  
 
Figure 4. The axial isomer reacts approximately 4 times faster with tetrazines than the equatorial isomer. 
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As well as different cycloaddition rates, the axial and equatorial isomers of trans-cyclooct-4-en-1-ol 
(4-TCO-OH, 11) were also shown to have different rates of tautomerisation. The axial isomer of 4-TCO-
OH reacts with DiPy-Tz to produce fluorescent 1,4-dihydropyridazine and the 4,5-dihydropyridazine is 
not observed.[92] It is proposed that the rapid tautomerisation occurs as a result of neighbouring group 
participation of the OH group. Indeed, removal of the OH (e.g. in a TCO-carbamate) prevents the rapid 
formation of the 1,4-dihyropyridazine. On the other hand, the equatorial isomer was shown to rapidly 
form the non-fluorescent 4,5-dihydropyridazine, which then slowly isomerises (t1/2 = 2 h) to the 1,4-
tautomer through addition of water followed by dehydration.[92] After tuning the tetrazine 
substituents, reaction with either the axial or equatorial isomer resulted in fluorescent products with 
different emission wavelengths, due to the formation of different tautomers.[99]  
Sterics on the tetrazine have also been shown to affect the rate of cycloaddition. Mono-substituted 
tetrazines can react faster than di-substituted tetrazines, even those containing a strong EWG.[91,100,101] 
In addition, 1,2,4,5-tetrazine displayed higher reactivity than 3,6-dimethyl-1,2,4,5-tetrazine (DiMe-Tz) 
in some cases.[102] However, slightly altering the substituents can alter the energy of the LUMO and 
cause the reaction to proceed via the normal Diels-Alder reaction.[102]  
Finally, water enhances the rate due to the hydrophobic effect (k2 = 2000 M1 s1 in 10% H2O/MeOH 
and k2 = 1400 M1 s1 in MeOH).[97] In aqueous conditions, hydrophobic reagents are forced together 
in order to maximise hydrophobic-hydrophobic interactions and to minimise their contact with 
hydrophilic water molecules. This increases the effective concentration of the reagents and 
accelerates the rate. It is also proposed that water stabilises the activated complex by 
coordination.[103] H-bonding to the tetrazine can also occur, which lowers the LUMO in a similar way 
to the presence of EWGs.[103,104]  
 
 
1.2.2 Alternative dienophiles 
In attempts to further enhance the reactivity of TCO, several derivatives have been reported (Figure 
5). Strained trans-cyclooctene[105] (s-TCO, 17) and dioxolane-fused trans-cyclooctene[97] (d-TCO, 18) 
are more reactive than TCO as the cis-fused rings force cyclooctene to adopt the higher energy half-
chair conformation.[105,106] s-TCO with an attached PEG linker (24) is water soluble and its reaction with 
a tetrazine (k2 = 3.30 x 106 M1 s1 in water, Table 1, Entry 2) is 160 times greater than TCO.[97] However, 
s-TCO is even more unstable than TCO and is easily isomerised in the presence of thiols.[105] This can 
be prevented by complexation with AgNO3, which increases the stability and enables it to be stored 
for a long period of time. This complex can be used directly in cells without the need for prior removal 
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of AgNO3.[107] d-TCO (18) exhibits a good balance between reactivity and stability. It is more reactive 
(k2 = 3.66 x 105 M1 s1 in water, Table 1, Entry 3 than TCO but, unlike s-TCO, it is stable to 
isomerisation (> 97% remaining after 4 days in human serum).[97] This increased stability is due to the 
presence of electron-withdrawing oxygen groups that make the double bond less reactive. d-TCO also 
has the additional advantage of being easier to prepare than s-TCO.  
 
Figure 5. Structures of TCO derivatives: s-TCO[105] (17), d-TCO[97] (18), oxazolone-fused trans-cyclooctene[108] 
(oxTCO, 19), oxoTCO[109] (20), 3-dioxacyclo-oct-5(E)-ene[110] (dioxo-TCO, 21), trans‐oxasilacycloheptene[111,112] 
(oxasilaTCO, 22) and Si-TCH[113] (23). 
As well as conformationally strained derivatives, heterocyclic versions of TCO (2023) have also been 
reported (Figure 5).[109–113] One example is the rationally designed trans-5-oxocene (oxoTCO, 20), 
which was proposed to be more reactive than TCO due to increased angle strain as a result of short 
CO bond lengths.[109] oxoTCO (20) was shown to be synthetically accessible from 7 high-yielding 
steps. However, the desired axial trans-isomer could not be easily separated from the equatorial 
isomer and, therefore, further studies were carried out using a mixture of diastereomers. oxoTCO (20) 
reacts rapidly with tetrazines (k2 = 9.5 x 104 M1 s1, 1:2.2 axial:equatorial diastereomeric mixture) and 
showed similar stability to d-TCO. Unlike TCO, it has the advantage of being highly hydrophilic and cell 
permeable, enabling it to enter E. coli cells overexpressing a tetrazine-modified green fluorescent 
protein (GFP). The fluorescence of GFP is quenched by the tetrazine and is restored upon reaction 
with oxoTCO. Other heterocyclic derivatives (19, 21, 22) also proved to be hydrophilic and more 
reactive than TCO.[108,110–112]  
Finally, stable AgNO3 complexes of trans-cycloheptene (TCH) and trans-1-sila-4-cycloheptene (Si-TCH, 
23) have also been reported (Figure 5).[113] TCH is highly unstable and can only be isolated through 
trapping or complexation with metals.[114] Si-TCH offers additional stability as a result of decreased 
ring strain[115,116] (CSi bonds are longer that CC bonds) and even metal-free Si-TCHs show good 
stability in solution.[113] The decomplexation of AgNO3 occurs in situ in cell media due to the presence 
of NaCl and reaction of decomplexed Si-TCH with a tetrazine is the fastest bioorthogonal reaction to 
date (k2 = 1.1 x 107 M1 s1 in 90% H2O/MeOH). This reaction was applied to protein labelling in live 
cells. Although all these derivatives offer advantages in rate and hydrophilicity, they have not been 
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widely utilised, and TCO is likely to remain the reagent of choice until other derivatives become 
commercially available or improved syntheses are reported. 
In addition to TCO derivatives, a wide variety of other dienophiles have been reported (Table 1). It 
should be noted that a direct comparison of the reaction rates in Table 1 is not reliable, since they are 
reported in different solvent systems. The fact that there is no standard solvent system for studying 
bioorthogonal reaction kinetics is a limitation of the field. Since the percentage of aqueous solvent 
and the presence of buffers has a large effect on the rate, a more useful approach would be for all 
reactions to be reported in the same solvent system. This would enable quantitative comparison of 
the reaction rates. However, the data in Table 1 still provides an approximate idea of the order of 
magnitude of the rates. It is also important to note that when reactions are carried out in vivo, lower 
concentrations of reagent are utilised to minimise toxicity and therefore the rate will be slower than 
in vitro. The kinetics of bioorthogonal reactions are usually only studied in vitro. An exception is the 
reaction of s-TCO with a GFP-tetrazine, which was also studied in cellulo. It displayed a second order 
rate constant of 72000 M1 s1 in cellulo compared to 87000 M1 s1 in phosphate-buffered saline (PBS) 
at 21 °C.[117]     
All dienophiles suffer from slower reaction rates than 4-TCO-OH (11, Table 1, Entry 1). For example 
cyclopropene[101] (25, Table 1, Entry 4) and norbornene[86] (26, Table 1, Entry 5) react rapidly with 
tetrazines and demonstrate a good balance between reactivity and stability. However, TCO (11, Table 
1, Entry 1) is significantly more reactive and, unlike norbornene (26) and cyclopropene (25), can even 
react with the less reactive triazines.[118] Other examples of dienophiles include N-acylazetine[119] 
(Table 1, Entry 6), BCN[120] (27, Table 1, Entry 7), vinyl boronic acids[121] (Table 1, Entry 8) and primary 
alkenes[122,123] (28, 29, Table 1, Entries 9 and 10). Although these dienophiles are significantly less 
reactive than TCO, there are cases where they are more suitable than TCO. For example, they are less 
hydrophobic than TCO and their smaller size allows them to be easily incorporated into biomolecules.  
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Table 1. Typical second order rate constants observed with selected dienophiles. Adapted from Oliveira et. al.[12] 
Entry Dienophile Typical k2 (M1 s1) 
Aqueous 
solvent % 
1 
 
     22,600 (eq)[97] 
80,200 (ax) 
100 
2 
 
3300000[97]  
 
100 
3 
 
   366,000 (syn)[97] 
318,000 (anti) 
100 
4 
 
2.3[101] 50 
5 
 
1.9[86] 100 
6 
 
0.39[119] 88 
7 
 
1245[120] 45 
8 
 
27[121] 100 
9 
 
0.05[122] 50 
10 
 
0.002[123] 50 
 
 
 
1.2.3 Applications of IEDDA ligation reaction 
Bioorthogonal ligation reactions have been widely used for the labelling and studying of biomolecules 
such as proteins, lipids and glycans.[124] The first use of the IEDDA reaction for protein labelling was 
reported in 2008 by Fox and co-workers.[41] Thioredoxin (Trx), which has a single, solvent-exposed 
disulfide in the active site, was labelled by site-selective chemical conjugation to TCO via a maleimide-
carbamate linker (30). This was followed by reaction with DiPy-Tz (15) which gave 31 in 100% 
conversion within 5 min (Scheme 18).[41]  
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Scheme 18. Application of the IEDDA reaction for protein labelling. 
Site-specific labelling of recombinant proteins in live E. coli cells was achieved through genetic 
encoding of a tetrazine-containing unnatural amino acid, followed by reaction with s-TCO.[117,125] A 
second order rate constant of 72500 M1 s1 was observed in cells, confirming the suitability of this 
reaction for in vivo applications.[117]  
Other bioorthogonal handles, including TCO,[120,126] norbornene,[126,127] BCN,[120,128] and 
cyclopropene[75] have been site-specifically incorporated into proteins through genetic code 
expansion.[129] Reaction of a genetically incorporated TCO handle with fluorogenic tetrazines was used 
to image intracellular proteins and observe the intracellular localisation and trafficking of a 
membrane-associated protein.[130] Imaging of endogenous kinases in live cells was also demonstrated 
through the subsequent addition of a TCO-modified inhibitor followed by a tetrazine-fluorophore.[131]  
A selective method for labelling proteins that are produced at a specific developmental stage in a 
certain tissue was developed.[132] By using genetic code expansion, cyclopropene handles were 
selectively incorporated into proteins synthesised in germ cells in the ovaries of Drosophila 
melanogaster. Reaction with a labelled tetrazine (fluorophore/biotin) then enabled 
imaging/identification of the proteins. The small size of cyclopropene is advantageous, as it does not 
perturb the structure and function of the protein. 
The IEDDA reaction has been applied for super resolution imaging of cytoskeleton[133] and intracellular 
proteins.[133,134] In a first example, site-specific labelling of proteins with BCN/TCO-modified amino 
acids through genetic encoding was followed by reaction with a tetrazine fluorophore.[133] In another 
example, a Click-PAINT strategy was described, in which the incorporated TCO reacts with a tetrazine-
DNA conjugate, followed by a fluorophore linked to the complementary DNA sequence. This strategy, 
based on DNA-PAINT, was used to label intracellular proteins of low abundance.[134]  
An appealing method for protein labelling is disulfide rebridging or stapling (the insertion of a chemical 
motif between the two sulfides, Scheme 19a). Since all IgG antibodies contain four disulphide bonds, 
stapling is a general strategy for antibody modification that offers a high degree of control. This is not 
the case for other modification methods, for example lysine modification, where the number of 
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reactive sites is much higher and varies between antibodies. Stapling can result in increased protein 
stability and cell permeability[124] and it has been used to site-selectively install tetrazines into 
peptides, proteins and antibodies. In a key example, Trx was reacted with 3,6-di-2-chloro-1,2,4,5-
tetrazine (DiCl-Tz, 32) to produce a stapled tetrazine handle (Scheme 19b).[135] The authors claim that 
this is advantageous as it enables selective incorporation of a tetrazine into proteins, which can then 
either be labelled through reaction with a dienophile or removed by photolysis. However, the resulting 
tetrazine showed poor reactivity (Trx-Tz was labelled by reaction with a BCN fluorophore (10 equiv.) 
for 10 days) and removal of the tetrazine staple by photolysis resulted in loss of protein activity. 
Therefore, the utility of this tetrazine stapling method is debatable. Recently, the incorporation of a 
tetrazine through an allyl sulfone handle (33) was reported (Scheme 19c).[136] The resulting tetrazine 
was highly reactive and reacted in near-quantitative yield with TCO-probes within 0.5 h. This approach 
enables rapid labelling of antibodies via the TCO-tetrazine reaction. Importantly, in both cases the 
protein conjugates were shown to be stable and the secondary structure was not affected by stapling.  
 
Scheme 19. Disulfide rebridging. a. Insertion of chemical motif between two sulfides. b. Stapling with DiCl-Tz 
(32) introduces a tetrazine with poor reactivity towards dienophiles. c. Allyl sulfone handle (33) to incorporate 
a highly reactive tetrazine.  
The IEDDA reaction can also be used for the identification of bioactive targets of small molecule drugs. 
Cells are incubated with a TCO-modified drug, followed by addition of a tetrazine-biotin conjugate and 
proteomic analysis.[137] The IEDDA reaction resulted in more efficient labelling than both the CuAAC 
and the SPAAC. In addition, a modular strategy involving co-incubation of the TCO-modified drug with 
the unmodified drug, followed by addition of a tetrazine-fluorophore was used to determine the 
target occupancy of the underivatised drug at subcellular resolution.[137]  
The IEDDA reaction has also been used to detect post-translational modifications in live cells. Sulfenic 
acid modifying trans-cyclooct-4-en-1-ol (SAM-TCO) probes react selectively with sulfenic acids to form 
thiiranium ions, which then undergo transannular attack by the axial hydroxyl group and 
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thioetherification to from stable adducts (Scheme 20).[138] Methods for detecting sulfenic acids involve 
addition of a probe, followed by cell lysis and detection of the modified sulfenic acids. However, cell 
lysis can result in oxidation of thiols to sulfenic acids, which can then react with the probe. An 
advantage of the SAM-TCO probes is that tetrazines can be added to cells before lysis to quench any 
unreacted probe and to prevent further labelling occurring during the lysis step. In addition, the 
probes are small, cell permeable and a proteomic method utilising SAM-TCO-alkyne probes, was able 
to detect significantly more proteins than previously reported probes. 
 
Scheme 20. SAM-TCO probes for detecting endogenous sulfenic acids. 
Tetrazines have been shown to quench the fluorescence of an attached fluorophore, which can be 
successfully turned on after IEDDA reaction.[92] Highly specific fluorogenic tetrazine probes for the 
detection and imaging of DNA/miRNA in live cells have also been developed.[139,140] Antisense 
oligonucleotide probes containing a fluorogenic tetrazine and either a benzonorbornadiene[139] or 
cyclopropene,[140] undergo a template driven reaction in the presence of the specific complementary 
strand (Scheme 21). Binding to the template strand brings the tetrazine and dienophile into close 
proximity and increases their effective concentration, resulting in rapid reaction and production of a 
fluorescent signal. This approach is highly specific and can detect a single base mismatch.  
 
Scheme 21. Detection of specific DNA sequences in live cells through a template driven IEDDA reaction. 
In addition to the use of ligation reactions for the labelling and tracking of biomolecules in biological 
systems,[141] several alternative applications have been reported. These include hydrogel[142,143] and 
polymer[144,145] synthesis, delivering NPs to target cells[12,146] and proteolysis targeting chimera 
(PROTAC) assembly in live cells.[147] A click-formed proteolysis targeting chimera (CLIPTAC) strategy 
was developed, in order to overcome the poor solubility and cell permeability of high molecular weight 
PROTACs.[147] A TCO-modified ligand for the protein of interest, followed by a tetrazine-thalidomide 
(E3 ligase recruiting ligand) conjugate were sequentially added to cells and demonstrated improved 
cell permeability. Upon intracellular formation of a CLIPTAC, the E3 ligase and protein are brought into 
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close proximity, which enables ubiquitination and proteasomal degradation of the target protein 
(Scheme 22). 
 
Scheme 22. CLIPTAC formation in live cells brings an E3 ligase into close proximity with the target protein, 
resulting in ubiquitination and proteasomal degradation of the target.  
Preparation of radioactive probes for nuclear imaging can be achieved through bioorthogonal ligation 
of a radioactive nuclei to a targeting molecule. Due to the short half-life of the radionuclide, the rapid 
clearance of small molecules and the low target expression in vivo, the preparation must be rapid and 
efficient. Therefore, the TCO-tetrazine IEDDA reaction has been applied for in vivo imaging and 
pretargeting applications.[148,149] 
Rossin et al. reported the first TCO-tetrazine pretargeting strategy for nuclear imaging.[150] Mice 
bearing colon cancer xenografts were injected with a TCO-CC49 antibody against TAG72, which is 
overexpressed in several solid tumours. After 24 h, 3.4 equiv. of an 111In-dodecane tetraacetic acid 
(DOTA)-tetrazine conjugate was injected, and localisation of radioactivity at the tumour was observed 
by single photon emission computed tomography (SPECT) imaging. However, a low tumour-to-blood 
ratio resulted from reaction with excess TCO in circulation. In addition, TCO was slowly inactivated in 
vivo. It was later shown that shortening the linker length reduced TCO deactivation by Cu-containing 
proteins[98] and that less hydrophobic TCO tags improved tumour uptake and in vivo stability.[151]  
As well as radiolabelling with metals, the TCO-tetrazine reaction has been used to rapidly generate 18F 
probes. 18F-labelling of TCO was achieved in 71% after 15 min and reaction with a tetrazine occurred 
in quantitative yield within 10 seconds.[152] Reaction of 18F-TCO with a tetrazine, conjugated to either 
a peptide[153] or a small molecule inhibitor,[154] resulted in positron-emission tomography (PET) probes 
that demonstrated good tumour uptake. Additional probes were generated from reaction of 
tetrazines with 18F-labelled norbornene,[155] s-TCO,[156] d-TCO[157] and oxoTCO.[158] The highest tumour-
to-background ratio was observed with oxoTCO due to rapid clearance as a result of its hydrophilic 
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nature. Dextran polymers have also been shown to improve labelling though increasing in vivo 
circulation time of the radioactive isotope.[159] 
Initially, tetrazines were found to be unstable to 18F labelling conditions. However, since then, several 
robust methods for generating 18F-Tz compounds have been reported.[160–162] Additionally, tetrazine 
derivatives of other radionuclides have been reported for in vivo labelling, including 177Lu-Tz,[163]      
64Cu-Tz,[164] 99mTc-Tz,[165] 68Ga-Tz[166] and even 11C[167] which has a half-life of only 20.3 minutes. 
Tetrazines linked to various chelating groups (DOTA for chelating 64Cu and deferoxamine (DFO) for 
chelating 89Zr) have also been used to label a norbornene-modified antibody.[168] Finally, by reaction 
of TCO-modified Trastuzumab with a fluorogenic chelate tetrazine (Tz-DFO-BODIPY), multimodal 
imaging of HER2 positive tumours was achieved.[169] 
Antibody-drug conjugates (ADCs) often suffer from heterogeneity due to a lack of control of both the 
site and number of modifications. However, incorporation of a bioorthogonal handle into the antibody 
enables controlled conjugation[170] and there are currently several bioorthogonally-prepared ADCs in 
clinical trial.[171] Furthermore, the first clinical trials of utilising bioorthogonal chemistry in humans are 
currently underway for the treatment of pancreatic ductal adenocarcinoma.[171] After pretargeting 
with a TCO-modified antibody (5B1), 64Cu-Tz will be added to radiolabel the antibody at the tumour 
site and enable PET imaging. This strategy was demonstrated to be more efficient than direct 
administration of a radiolabelled antibody in mice, likely because the radioactive probe is only 
administered after clearance of excess antibody.[170] The fact that this radiolabelling strategy based on 
the IEDDA reaction is currently in clinical trials, highlights the significant progress that has been made 
in the field of bioorthogonal chemistry. 
 
 
1.2.4 Conclusion 
The IEDDA reaction between a tetrazine and TCO is one of the fastest and most selective 
bioorthogonal reactions reported to date. As a result, it has attracted a lot of attention and has been 
utilised for a diverse range of applications beyond the typical labelling of biomolecules. The significant 
amount of work done in this area has led to this reaction reaching clinical trials. However, the full 
potential of the TCO-tetrazine reaction is still unknown and it is envisaged that further clinical trials 
will follow. In addition, it is likely that the applications of this reaction will continue to increase as a 
wider range of tetrazine and TCO reagents become commercially available.  
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1.3 Bioorthogonal decaging reactions for prodrug activation 
1.3.1 Prodrug activation 
Conventional chemotherapy involves injection of an active drug, which then circulates around the 
body and binds to the intended target. The lack of specificity for the target tissue results in toxic side 
effects, which restrict the maximum dose that can be administered. This means treatment often fails 
as a sufficiently high drug concentration at the target site cannot be achieved.  
A prodrug is an inactive form of a drug, in which a functional group essential for the activity of the 
drug has been masked with a protecting group. By selectively activating the prodrug at the target site, 
for example at a tumour, it is possible to reduce unwanted side effects that occur as a result of off-
target interactions with healthy cells (Scheme 23). Therefore, this enables higher doses to be 
administered, improving the efficacy of the drug. Prodrugs can also be used to improve the 
pharmacokinetics of the drug, for example the solubility and cell permeability.  
 
Scheme 23. Prodrug activation. 
Prodrugs are commonly activated by endogenous factors in target cells, such as a difference in pH[172] 
or the overexpression of an enzyme[173–176] compared to healthy cells. Other examples of prodrug 
activation have been reported that exploit levels of H2O2,[177] glutathione[178] and thiols.[179] However, 
endogenous activation often suffers from low selectivity because the difference, for example in 
enzyme expression, between target and healthy cells is usually small. In order to increase specificity, 
an exogenous enzyme can be installed at the target site through the use of an antibody-enzyme 
conjugate.[180] Antibody-directed enzyme prodrug therapy (ADEPT) results in site-selective, 
extracellular release of a small molecule drug, which can then diffuse through the tumour and kill 
cancer cells (Scheme 24a). However, immunogenicity of the exogenous enzyme prevents treatment 
being repeated. An alternative strategy to increase the specificity of endogenous activation is to use 
ADCs containing cleavable linkers, such as acid labile hydrazones, disulfides and enzymatically 
cleavable linkers (Scheme 24a).[181] For example, the commonly used valine-citrulline-p-aminobenzyl 
carbamate (Val-Cit-PABC) linker is a peptide linker that releases the payload through 1,6-elimination 
following protease cleavage by Cathepsin B (Scheme 24b).[182] Disadvantages of antibody-directed 
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approaches include the rapid mutation of antigens that generates resistance,[183] hydrolysis of the 
linker that leads to non-specific drug release and high ADC heterogeneity.[184] 
 
Scheme 24. Antibody-directed approaches for site-specific drug release. a. Antibody-enzyme conjugates 
catalyse extracellular prodrug activation and ADCs are cleaved by intracellular enzymes upon internalisation. b. 
mechanism of cleavage of a Val-Cit-PABC linker commonly used in ADCs. 
A new class of bioorthogonal reactions has been developed in which a bond is broken to release a 
molecule of interest.[185–188] These bioorthogonal decaging reactions provide a method to activate 
prodrugs with a high level of control and selectivity, and are, therefore, appealing for site-selective 
therapies. Like ligation reactions, many decaging reactions have been reported that involve light, 
metal or small molecule triggers. Several of these will be discussed here, with a focus on chemical-
triggered reactions that have been used for prodrug activation.  
 
 
1.3.2 Photo-triggered decaging reactions 
In a photo-triggered decaging reaction, a protecting group absorbs photons and is transferred to an 
excited state, where it undergoes a reaction to release the molecule of interest. UV-triggered decaging 
of o-nitrobenzyl (ONB) ether protecting groups has been widely explored (Scheme 25).[189,190] 
However, UV light (350365 nm) suffers from issues of cytotoxicity and poor tissue penetration, 
limiting its use in vivo.  
 
Scheme 25. UV-triggered decaging of ONB ethers. 
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Using light of a lower energy and longer wavelength (near-IR, 650900 nm) is appealing as it offers 
increased tissue penetration and low toxicity in comparison to UV radiation. Near-IR light was used to 
decage a prodrug consisting of a cyanine fluorophore connected to an alcohol-containing drug 
(hydroxy-cyclofen) in mammalian cells (Scheme 26).[191] Upon irradiation with near-IR light, 
photooxidative CC bond cleavage occurs, followed by hydrolysis to release an amine. This then 
undergoes intramolecular cyclisation to release the alcohol. This near-IR cyanine-based cleavable 
linker has been incorportated into an ADC and the intrinsic fluorescence of the cyanine caging group 
was used to demonstrate good in vivo stability and high tumour uptake.[192] Further work resulted in 
a second generation ADC with improved stability, a longer wavelength absorbance maximum and a 
more potent duocarmycin payload, which resulted in a significant decrease in tumour size and 
increased survival of the mice after a single dose.[193] 
 
Scheme 26. Near-IR-cyanine-based cleavable linker for protecting alcohols.  
A photo-triggered Ru-catalysed azide reduction has been described in which a catalytically active Ru 
species is generated upon treatment with visible light.[194] The reduction of azides that were connected 
to self-immolative linkers, was applied to release fluorophores in living cells (Scheme 27).[195,196] The 
reduction of aromatic azides to amines in mammalian cells has also been reported through the use of 
iron catalysts.[197]  
 
Scheme 27. Visible light-triggered reduction of azides followed by 1,6-elimination to release fluorophore in cells.  
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1.3.3 Metal-triggered decaging reactions 
Metal-triggered bioorthogonal decaging reactions have been widely explored,[198,199] with the most 
extensively studied metal being palladium. In 2014 Chen and co-workers reported the first use of 
palladium for specific protein activation in cells.[200] Palladium catalysts were used to deprotect a 
propargyl-carbamate-lysine that was genetically incorporated into the protein of interest            
(Scheme 28a). The same group also reported palladium-catalysed protein activation in cells through 
removal of an allene-protected tyrosine residue (Scheme 28b).[201]  
 
Scheme 28. Palladium-triggered decaging for the activation of proteins in cells. a. removal of a propargyl-
carbamate protecting group from a lysine residue. b. removal of an allene protecting group from a tyrosine 
residue. 
In 2014 Weiss et al. reported one of the first uses of bioorthogonal decaging for prodrug activation.[202] 
A biocompatible palladium resin was used to cleave a propargyl group from a 5-fluorouracil prodrug 
(34) in vitro (Scheme 29). In addition, fluorescence recovery was performed in vivo for the imaging of 
zebrafish embryos. 
 
Scheme 29. Palladium-triggered activation of a 5-fluorouracil prodrug (34). 
The same group then reported several carbamate prodrugs of gemcitabine which could also be 
activated using palladium-mediated decaging.[203] The most successful carbamate protecting group 
tested was N-propargyloxycarbonyl (N-Proc) which resulted in the greatest amount of free drug 
release, and therefore cytotoxicity, in cells (Scheme 30a). In addition, the activation of N-Proc-
rhodamine in zebrafish embryos was shown by fluorescence to occur locally at the site of the 
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palladium resin. Palladium-catalysed depropargylation to release Floxuridine, a cytotoxic anti-cancer 
drug, under hypoxic conditions in cells has also been reported (Scheme 30b).[204] 
 
Scheme 30. Palladium-triggered release of anti-cancer drugs. a. Activation of N-Proc-gemcitabine prodrug 36. 
b. activation of propargyl-floxuridine prodrug 38.  
Palladium-mediated decaging has also been extended to the release of hydroxamic acid functional 
groups. Successful activation of Vorinostat (43), a histone deacetylase, was achieved in cells using 
palladium-catalyzed depropargylation to release phenol 41 which then undergoes 1,6-elimination to 
release the alcohol of the hydroxamic acid group (Scheme 31).[205]  
 
Scheme 31. Release of hydroxamic acid-containing drug, Vorinostat (43): palladium-catalysed depropargylation 
is followed by 1,6-elimination of a 4-hydroxybenzyl group.  
In addition to palladium, ruthenium decaging[206] has also been used for prodrug activation. Meggers 
developed organometallic ruthenium (IV) catalysts for decaging of N-allyoxycarbonyl (N-Alloc) 
protected amines (Scheme 32).[207] These catalysts were highly cell permeable and exhibited high 
turnover numbers (TONs) of up to 270 cycles in the presence of thiols at millimolar concentrations. 
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Thiols usually result in deactivation of metal catalysts, however, the authors propose that in this case 
the biological nucleophiles reduce the Ru (IV) complex to the catalytically active Ru (II) species. 
Catalytic activation of doxorubicin (Dox) was achieved in the cytoplasm of HeLa cells, which resulted 
in apoptosis. 
 
Scheme 32. Ruthenium-triggered removal of an N-Alloc protecting group from amines.  
Recently, a bioorthogonal decaging method based on ring-closing metathesis (RCM) was reported.[208] 
This “close-to-release” strategy involves ruthenium-catalysed RCM followed by 1,4-elimination, driven 
by formation of an aromatic compound. Treatment of several diolefinic esters with Hoveyda-Grubbs 
2nd generation catalyst (HG-II) resulted in the release of carboxylic acids, although mostly with yields 
of < 50% (Scheme 33). Examples include release of nicotinic acid (44, an NAD(P)-H precursor) and 
valproic acid (45, an antineuroleptic drug).  
 
Scheme 33. Close-to-release decaging strategy involving RCM followed by 1,4-elimination: decaging of an ester 
linker to release carboxylic acids 44 and 45.  
It was also shown that analogous ether, carbonate and carbamate linkers could be decaged to release 
alcohols or amines, respectively. However, lower yields (often < 20%) and TONs were observed than 
from the ester linker with similar catalyst loading. Although the decaging of esters and ethers occurred 
in the presence of serum, mammalian cells and in the periplasm of E. coli, reduced yields and catalyst 
TONs were observed. For example, with 5 mol% HG-II in the presence of HeLa cells in DMEM (10% 
FBS), which are representative of standard cell culture conditions, ether decaging resulted in 27% of 
free alcohol with a low TON of 5. This is likely due to Ru catalyst deactivation by reaction with 
glutathione.[209] However, it is possible to improve the stability of the catalyst towards biological 
nucleophiles by altering the ligands.[207]  
An example of gold-mediated decaging has also been reported.[210] Gold is known to coordinate 
preferentially to alkynes, however, it also has a high affinity for thiols. The authors proposed that by 
using solid-supported gold NPs, reaction with large thiol-containing biomolecules could be prevented 
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whilst allowing deprotection of small molecule drugs in biological systems. The decaging of three 
alkyne-protected cancer drugs (vorinostat, 5-fluorouracil and doxorubicin) using heterogeneous gold 
NPs was demonstrated in live cells (Scheme 34). This was also the first bioorthogonal decaging 
reaction to be carried out in the brain of zebrafish embryos. Intracranial activation of a caged 
rhodamine was achieved, highlighting the potential of gold-mediated decaging reactions in vivo.  
 
Scheme 34. Gold-triggered decaging of alkyne-protected anticancer drugs.  
In the area of drug activation, metal-triggered decaging has mainly been used to cleave 
monofunctional protecting groups from anticancer prodrugs. Recently, our group reported a 
bifunctional thioether propargyl carbamate linker for palladium-mediated drug release (Scheme 
35).[211] The thioether group was shown to bind to palladium and direct the decaging. After 
demonstrating palladium-triggered drug release from a PEGylated doxorubicin prodrug in live cells, 
the application was extended to the development of a palladium-activated ADC (46). Doxorubicin (48) 
was connected to a nanobody targeted to the HER2 antigen via the bifunctional thioether propargyl 
carbamate linker. The ADC (46) proved stable and thioether-directed palladium-triggered decaging in 
cells was achieved using non-toxic concentrations of palladium.  
 
Scheme 35. Palladium-triggered release of doxorubicin (48) from an ADC (46). 
Performing metal-triggered decaging reactions in vivo poses several challenges such as ensuring 
efficient cellular uptake of the catalyst at the target organ and avoiding loss of catalytic activity 
through reaction with thiols and intracellular proteins.[212] However, methods for the effective, 
intracellular delivery of palladium in vivo have been developed, including metal NPs,[213,214] NPs 
entrapped in microspheres[199,215] and metal complexes.[216] For example, cell-penetrant Pd NPs have 
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been shown to accumulate at the tumour site in mice and catalyse the activation of a doxorubicin 
prodrug, resulting in inhibited tumour growth and increased survival of the mice.[213] Linking metal 
complexes to cancer-targeting cyclic peptides is another strategy to generate efficient internalisation 
at the desired site.[216] Pd-NP functionalised microspheres that were linked to a cancer targeting cyclic 
peptide were shown to selectively and rapidly enter glioblastoma cells. They successfully catalysed 
the simultaneous intracellular decaging of a 5-fluorouracil prodrug and the synthesis of PP-121 (6) via 
Suzuki-Miyaura cross coupling.[217] This dual anti-cancer drug-formation strategy resulted in increased 
therapeutic effect compared to either strategy alone.  
The development of optimised, biocompatible palladium devices for in vivo catalysis has been 
reported.[218] These Pd NP-functionalised polymers were inserted directly into the tumour in murine 
models of prostate cancer by ultrasound-guided injection. It was observed that after being in the 
tumour for 3 weeks, the catalytic activity remained the same as that of a newly installed Pd device, 
showing that the device was resistant to the deactivating effect of thiols and proteins. This study 
highlights the potential for metal-catalysed decaging reactions in localised prodrug activation therapy. 
Metal-triggered ligation reactions are unlikely to occur in vivo due to the small probability of 3 
components coming together at sufficient concentration to react. However, for decaging reactions, 
only two components (the caged molecule and the metal trigger) need to be in close proximity for the 
reaction to occur. Therefore, the potential for metal triggered decaging is much greater than for 
ligation reactions.  
 
 
1.3.4 Small molecule-triggered decaging reactions  
Decaging reactions that do not involve a tetrazine have been reported. For example, the SPAAC was 
successfully transformed into a cleavage reaction by linking an azide to a self-immolative linker 
(Scheme 36).[219] Azide 49 undergoes a [1+3] cycloaddition with TCO (16) to form unstable triazoline 
50 which decomposes to form imine 51. Hydrolysis of the imine is followed by self-immolation of the 
PABC linker to release an amine. This was applied to decage a prodrug in cells and had a similar rate 
constant to the SPAAC ligation (k2 = 0.027 M1 s1 in 50% MeCN/PBS for the cycloaddition). Azide 49 
could also be reduced by phosphines (via a Staudinger reaction) to form aniline 52 directly, which then 
underwent 1,6-elimination to release doxorubicin (48).[220]  
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Scheme 36. Strain promoted 1,3-dipolar cycloaddition of TCO (16) and an azido-PABC linker for the activation of 
a doxorubicin prodrug (49).  
The Staudinger reaction was also adapted for decaging and applied to activate a doxorubicin prodrug 
(Scheme 37).[221] By modifying the phosphine with a phenyl carbamate substituent, the aza-ylide 
undergoes intramolecular cyclisation and cleaves the carbamate bond. The resulting intermediate 
then undergoes 1,6-elimination to release doxorubicin (48).  
 
Scheme 37. The Staudinger ligation was adapted for decaging by connecting the phosphine to a phenyl 
carbamate.  
A decaging reaction between iminosyndones and strained alkynes has also been reported.[222] The 
reaction proceeds via a [3+2] dipolar cycloaddition, followed by a retro Diels-Alder reaction to release 
a free amine (Scheme 38). A second order rate constant of 0.18 M1 s1 was observed with BCN (27), 
which could be increased up to 29 M1 s1 by using the more strained alkyne TMTH (1).  
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Scheme 38. Cyclooctyne-triggered decaging of aminosyndones to release amines.  
Most decaging reactions are modified forms of ligation reactions, in which the intermediate that forms 
upon ligation is unstable and therefore undergoes rearrangement followed by subsequent 
elimination. Other examples of bioorthogonal cleavage reactions that are not based on the ligation 
reactions have been reported, such as the reaction of N-oxides with boron reagents (Scheme 39).[223]  
 
Scheme 39. Decaging of N-oxides with boron reagents. 
 
Although several bioorthogonal decaging reactions have been reported, they have not been widely 
utilised. This is likely due to the fact that they suffer from slow reaction rates and the reagents undergo 
oxidation (Staudinger) or react with biological nucleophiles (SPAAC). Therefore, they cannot compete 
with the rapid IEDDA reaction for in vivo and cellular applications.  
 
1.3.5 TCO-tetrazine IEDDA decaging  
Small molecule triggers are advantageous over metal/photo-triggers since they provide a controlled, 
non-invasive method that does not require the use of a catalyst. The Robillard group showed that the 
IEDDA reaction could be adapted for fast decaging by placing an alcohol substituent in the allylic 
position of TCO, where it is appropriately placed to eliminate upon tautomerisation of the 4,5-
dihydropyridazine (Scheme 40).[224]  
 
Scheme 40. IEDDA decaging reaction between a tetrazine and alkene. 
This reaction was applied to decage a TCO-carbamate-Dox prodrug (56) in vitro through a click-to-
release strategy (Scheme 41).[224] The axial isomer reacted 16 times faster with DiPy-Tz (15,                          
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k2 = 57.7 M1 s1 in MeCN) than the equatorial (k2 = 0.37 M1 s1, which was attributed to the sterically 
hindered approach of the tetrazine to the equatorial isomer. Despite this fast rate of cycloaddition, 
only 7% free doxorubicin was released after 3 h. 3-methyl-6-(pyridin-2’-yl)-1,2,4,5-tetrazine (MePy-Tz) 
and DiMe-Tz resulted in much faster release rates (55% complete in 3 min and 79% complete in             
16 min, respectively) even though the cycloaddition step was an order of magnitude slower. The 
prodrug (56) showed significantly reduced toxicity in A431 tumour cells (EC50 = 3.834 µM) compared 
to the parent drug (EC50 = 0.037 µM) and a combination of the prodrug and DiMe-Tz almost completely 
restored cytotoxicity (EC50 = 0.049 µM).[224]  
 
Scheme 41. Click to release strategy for activation of a TCO-carbamate-Dox prodrug (56) in vitro.  
The IEDDA decaging reaction consists of two steps: a cycloaddition followed by an elimination step. 
Initial studies showed that DiPy-Tz resulted in a fast cycloaddition, but negligible drug release 
occurred. On the other hand, DiMe-Tz resulted in the highest percent of drug release even with a slow 
rate of cycloaddition. The effect of tetrazine substituents was then studied and it was shown that 
EWGs enhance the rate of cycloaddition but hinder the rate of elimination (due to the formation of a 
stable cycloaddition intermediate).[225] Therefore, a non-EWG is required for efficient elimination and 
optimised, asymmetric tetrazines bearing one EWG and one small alkyl non-EWG were reported 
(Figure 6). Asymmetric tetrazine 57 showed the highest decaging efficiency in vitro while 58 
performed better in cells (90% decaging in 4 min), likely due to the poor membrane permeability of 
the OH group in 57 reducing the decaging efficiency in cells).  
 
Figure 6. Electronic effects of tetrazine substituents on the rate of decaging.  
TCO-tetrazine decaging often results in incomplete release and detailed studies concluded that this 
was due to the formation of a dead-end tricyclic product as a result of cyclisation of the carbamate 
amine onto the tetrazine (Scheme 42).[226] This dead-end pathway could be completely prevented by 
utilising a tertiary amine, however, it is not always practical to modify the N on the drug.  
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Scheme 42. Formation of a dead-end tricyclic product results in incomplete release. 
The same study showed that the decaging is pH dependent, with higher rates and yields of release 
observed at acidic pH. Since the click reaction is rapid, it is likely that the pH affects the rate of the 
tautomerisation step. An alternative to lowering the pH of the reaction is to use carboxylic acid-
functionalised tetrazines such as 59, which provide a nearby proton source and accelerate the rate of 
tautomerisation. In addition, complete release was observed as rapid tautomerisation disfavours the 
dead-end cyclisation.  
Asymmetric tetrazines can react with functionalised TCO in two orientations: head-to-head or head-
to-tail (Scheme 43). The click orientation favours a particular isomerisation pathway due to assisted H 
transfer from the vicinal carboxylic acid. It was shown that the head-to-head isomer preferentially 
forms the releasing isomer, whereas the head-to-tail isomer favours formation of the non-releasing 
isomer.[226] 
 
Scheme 43. Mechanistic studies of the TCO-tetrazine decaging reaction found that carboxylic acid-functionalised 
tetrazine 59 enhanced the rate of tautomerisation and drug release.  
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Following on from this, the group of van Kasteren reported a class of amino-ethyl functionalised 
tetrazines (62 and 64) that give rapid and pH independent release.[227] Under the biologically relevant 
pH range (pH 3.57.5), the amino ethyl group is protonated and can function as an intramolecular 
proton source, enhancing the rate of tautomerisation. In addition, it can also catalyse the elimination 
step through close proximity to either the dihydropyridazine or the carbamate (Scheme 44). It was 
demonstrated that the presence of an aminoethyl group leads to a 4-fold increase in elimination rate 
when compared to the carboxylic acid group and this can be increased a further 4.4-fold by the 
presence of EWGs.  
 
Scheme 44. Aminoethyl-functionalised tetrazines for rapid and pH independent elimination. 
 
 
1.3.6 Applications of TCO-tetrazine IEDDA decaging  
Mejia-Oneto reported a ‘catch and release’ strategy for controlled tissue-specific drug release from a 
TCO-carbamate-Dox (56) in vivo (Scheme 45).[228] This method involves installing a tetrazine-modified 
hydrogel at the site of the tumour in mice, followed by intravenous injection of prodrug 56 (75 times 
less active against HT1080 cells than doxorubicin (84)), which circulates around the body. When close 
to the hydrogel, the bioorthogonal reaction occurs (the ‘catch’ step), which traps and concentrates 
the prodrug at the site of the tumour. Tautomerisation and release of the active drug then occurs. This 
method was applied to mice bearing xenograft soft tissue sarcoma tumours and tumour remission 
occurred in 50% of cases, with fewer side effects observed compared to standard doxorubicin 
treatment. This approach has also been applied to the concentration and activation of systemically 
administered antibiotic prodrugs in vivo.[229] The presence of multiple tetrazines on the hydrogel 
enabled the activation of several doses of prodrug. However, since this method requires instalment 
of a hydrogel at the target site, it is mainly limited to the treatment of resectable tumours.  
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Scheme 45. Catch and release strategy for tissue-specific prodrug activation in vivo.  
In an alternative strategy, the Robillard group developed an ADC containing a bifunctional TCO linker 
(65) that enabled targeted drug release in mice (Scheme 46).[230] The TCO-carbamate prodrug was 
attached to an antibody via functionalisation of TCO with an activated succinimidyl ester. When 
reacted with a tetrazine ≈ 65% decaging was observed after 2 minutes in PBS, and ≈ 25% in mouse 
serum. Isomerisation of the trans-alkene in the TCO-carbamate prodrug occurs in biological systems 
due to the presence of copper ions. Importantly, this does not lead to off-target drug release. 
However, it limits the utility of the hydrogel approach as deactivation of the prodrug may occur before 
it can reach the tetrazine-modified hydrogel. On the other hand, the ADC displayed good stability in 
vivo with a half-life almost identical to the free antibody, due to steric hindrance preventing this 
deactivating isomerisation from occurring.[98] This highlights the fact that the ADC affects the stability 
and reactivity of the caging group. Importantly, when applied to a tumour xenograft in mice, the ADC 
showed excellent tumour uptake and reaction occurred with a radiolabelled tetrazine. It was shown 
that good levels of free doxorubicin were retained in the tumour, however it was not shown that this 
resulted in tumour shrinkage or increased survival of the mice. Although this was a huge breakthrough 
as the first example of ADC activation using metal-free bioorthogonal chemistry, there are still several 
factors which limit its widespread application, including the challenging 11-step synthesis (which 
requires a specialised UV-irradiation under flow).[230] 
 
Scheme 46. 1st generation ADC (65) containing a bifunctional TCO linker than can be cleaved upon reaction with 
a tetrazine to release the free drug. 
Following on from this, the Robillard group reported the first example of therapy using bioorthogonal 
decaging in tumour-bearing mice.[231] An ADC (66) consisting of a cytotoxic payload, monomethyl 
auristatin E (MMAE, 67), conjugated to the cysteine residues in a diabody via a bifunctional TCO linker, 
was developed for targeting non-internalising receptors (Scheme 47). Near-quantitative drug release 
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was achieved by the use of new tetrazine derivatives. It was found that installing a DOTA chelate on 
the tetrazine reduced the rate of clearance and, therefore, increased the decaging yield. It also 
enabled direct imaging of the tetrazine trigger, which was used to show that a good distribution 
occurred throughout the tumour. The ADC showed selective uptake in the tumour and fast blood 
clearance. Importantly, a potent therapeutic effect was observed in two mouse xenograft models. In 
the same models, an analogous ADC bearing the Val-Cit linker that is cleaved intracellularly by 
proteases failed to control tumour growth. This work expands the scope of ADCs to non-internalising 
receptors and, therefore, the range of solid tumours that can be treated using ADC therapy. It also 
highlights the potential of small molecule-triggered decaging reactions for therapeutics.  
 
Scheme 47. 2nd generation ADC (66) containing a bifunctional TCO linker. In vivo decaging resulted in tumour 
shrinkage. 
Recently, Robillard reported a reverse strategy in which TCO is used as the activator to trigger release 
from tetrazine methylene-carbamate linkers (Scheme 48).[232] Upon IEDDA cycloaddition, a 4,5-
dihydropyridazine is formed, which selectively tautomerises to the 2,5-isomer. This then undergoes 
1,4-elimination to release the amine. Previously, the reactivity of TCO was reduced due to the 
requirement of an allylic substituent bearing the payload.[224] Additionally, in a pretargeting strategy, 
the targeting moiety must be stable, which prevents the use of more reactive s-TCO derivatives. Since 
the trigger has a shorter exposure to in vivo conditions, the stability requirements are not as strict. 
Therefore, it was proposed that by using TCO as the trigger, the reaction rate could be increased 
through the use of more reactive TCOs (unsubstituted TCO (16) and s-TCO (17)).[232] Indeed, reaction 
in 25% MeCN/PBS with TCO (16) was 5 times faster (k2 = 287 M1 s1, for the cycloaddition) than 
tetrazine-triggered cleavage of a TCO-carbamate (k2 = 57.7 M1 s1By using s-TCO, a rate                           
(k2 = 23800 M1 s1) 3 orders of magnitude higher than the TCO-carbamate was achieved. However, 
the reaction displayed much slower release kinetics (t1/2 = 20 h in 25% MeCN/PBS and it was predicted 
to be complete in < 3h in aqueous conditions).  
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Scheme 48. TCO-triggered cleavage of tetrazine methylene-carbamate linkers.  
An ADC (69) containing a cleavable tetrazine linker was synthesised and reacted with TCO (16) or             
s-TCO (17) in PBS to give decaging yields of 90% and 63%, respectively (Scheme 49).[232] Treatment of 
the ADC with a DOTA-PEG-s-TCO conjugate in human colorectal cancer cells resulted in reinstation of 
the cytotoxicity upon release of 67. At low concentrations in PBS, 37 °C, the cycloaddition reaction of 
the Tz-ADC with DOTA-PEG-s-TCO was complete within 1 min, whereas under identical conditions, the 
previously reported reaction of TCO-ADC and DOTA-Tz had a half-life of 3 h. Pretargeting strategies 
often require a large excess of the activator. However, in this case the high rate of cycloaddition 
enables lower doses to be used. Finally, tetrazine linkers are easier to synthesise than TCO linkers, 
which makes this strategy more widely applicable. Tetrazine protecting groups hold great potential 
and may offer improved cycloaddition kinetics and ADC stability compared to TCO. 
 
Scheme 49. ADC containing a cleavable tetrazine linker that released the active drug 67 upon reaction with TCO.  
An alternative method for spatiotemporally controlled prodrug activation was achieved by using an 
enzyme, that is overexpressed in cancer cells, to trigger supramolecular self-assembly.[233] This 
resulted in accumulation of the tetrazine trigger inside cancer cells and when treated with a TCO-Dox 
prodrug (56), tumour inhibition in mice was achieved. In another example, image-guided prodrug 
activation has been achieved through the use of magnetic iron oxide NPs modified with both tetrazine 
and a fluorophore.[234] After fluorescent imaging to confirm accumulation of the NPs inside breast 
cancer cells, TCO-Dox prodrug 56 was added to trigger release of the active drug. Finally, a TCO-
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thiocarbamate has also been described for the release of carbonyl sulfide, which is converted to H2S 
by carbonic anhydrase.[235]  
The TCO-tetrazine reaction has also been utilised for controlling cell function, such as the chemically-
controlled activation of protected enzymes.[236,237] The activity of the enzyme was masked through 
genetic incorporation of TCO-caged lysine and it was then demonstrated that reaction with a tetrazine 
successfully restored the catalytic activity of the enzyme in mammalian cells[236,237] and mice.[237] In a 
second example, the controlled activation of T-cells was demonstrated both in vitro and in vivo.[238] 
Epitopes that are essential for T-cell activation were caged by modification of a key lysine residue with 
cis-CO, TCO or bifunctional TCO protecting groups. Upon addition of a tetrazine the free lysine was 
released from the TCO protecting groups, which enabled epitope recognition and T-cell activation. A 
bifunctional TCO protecting group containing an additional polar group resulted in the highest 
solubility and decaging yield. In another case, siRNA molecules were inactivated by conjugation to NPs 
through a bifunctional TCO linker.[239] After accumulation in cells, addition of a tetrazine resulted in 
linker cleavage and activation of siRNA, leading to RNA interference and gene silencing in cells. 
Alternative applications include cell-selective proteome labelling.[240] This is achieved by using an 
antibody-tetrazine conjugate to target specific cells, followed by addition of a TCO-protected 
nucleoside puromycin. Upon IEDDA decaging at the target site, the TCO protecting group is removed, 
enabling incorporation of puromycin into protein synthesis. In a heterogeneous cell mixture, labelling 
was only observed in cells expressing the antigen. The TCO-tetrazine reaction has also been applied 
to the High-Performance Liquid Chromatography (HPLC)-free synthesis of RNA.[241] This method 
incorporates a cleavable TCO linker in the final coupling step, enabling selective trapping of the 
product onto tetrazine-modified agarose after cleavage from the solid support. By using a tetrazine 
that results in slow elimination, all by-products can be filtered from the resin before the TCO group is 
cleaved to generate the desired product. 
 
 
1.3.7 Other tetrazine-triggered decaging reactions  
Other examples of tetrazine-mediated IEDDA decaging have been reported, for example, the vinyl 
ether-tetrazine reaction for the release of alcohols.[242–244] Our group applied this to the decaging of a 
vinyl ether-duocarmycin prodrug (70) in live cells (Scheme 50).[242] This reaction is considerably slower 
than the TCO-tetrazine reaction (k2 = 5.37 x 104 M1 s1 in 10% H2O/DMF for the cycloaddition step) 
and the RDS was shown to be the initial cycloaddition step, the opposite of the TCO-carbamate IEDDA 
reaction.[224] 
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Scheme 50. Tetrazine-triggered decaging of a vinyl ether-duocarmycin prodrug. 
The vinyl ether handle has also been connected to a self-immolative linker and applied to the 
tetrazine-triggered release of doxorubicin (48) via remote functional group activation followed by 1,6-
elimination (Scheme 51).[243] Although the reaction of 73 with tetrazines suffers from a slow reaction 
rate, it has expanded the scope of functional groups that can be used in bioorthogonal chemistry. 
Following on from this work, vinylboronic acids (75) showed a slight improvement in reaction rate       
(k2 = 3.3 x 103 M1 s1 in 25% PBS/MeOH) compared to vinyl ethers.[245] In this case, it is essential that 
the tetrazine contains substituents that can coordinate to boron (for example, pyridyl). 
 
Scheme 51. Tetrazine-triggered decaging of vinyl ether 73 and vinylboronic acid 75 self-immolative linkers to 
release doxorubicin (48). 
Tetrazines have also been used for the cleavage of a benzonorbornadiene protecting group from 
amines (Scheme 52). Although this reaction is also significantly slower than the TCO-carbamate 
reaction (k2 = 0.028 M1 s1 in 10% H2O/DMSO for the cycloaddition step), it offers other advantages, 
such as the simple synthesis of the benzonorbornadiene probes and the high stability of the probe 
under physiological conditions.[246]  
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Scheme 52. Benzonorbornadiene reaction with tetrazines for the release of primary amines. 
Recently, 3-isocyanopropyl (ICPr) protecting groups have been cleaved by reaction with tetrazine, 
resulting in the release of drugs containing amines (doxorubicin and mitomycin C), alcohols (SN-38) 
and thiols (mercaptopurine) in vitro (Scheme 53).[247] The isocyano group undergoes a [4+1] 
cycloaddition with the tetrazine to generate a pyrazole-imine intermediate which is then hydrolysed 
to a 3-oxypropyl species. β-elimination then occurs to release the molecule of interest and acrolein 
(77), a highly toxic compound, which may be a limitation of this reaction. Advantages include fast 
kinetics, near-quantitative yields and the synthetic ease of the protecting group. This reaction holds 
great potential as the isonitrile group is much smaller and more hydrophilic than TCO, potentially 
making it a more useful bioorthogonal handle. Tetrazine-modified beads were then implanted in 
zebrafish embryos and the release of mexiletine (a voltage-gated sodium channel blocker) was 
successfully shown to cause a decrease in heart rate.  
 
Scheme 53. Tetrazine-triggered decaging of isonitriles to release a free alcohol. 
The use of tetrazines as protecting groups has also been reported. In an early example, a pyridazine 
microRNA 21 inhibitor (80) was masked as a tetrazine (78) and reaction with a vinyl prodrug (79) of 
camptothecin (CPT, 81) resulted in dual drug release (Scheme 54).[248] An increased cytotoxic effect 
was observed in live cells compared to activation of either prodrug individually. 
 
Scheme 54. Prodrug-prodrug activation strategy for dual drug release.  
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Tetrazylmethyl (TzMe)-based protecting groups that react with isonitriles in near-quantitative yield to 
release amines and alcohols have also been reported (Scheme 55).[249] It was shown that reaction with 
other alkenes, such as TCO and cyclopropene, resulted in low release yields. By reacting a TzMe-
protected fluorescein with an ICPr-protected resorufin, the release of two fluorophores was achieved 
by a single bioorthogonal decaging reaction. Most reported examples of dual release rely on the use 
of two orthogonal reactions. However, this approach requires four reagents, which would be 
challenging in vivo. The ability to release two molecules from a single reaction is more useful and may 
enable the controlled release of synergistic drug combinations.  
 
Scheme 55. Dual release from a single bioorthogonal reaction between TzMe-groups and ICPr handles. 
In another example of tetrazines being used as protecting groups, Tz-Dox prodrugs were selectively 
decaged in mitochondria through the use of concentration-dependent chemistry.[250] The reaction 
involved tetrazine-cyclooctyne ligation, followed by lactonisation and elimination of the free drug 
(Scheme 56). This is a unique example that utilises rationally designed chemistry to remove a tetrazine 
protecting group from a drug. Both the Tz-prodrug (82) and the cyclooctyne trigger were connected 
to triphenylphosphonium (TPP), which is known to be enriched in mitochondria. In circulation, both 
reactants are present in low concentrations and no decaging occurs. After enrichment in the 
mitochondria, reactant concentration is enhanced and site-selective drug delivery occurs. Since this 
targeting approach relies on small molecules, it has the advantage of being able to target subcellular 
compartments.  
 
Scheme 56. Cyclooctyne-triggered removal of tetrazine protecting groups for activation of a doxorubicin 
prodrug. 
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1.3.8 Project aims 
The development of bioorthogonal decaging reactions has provided methods for site-specific drug 
release, which offer a greater degree of control compared to prodrug activation by endogenous 
factors. The IEDDA reaction demonstrates particularly high selectivity and fast kinetics and, for these 
reasons, it remains the bioorthogonal reaction of choice. Its in vivo application for the release of amine 
containing drugs has been described above and this highlights the therapeutic potential for 
bioorthogonal bond-cleavage chemistry. However, further work is required to make this strategy more 
widely applicable by increasing the number of targets, antibodies and payloads that can be used. In 
addition, the pharmacokinetics of the current bioorthogonal reactions need improving. Due to the 
need for the selective accumulation and reactivity of the two components at the desired tissue, the 
reagent stability, as well as the reaction kinetics and selectivity, must be extremely high. Additionally, 
the reagents should be easy to synthesise in order to enable the widespread use of the reaction. All 
approaches to date have some issues and therefore, the aim of this PhD was to investigate alternative 
mechanisms and approaches using the IEDDA reaction. 
Bioorthogonal decaging reactions have mainly been limited to the release of amines with some 
examples of alcohol release also reported. Although amines are common in small molecule drugs, they 
are not always present. In addition, the amine may not be vital for the function of the drug meaning 
that chemical modification at this site does not lead to reduced activity. In order to develop a broadly 
applicable prodrug activation strategy, the bioorthogonal toolkit needs to be extended to encompass 
a wider range of functional groups. The aim of this PhD was to extend the IEDDA reaction to the release 
of alcohol and carboxylic acid functional groups in order to increase the range of drugs that can be 
used in this strategy (Scheme 57). Chapter 2 will cover the application of the IEDDA reaction to the 
release of carboxylic acids and chapter 3 will cover the release of alcohols. 
 
Scheme 57. Project aims: to extend the IEDDA reaction to the release of alcohol and carboxylic acid functional 
groups.  
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Chapter 2 
 
Decaging TCO-esters for the release of carboxylic acids 
This chapter is based on the following publication and all figures are adapted from the published 
manuscript:  
Tetrazine-Triggered Release of Carboxylic-Acid-Containing Molecules for Activation of an Anti-
inflammatory Drug. Sarah Davies†, Luxi Qiao†, Bruno L. Oliveira, Claudio D. Navo, Gonzalo Jiménez-
Osés  and Gonçalo J. L. Bernardes. ChemBioChem, 2019, 20, 1541-1546.  
† These authors contributed equally. Density functional theory calculations were performed by 
Claudio Navo and Gonzalo Jiménez-Osés. 
 
2.1 Introduction 
Bioorthogonal decaging reactions have mainly been limited to the release of amine- or alcohol-
containing anticancer drugs. Although these groups are common in small molecule drugs, they are not 
always present and they may not be essential for the function of the drug. Therefore, we aimed to 
develop bioorthogonal decaging reactions for the release of non-steroidal anti-inflammatory drugs 
(NSAIDs), an important class of drugs that contain a carboxylic acid group essential for their activity. 
It was proposed that chemically masking the carboxylic acid as an ester would result in a prodrug and 
the activity could then be restored upon decaging of the ester. The IEDDA reaction between a tetrazine 
and an alkene was chosen as the decaging strategy due to its high selectivity and reaction rate. In this 
chapter, both the vinyl handle and TCO handle were investigated as potential protecting groups for 
carboxylic acids (Scheme 58). 
 
Scheme 58. Project aims: release of carboxylic acid-containing molecules from IEDDA tetrazine-triggered 
decaging of vinyl esters and TCO-esters.  
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In the course of this work, the release of carboxylic acids from TCO-esters was reported by the group 
of Robillard.[1] TCO-esters 83 and 85 were decaged in 25% acetonitrile/PBS to release model 
compounds benzoic acid (84) and 3-phenylpropionic acid (86) (Scheme 59). However, the reported 
TCO-protected carboxylic acids proved highly unstable (≈ 90% fragmentation in 50% mouse serum at 
37 °C). Therefore, no further studies of TCO-esters were reported.  
 
Scheme 59. Reported cleavage of TCO-esters to release model compounds containing carboxylic acids.[1]  
 
 
2.2 Vinyl esters 
2.2.1 Preliminary studies and reagent synthesis 
Initially, we investigated the protection of carboxylic acids with the vinyl handle. A model system was 
designed to confirm if the IEDDA reaction could be extended to the release of carboxylic acids from 
vinyl esters. Vinyl 3-phenylpropanoate (87) was synthesised in 46% yield from commercially available 
86 according to the procedure by Krejzová et al.[2] (Scheme 60).  
 
Scheme 60. Installation of the vinyl handle on model compound 86. 
Next the decaging of model compound 87 was attempted using the commercial DiPy-Tz (15), following 
the procedure by Jiménez-Moreno et al.[3] After 16 h, a 2:1 ratio of starting material:product was 
observed by 1H NMR. Carboxylic acid 86 and the pyrizidine side product (88) were isolated in 28% and 
31% yields, respectively (Scheme 61).  
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Scheme 61. Decaging of model compound 87 upon reaction with tetrazine 15.  
After confirming that carboxylic acids could be released from vinyl esters upon IEDDA reaction, several 
tetrazines were selected for further studies (Figure 7). The nature of the substituents on the tetrazine 
core affects the stability and solubility of the tetrazine, along with the rate of IEDDA reaction. As 
mentioned in the introduction, the rate of decaging of a TCO-carbamate was enhanced with 
asymmetric tetrazines containing both an EWG and a small alkyl group.[4] This is due to the fact that 
EWGs accelerate the cycloaddition step, whereas small, non-bulky groups increase the rate of the 
elimination step. Tetrazine 58 was chosen as it resulted in the fastest rate of decaging in cells with the 
analogous TCO-carbamate.[4] The less electron deficient tetrazine 89 was also selected in order to 
assess the effect of electron withdraw substituents on the tetrazine core. Another asymmetric 
tetrazine (89) bearing a H atom substituent was chosen to determine the effect of sterics. In addition, 
symmetrical tetrazines 15 and 91 were chosen for comparison. 15 is a commercially available, electron 
deficient tetrazine, whereas 91 has previously been shown to result in high release yields.[1] 
 
Figure 7. Tetrazines chosen for this study. 
Asymmetric tetrazines 58 and 89 were synthesised in 27% and 18% yields, respectively, according to 
the procedure by Fan et al.[4] (Scheme 62). Tetrazines 90 and 91 were prepared by other members of 
the Bernardes group (Ester Jiménez-Moreno and Russel Guo, respectively).  
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Scheme 62. Synthesis of asymmetric tetrazines 58 and 89.  
 
2.2.2 Kinetic and stability studies  
Next, the kinetics of decaging were assessed. Computational studies (carried out by our collaborators 
Claudio Navo and Gonzalo Jiménez-Osés at the University of La Rioja) on the reaction between vinyl 
acetate (94) and DiPy-Tz (15) predicted that the first cycloaddition step was rate determining       
(Figure 8).  
 
Figure 8. Minimum energy pathway for the reaction of vinyl acetate (94) with tetrazine 15 calculated with 
PCMH2O/M06-2X/6-31+G(d,p). The RDS is the cycloaddition step.  
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This was also confirmed by 1H NMR. The reaction between tetrazine 15 and 87 (4 equiv.) in  90% 
DMSO-D6/D2O was followed over time and no peaks were observed in the region 2.56 ppm that could 
be attributed to the intermediates (Figure 9). This supports the prediction that the cycloaddition is 
rate-limiting and, once it occurs, a fast elimination step affords the decaged product.  
 
Figure 9. 1H NMR studies to monitor the reaction of 87 with tetrazine 15. 
It was also predicted that the tetrazines should show similar reactivity, with the exception of DiMe-Tz 
(91) which was expected to be the least reactive (Table 2).  
Table 2. Theoretical relative reaction rates and observed experimental second order rate constants for the rate-
limiting cycloaddition step between vinyl acetate and tetrazines 15, 58, 89, 90, 91. n.d.= not determined. 
Tetrazine 
Theoretical relative  
reaction rate (M1 s1) 
Rate Constant, k2 
(M1 s1) 
R2 
15 1 (1.70 ± 0.05) x 104 0.9973 
58 0.2 (2.15 ± 0.62) x 104 0.9975 
89 0.6 (4.93 ± 0.17) x 105 0.9963 
90 0.1   (2.81 ± 0.05) x 104 
 
0.9990 
91 1 x 104 n.d. 
 
n.d. 
 
Initially we aimed to measure the overall rate of the reaction by following the release of the carboxylic 
acid. To that purpose we sought a carboxylic acid-containing fluorescent molecule whose fluorescence 
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is quenched (or shifted to a different wavelength) when it is caged. First, coumarin-3-carboxylic acid 
(95) was converted into vinyl ester 96 using the previously described palladium coupling[2] (Scheme 
63). The fluorescence of both the caged and free acid were then compared. However, unfortunately 
there was no quenching of the fluorescence (ex = 300 nm, em = 430 nm). This suggests that the 
carboxylic acid functional group does not contribute to the fluorescence, despite being directly 
conjugated to the fluorophore.  
 
Scheme 63. Synthesis of vinyl-protected coumarin 96. Converting the carboxylic acid to the vinyl ester did not 
quench the coumarin fluorescence. 
In another attempt, 7-hydroxycoumarin-3-carboxylic acid (100) was synthesised by formation of ester 
99 followed by base hydrolysis (Scheme 64). 
 
Scheme 64. Synthesis of 7-hydroxycoumarin-3-carboxylic acid (100). 
Next, reaction of 100 with vinyl acetate resulted in the doubly caged coumarin 101. Selective decaging 
of the alcohol group, using 4 M HCl produced vinyl-protected coumarin 102 (Scheme 65). 
 
Scheme 65. Synthesis of vinyl-protected coumarin 102.  
Subsequent  studies  of  the  fluorescent  properties  of  coumarin  102  showed  that  its  fluorescence 
(ex = 340 nm, em = 450 nm) was not quenched. However, it possesses an additional excitation 
wavelength (ex = 420 nm, em = 450 nm) that 100 does not have. This means it is possible to monitor 
the consumption of 102 by measuring the decrease in fluorescence at ex = 420 nm. However, it is not 
possible to detect formation of product 100 upon decaging. 
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Therefore, we decided to follow the kinetics by monitoring the decrease in absorption of the tetrazine 
in the visible region. This gives the rate of the IEDDA cycloaddition, which, as previously demonstrated, 
is the RDS. Therefore, since the subsequent steps are much faster, we can assume that the rate of the 
cycloaddition step is the same as the overall reaction rate. 
The kinetics of the cycloaddition were experimentally determined with these tetrazines and 
commercially available vinyl propionate (103) under pseudo-first order conditions (Scheme 66,     
Figure 10).  
 
Scheme 66. Reaction of tetrazines 15, 58, 89, 90, 91 (2 mM) with vinyl propionate (103, 150350 mM). 
Briefly, each tetrazine was reacted with an excess of vinyl propionate (75175 equiv.) in 30% H2O/DMF 
at 37 °C and the decrease in tetrazine absorbance at 530 nm was measured over 22 h (Figure 11). This 
experiment was performed by Luxi Qiao. The observed rate constants (kobs) were obtained by fitting 
the data to an exponential one-phase decay equation (Y = (Y0 – Plateau)e(kX) + Plateau). Finally, for 
each tetrazine, kobs was plotted against concentration of vinyl propionate (103) and the second order 
rate constant, k2, was found from the gradient (Figure 10, Table 3). The fastest rate occurred with 
tetrazine 90, a mono-substituted tetrazine bearing a moderately electron-withdrawing benzoic acid 
group.  
 
Figure 10. Kinetics of the cycloaddition step for the reaction of vinyl propionate with tetrazines 15, 58, 89, 90, 
91. K2 was obtained from the gradient of plots of kobs vs vinyl propionate concentration. Experiment performed 
by Luxi Qiao. 
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Figure 11. Plots of absorbance (530 nm) vs time for reaction of tetrazines 15, 58, 89, 90, 91 (2 mM) with vinyl 
propionate (150350 mM) in 30% H2O/DMF at 37 °C. The data were fitted to an exponential one-phase decay 
equation Y = (Y0 – Plateau)e(kX) + Plateau. Each measurement was repeated three different times. Experiment 
performed by Luxi Qiao. 
Next, the stability of tetrazines 15, 58, 89, 90, 91 was assessed in 50% DMSO/H2O by monitoring the 
UV absorbance at 530 nm (Figure 12). Tetrazine 15 showed moderate stability (t1/2 = 15.8 h) and 
tetrazine 58 was the most unstable (t1/2 = 5.7 h). Tetrazines 89–91 proved highly stable (≈ 8590% 
intact after 24 h).  
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Figure 12. Stability of tetrazines 15, 58, 89, 90, 91 in 50% DMSO/H2O. Decay of the UV absorbance of the 
tetrazines at 530 nm was followed over 24 h at 37 °C. The data for tetrazines 15 and 58 were fitted to an 
exponential one-phase decay equation Y = (Y0 – Plateau)e(kX) + Plateau. Each experiment was performed in 
triplicate and repeated two independent times.  
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The biological stability of tetrazine 90 was then assessed by Luxi Qiao and it proved to be stable in PBS 
pH 7.4, cell culture media (DMEM + 10% FBS) and 10% human plasma for at least 24 h (Figure 13). 
Therefore, tetrazine 90 was chosen for further studies. 
 
Figure 13. Stability of tetrazine 90 in PBS, DMEM + 10% FBS and 10% human plasma/PBS. Decay of the UV 
absorbance of the tetrazine at 530 nm was followed over 24 h at 37 °C. This experiment was performed by Luxi 
Qiao. 
After the initial studies on the model compounds, we next synthesised a vinyl-protected prodrug. 
Ketoprofen (105) is a NSAID with a chiral centre. Although it is used as a racemate, the anti-
inflammatory activity of ketoprofen mainly resides with the S-enantiomer. While the R-enantiomer is 
approximately 100 to 1000 times less potent than the S-enantiomer as a cyclooxygenase inhibitor, 
research has shown that the R-enantiomer is still important in that it contributes to the analgesic 
effect of ketoprofen.[5] We started by converting ketoprofen (105) into vinyl ester 106 using palladium 
coupling (Scheme 67).[2]  
 
Scheme 67. Synthesis of vinyl-protected ketoprofen (106). This experiment was performed by Luxi Qiao. 
The stability of vinyl ester 106 was then assessed using HPLC. It proved stable in PBS, however, limited 
stability was observed in 10% human plasma (t1/2 = 12 min) and DMEM + 10% FBS (t1/2 = 4 h, Figure 
14). This is likely because the vinyl group does not provide steric protection of the ester group from 
nucleophilic attack and subsequent hydrolysis. This fact, along with the slow rate of reaction 
(approximately 20% of free drug observed after 24 h with 30 equiv. of tetrazine, Figure 15) resulted 
in the vinyl handle being abandoned, as its use for in vivo applications would be rather limited.  
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Figure 14. Stability of vinyl-ketoprofen (106) in PBS, DMEM + 10% FBS, and 10% human plasma/PBS assessed by 
HPLC. This experiment was performed by Luxi Qiao. 
 
Figure 15. HPLC traces of decaging of vinyl-ketoprofen (106) upon reaction with 30 equiv. tetrazine 90. Traces 
shown at time 0 h and after 24 h of reaction. This experiment was performed by Luxi Qiao. 
 
 
2.3 TCO-esters 
2.3.1 Computational studies 
Next, we decided to investigate TCO as a caging group to render ketoprofen inactive. A more reactive 
alkene was necessary in order to make this a rapid, useful bioorthogonal cleavage reaction. Quantum 
mechanical calculations (carried out by our collaborators Claudio Navo and Gonzalo Jiménez-Osés at 
the University of La Rioja) suggested that the RDS depends on the nature of the tetrazine substituents. 
Hence, while the initial cycloaddition step is rate-limiting for DiMe-Tz (91, Figure 16), for DiPy-Tz (15) 
the allylic elimination step (decaging) is rate-limiting (Figure 17). Of note, the calculations reproduced 
the experimentally observed trend of axial-TCO being slightly more reactive than its equatorial isomer. 
Irrespective of which step determines the reaction rate, all reactions involving TCO acetate (107) were 
calculated to be much faster than those with vinyl acetate (94, Table 3). 
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Figure 16. Minimum energy pathway for the reaction of TCO 107ax (top, blue) and 107eq (bottom, orange) with 
tetrazine 91 calculated with PCMH2O/M06-2X/6-31+G(d,p). The RDS is the IEDDA cycloaddition step, the reaction 
being slightly more favorable for 107ax. Experiment performed by Claudio Navo and Gonzalo Jiménez-Osés. 
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Figure 17. Minimum energy pathway for the reaction of TCO 107ax (top, blue) and 107eq (bottom, orange) with 
tetrazine 15 calculated with PCMH2O/M06-2X/6-31+G(d,p). The RDS is the elimination of the acetate group, the 
reaction being slightly more favorable for 107ax. Experiment performed by Claudio Navo and Gonzalo Jiménez-
Osés. 
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Table 3. Activation barriers for the RDS of the reaction of vinyl acetate (94) and either the axial or the equatorial 
isomer of TCO acetate (107ax or 107eq) with either DiPy-Tz (15) or DiMe-Tz (91). 
 
Caging group Tetrazine ΔG‡ (kcal mol1) 
Vinyl DiPy-Tz (15) 26.6 
TCOax DiPy-Tz (15) 22.3 
TCOeq DiPy-Tz (15) 23.0 
Vinyl DiMe-Tz (91) 31.8 
TCOax DiMe-Tz (91) 20.6 
TCOeq DiMe-Tz (91) 21.1 
 
 
2.3.2 Synthesis of TCO-esters 
Based on the promising computational predictions, we started by synthesising a cis-CO-protected 
ester, in order to assess both the synthetic feasibility and the stability of the ester bond. First, cis-
cycloocten-1-ol (111) was synthesised according to the reported procedure (Scheme 68).[6] 
 
Scheme 68. Synthesis of cis-cycloocten-1-ol (111). 
Next, cis-CO-protected ketoprofen (113) was synthesised in 75% yield (Scheme 69) and, unlike the 
vinyl ester, proved to be stable in cell media, PBS pH 7.4, and 10% plasma (only 5% free drug was 
observed after 24 h, Figure 18). This study was performed by Luxi Qiao. 
 
Scheme 69. Synthesis of cis-cyclooctene-protected ketoprofen (113), by Luxi Qiao. 
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Figure 18. Stability of cis-cyclooctene-ketoprofen (113) in PBS, DMEM + 10% FBS and 10% human plasma/PBS 
assessed by HPLC by Luxi Qiao. 
We propose that this increase in stability is due to the increased steric hindrance at the ester bond 
due to the TCO handle compared with the vinyl handle. It appears that significant steric hindrance is 
required on both sides of the ester bond and the ester proves unstable if either the protecting group 
(vinyl handle) or the active molecule (in the case of the TCO-esters reported by Robillard)[1] are not 
sterically bulky. In the case of 113, a stereocentre α to the ester bond provides steric protection on 
one side, as does TCO on the other. 
With these results in hand, we decided to further evaluate the TCO-ester for bioorthogonal IEDDA 
decaging. When incorporating TCO into compounds, it is common to synthesise the cis-product and 
then convert this to the trans-isomer using photochemical isomerisation under flow.[7] The reaction 
mixture is irradiated with UV light, which causes isomerisation of the cis double bond. It is then 
pumped through a column containing silver nitrate-coated silica. The trans-isomer selectively binds to 
silver nitrate and is removed from the equilibrium, while the cis-isomer returns to the flask where it is 
isomerised again. When isomerisation is complete, the trans-isomer is obtained by extraction from 
the silica using ammonium hydroxide, followed by extraction into organic solvent. This results in two 
isomers of functionalised TCO (axial and equatorial), which it is not always possible to separate using 
column chromatography. This photochemical isomerisation method is very low yielding[1] and is not 
always suitable for the final step in syntheses that require a large amount of valuable drug. Ketoprofen 
contains a benzophenone group, which is a widely used photo-crosslinking reagent. This means that 
the usual photochemical isomerisation method is unsuitable for this compound.[8] Therefore, in both 
projects we decided to start from the commercially available trans-cyclooct-2-en-1-ol (TCO-OH, axial 
isomer, purchased from Sirius Fine Chemicals). Repeating the synthesis with trans-cyclooct-2-en-1-ol 
resulted in the desired product 114, with approximately 50% of the trans double bond isomerising to 
the cis-form (113, Scheme 70).  
 70 
Chapter 2: Decaging TCO-esters for the release of carboxylic acids  
 
Scheme 70. Synthesis of TCO-protected ketoprofen resulted in 84% yield of the product as a mixture of cis-(113) 
and trans-isomers (114) (NMR ratio 51:49 cis:trans). Experiment performed by Luxi Qiao.  
This highlights a common problem with synthesising TCO-functionalised molecules. The double bond 
in TCO is highly strained and therefore highly reactive, which makes it incompatible with several 
reaction conditions, such as the halide ions used in the formation of the acyl chloride intermediate. 
This can result in partial isomerisation to the cis-isomer, which is 7 orders of magnitude less reactive 
than the trans-isomer.[9] In addition to the modes of chirality on the cis- and trans-isomers of the TCO 
protecting group, ketoprofen also has a chiral centre. Indeed, using thionyl chloride as an activating 
agent we observed the formation of 8 diastereomers by HPLC (Figure 19) from the cis-and trans- 
isomers of TCO and the chiral centre of the protected ketoprofen.  
 
Figure 19. Separation of the 8 product diastereomers using chiral HPLC, by Luxi Qiao. 
Using chiral HPLC we were able to separate each diastereomer, analyse them by NMR and characterise 
the four trans-isomers as enantiomeric pairs of either the axial (114ax) or equatorial (114eq) isomer 
(Figure 20). Since the axial TCO-isomer has previously been shown to have different reaction rates 
than the equatorial isomer, each enantiomeric pair of axial and equatorial isomers were combined. 
Both the axial and equatorial isomers of the prodrug were tested in further experiments.  
We demonstrated a method of separating isomers of TCO and successfully overcame the 
isomerisation problem commonly experienced in syntheses using TCO, even in the challenging case of 
having an additional chiral centre in the drug. Now, although a low yield may be obtained, it is possible 
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to subject TCO to reaction conditions that readily cause isomerisation and still obtain the pure trans-
isomer.  
 
Figure 20. Alkene region from 1H NMR spectra of trans-isomers of TCO-ketoprofen (114), after separation by 
HPLC by Luxi Qiao. 
 
 
2.3.3 Studies of TCO-esters 
The reaction of TCO ketoprofen (114, axial and equatorial isomers) with various tetrazines in the 
presence of an internal standard (benzoic acid) was then studied by HPLC (Scheme 71). Considering 
the fast kinetics observed for the decaging, an excess of free TCO-OH was added to quench the 
reaction at various time points. Liquid Chromatography-Mass Spectrometry (LC-MS) analysis of the 
quenched solution showed similar reaction profiles and decaging yields for both isomers of 114 with 
tetrazine 90 (Figure 21). Therefore, other tetrazines were tested with only the axial isomer of 114.  
 
Scheme 71. Reaction of TCO-ketoprofen (114) with tetrazines 15, 58, 89, 90, 91 monitored by LC-MS. 
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 72 
Chapter 2: Decaging TCO-esters for the release of carboxylic acids  
 
Figure 21. Reaction of TCO-ketoprofen (114ax and 114eq) with tetrazine 90, monitored by LC-MS at 10 s, 30 s,  
2 min, 1 h and 3 h time points. Both axial and equatorial isomer showed similar reaction profiles and decaging 
yields (axial: 25%, equatorial: 24%).  
The reaction of TCO-ketoprofen (114ax) was then also studied with tetrazines 15, 89, and 91 (tetrazine 
58 was not chosen due to its high instability compared to other tetrazines, Figure 12). For tetrazines 
15, 89 and 90, TCO-ketoprofen (114ax) is consumed within 30 seconds and after 2 minutes the change 
in the amount of ketoprofen (105) is negligible (Figure 22), which is in good agreement with the low 
activation barriers predicted computationally. The observed accumulation of dihydropyridazine 
intermediate(s) A/B demonstrates our prediction (for tetrazine 15, Figure 17) that elimination of the 
carboxylate is the RDS. Also in agreement with computational predictions, tetrazine 91 showed a 
different reaction profile (Figure 22). In this case, no significant amount of long-lived intermediate was 
observed, indicating that the elimination is much quicker and therefore, for this tetrazine, it is the 
cycloaddition step which is rate-limiting. This is also confirmed by the much slower disappearance of 
TCO-ketoprofen (114ax) and the corresponding formation of ketoprofen (105), (incomplete after 2 
min). 
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Figure 22. Reaction of TCO-ketoprofen (114ax) and tetrazines 15, 89, 90, 91 monitored by LC-MS at 10 s, 30 s,   
2 min, 1 h and 3 h time points. For tetrazine 89 the product from the quenching reaction with TCO (not shown), 
has the same retention time as the pyridazine by-product.  
It is also important to note that the three tetrazines with the same RDS all show comparable decaging 
yields (≈ 25%, Figure 23). Interestingly, Tetrazine 91, which showed no reaction with vinyl ketoprofen, 
gives a decaging yield double that of the other tetrazines (54%). This highlights the fact that different 
tetrazines are optimal for different decaging reactions. 
ketoprofen (105)internal standard
pyridazine Intermediate A/B
TCO-ketoprofen (114ax)
2 min
Time (min)
30 s
10 s
1 h
3 h
DiMe-tetrazine (91)DiPy-tetrazine (15)
Time (min) Time (min)
MePy-tetrazine (89) BzOOH-tetrazine (90)
Time (min)
Product from TCO-quench
 74 
Chapter 2: Decaging TCO-esters for the release of carboxylic acids  
 
Figure 23. Decaging yields after 3 h assessed by HPLC with benzoic acid as an internal standard.  
Next, the effect of water content and pH on decaging yield were assessed. Tetrazine 89 was chosen 
as a representative example of tetrazines 15, 89 and 90. It was shown that the reaction yield increased 
from 26% (0% water) to 33% (75% water). However, no increase in yield was observed by the addition 
of 1% formic acid (Figure 24, Figure 25).  
 
Figure 24. Effect of water content and the addition of 1% formic acid on the decaging yield for reaction of 114ax 
with tetrazines 89 and 91, which both have a different RDS. * + 1% Formic acid. 
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Figure 25. Effect of water content and addition of 1% formic acid on the decaging reaction of TCO-ketoprofen 
(114ax) and tetrazine 89 monitored by LC-MS at 10 s, 30 s, 2 min, 1 h and 3 h time points. The product from the 
quenching reaction with TCO (not shown), has the same retention time as the pyridazine by-product.  
Conversely, tetrazine 91 showed no increase in yield upon increasing water concentration. However, 
the yield was increased to 65% by the addition of 1% formic acid (Figure 24, Figure 26). 
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Figure 26. Effect of water content and addition of 1% formic acid on the decaging reaction of TCO-ketoprofen 
(114ax) and tetrazine 91 monitored by LC-MS at 10 s, 30 s, 2 min, 1 h and 3 h time points.  
This study highlights the importance of optimising the tetrazine for each reaction, as the tetrazine 
substituents can alter the RDS of the reaction, resulting in different kinetics and yields of decaging.  
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2.3.4 Live cell studies 
The promising stability and decaging results prompted us to further evaluate the application of this 
strategy in live cell studies. Using the macrophage cell line RAW264.7 (ATCC® T1B-71), we started by 
establishing non-toxic concentrations of each compound. The toxicity of tetrazines 8991 were 
assessed using the CellTiter-Blue cell viability assay (Figure 27) and tetrazines 89 and 91 proved toxic 
to macrophages even at low concentrations (≈ 7080% viability at 5 μM). In addition, the volatility of 
tetrazine 91 made it impractical for use in cell experiments, despite this tetrazine resulting in a higher 
decaging yield by LC-MS. Further studies were carried out using tetrazine 90 as it proved to be non-
toxic at high concentrations (≈ 90% viability at 148 μM).  
 
Figure 27. Representative toxicity data in RAW264.7 cells (ATCC® T1B-71) for tetrazines 8991. Compounds were 
dissolved in DMSO and added to cells in technical triplicates. Final concentration of DMSO in each well was              
< 0.5%. The experiment was performed 3 independent times and similar results were obtained each time. 
Next, the toxicity of ketoprofen (105), TCO-ketoprofen (114ax and 114eq), and the bioorthogonal 
reactant pair (114 and 90) were assessed (Figure 28). Based on these results, a concentration of              
10 µM was chosen for further experiments.  
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Figure 28. Representative toxicity data in RAW264.7 cells (ATCC® T1B-71) for ketoprofen (105), equatorial-TCO-
ketoprofen (114eq), axial-TCO-ketoprofen (114ax), 114ax + 90, 114eq + 90. Compounds were dissolved in DMSO 
and added to cells in technical triplicates. Final concentration of DMSO in each well was < 0.5%. The experiment 
was performed 3 independent times and similar results were obtained each time. 
Next, the amount of lipopolysaccharide (LPS) required to induce inflammation was determined. An 
inflammatory response results in an increased level of nitric oxide (NO) which has a half-life of 6 s. 
Nitrite (NO2) is a stable, non-volatile, primary degradation product of NO. Therefore, NO production 
can be quantified by detection of nitrite using the Griess assay. This colorimetric assay utilises a 
mixture of reagents (115, 117) that, in the presence of nitrite, can form an azo dye (118), resulting in 
an increase in absorbance at 540 nm (Scheme 72).[10]  
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Scheme 72. Griess assay for the detection of nitrite ions. 
After assessing both cell viability (Figure 29) and concentration of NO produced using the Griess assay, 
(Figure 30), it was found that the optimal concentration of LPS was 0.5 µg/mL. This was the least toxic 
concentration that could be used whilst still achieving the maximum inflammatory effect.  
 
Figure 29. Representative toxicity data in RAW264.7 cells (ATCC® T1B-71) for LPS. The experiment was performed 
in technical triplicates (3 wells), 3 independent times and similar results were obtained each time. 
 
Figure 30. Representative concentration of NO produced in live macrophages upon addition of LPS. LPS was 
added to the cells in phenol red-free complete media. The optimal concentration of LPS was found to be 0.5 
μg/mL. The experiment was performed in technical triplicates (3 wells), 3 independent times and similar results 
were obtained each time. 
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Next, the anti-inflammatory effect of tetrazine 90 was assessed using the Griess assay (Figure 31). 
Surprisingly, the anti-inflammatory effect of tetrazines and their reactivity with nitric oxide was 
observed as previously described.[11] However, a concentration of tetrazine 90 (50 μM) was chosen 
such that no anti-inflammatory activity was observed. In fact, it was observed that the NO 
concentration was higher for 50 μM tetrazine 90 than the LPS control. This may be due to endotoxin 
contamination as this difference was not observed in later experiments (Figure 33 and Figure 37). 
 
Figure 31. Optimisation of the concentration of tetrazine 90 using the Griess assay. 50 μM of tetrazine was 
chosen for further studies as no anti-inflammatory activity was observed at this concentration.  The experiment 
was performed in technical triplicates (3 wells), 3 independent times and similar results were obtained each 
time. Representative data from 1 experiment is shown.  
After the optimal concentration of LPS and tetrazine 90 were found, the anti-inflammatory effect of 
the bioorthogonal pair (114ax/eq + 90) was assessed (Figure 32). RAW 264.7 cells were treated with 
LPS to induce an inflammatory response, then the compounds were added at non-toxic concentrations 
and the level of inflammation was assessed after 11 h. By using the Griess reagent to monitor the 
concentration of NO (Figure 33), we verified that when TCO-ketoprofen (114) was reacted with 
tetrazine 90 on LPS-stimulated macrophages a significantly enhanced anti-inflammatory effect was 
observed after 11 h (p < 0.001 for equatorial, p < 0.01 for axial). This reduction in inflammation 
corresponds to the successful cleavage of the TCO-ester bond from the caged drug leading to the 
release of ketoprofen. 
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Figure 32. Tetrazine-mediated prodrug activation in live cells. 
 
Figure 33. Griess assay used to determine the concentration of nitric oxide in the supernatant after incubation 
with compounds and LPS (0.5 μg/mL) for 11 h. Decaging of TCO-ketoprofen (114) resulted in decreased NO 
concentrations. The experiment was performed in technical triplicates (3 wells), 3 independent times and similar 
results were obtained each time. Representative data from 1 experiment is shown. ** (P ≤ 0.01), *** (P ≤ 0.001). 
During our studies, we also observed that ketoprofen itself failed to reduce the NO levels, whereas 
TCO-ketoprofen (114) has a moderate effect on reducing NO levels (Figure 33). This is likely due to the 
poor membrane permeability of ketoprofen when compared to the caged drug. When protected as 
the TCO-ester, the cell permeability of ketoprofen was greatly improved, leading to a higher 
concentration of free drug in the cell as assessed by HPLC (Figure 34). Briefly, this study involved 
incubation of cells for 24 h with either the prodrug (114) or free drug (105). Subsequent HPLC analysis 
of the extracellular media revealed that almost no prodrug was detected, whereas a significant 
amount of ketoprofen was still observed. This experiment was performed by Luxi Qiao. 
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Figure 34. Concentration of TCO-ketoprofen (114) and ketoprofen (105) present in the media after 24 h after 
incubation of RAW264.7 cells with 1 mM of either 114ax, 114eq or 105. The high presence of ketoprofen that 
remains in the media confirms the relatively poor membrane permeability of ketoprofen (105). Results are 
expressed as an average of three independent experiments. Experiment performed by Luxi Qiao. 
The incubation time before analysis of the supernatant using the Griess reagent was shown to be 
important. Compounds and LPS (0.5 μg/mL) were added to the cells and plates were incubated for 
either 5h, 11h or 24h before analysis. After 5 h (Figure 35) the concentration of NO in all wells was 
below or too close to the detection limit of the Griess assay (0.5 μM).  
 
Figure 35. Griess assay used to determine the concentration of NO in the supernatant after incubation with 
compounds and LPS (0.5 μg/mL) for 5 h. Final concentration of DMSO in each well was ≤ 0.125%. Results were 
below (or too close to) the detection limit of the Griess assay.  
After 11 h, a statistically significant reduction in NO was observed for the bioorthogonal pair compared 
to both the prodrug and tetrazine alone (Figure 33). However, after 24 h, the level of NO from the 
prodrug alone was the same as the bioorthogonal pair (Figure 36). While we expected the caged drug 
to show very little anti-inflammatory activity, this result suggested that activation might also happen 
without the tetrazine trigger.  
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Figure 36. Griess assay used to determine the concentration of NO in the supernatant after incubation with 
compounds and LPS (0.5 μg/mL) for 24 h. Final concentration of DMSO in each well was ≤ 0.125%. The difference 
between prodrug 114 and the bioorthogonal pair (114 + 90) was not statistically significant. *** (P ≤ 0.001). 
As previously mentioned, the ester bond was shown to be fully stable in complete cell culture media 
for 24 h at 37 °C. Therefore, this observation may be due to the hydrolytic enzymes inside the cell, 
which was confirmed by a reaction carried out with TCO-ketoprofen (114) and esterase from porcine 
liver (Scheme 73). This experiment was performed by Luxi Qiao. After 4 h, a small amount of 
ketoprofen was already released, and the amount increased over the next 20 hours to a yield of 71% 
for the axial isomer and 14% for the equatorial isomer. The release of carboxylic acids from ester 
prodrugs via intracellular esterases has been widely reported.[12–14]  
 
Scheme 73. Reaction of esterase from porcine liver with either the axial or equatorial isomer of TCO-ketoprofen 
(114). Yields were found by HPLC analysis. Experiment performed by Luxi Qiao. 
The levels of inflammation were then assessed using an enzyme-linked immunosorbent assay (ELISA) 
to monitor the levels of prostaglandin E2 (PGE2), which has been shown to be overexpressed in this 
cell line when inflammation is stimulated by LPS.[15] Briefly, this assay uses a monoclonal antibody that 
competitively binds both PGE2 in the samples and PGE2-alkaline phosphatase molecules. The alkaline 
phosphatase produces a chromogenic signal upon the addition of p-nitrophenyl phosphate. Therefore, 
the concentration of PGE2 present in a sample (Figure 37) is inversely proportional to the absorbance 
produced by the bound enzyme.  Cells with only LPS showed the highest level of PGE2 (4060 pg/mL), 
which confirmed that inflammation was successfully stimulated (Figure 37). A similarly high 
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concentration (4010 pg/mL) was observed with the tetrazine, confirming that the tetrazine alone does 
not have an anti-inflammatory effect. Despite the poor cell permeability of ketoprofen, cells incubated 
with ketoprofen (105) showed the lowest level of PGE2 (215 pg/mL). The anti-inflammatory effect of 
ketoprofen can be seen using this assay as the ELISA has a higher sensitivity than the Griess assay 
(detection limit 0.5 μM). TCO-ketoprofen (114) also showed lower levels of PGE2 than the LPS control 
(114ax: 686 pg/mL, 114eq: 486 pg/mL). The bioorthogonal pair resulted in a statistically significant 
reduction in PGE2 concentration compared to the prodrug alone (114ax + 90: 193 pg/mL, 114eq + 90: 
200 pg/mL) (p < 0.001 for axial, p < 0.01 for equatorial). It was observed that the concentration of 
PGE2 was the same for the bioorthogonal pair as for free ketoprofen, therefore confirming that the 
anti-inflammatory activity was successfully reinstated upon decaging in live macrophages. 
 
Figure 37. ELISA used to determine the concentration of PGE2. Results expressed as the concentration of PGE2 
in the sample. Decaging of TCO-ketoprofen (114) resulted in decreased concentrations of PGE2. The experiment 
was performed in technical triplicates (3 wells), 2 independent times and similar results were obtained each 
time. Representative data from 1 experiment is shown. ** (P ≤ 0.01), *** (P ≤ 0.001). 
2.4 Conclusion and future directions 
In summary, we have expanded the application of bioorthogonal cleavage reactions to the carboxylic 
acid functional group. Both vinyl and TCO handles were investigated for masking carboxylic acid 
groups and their cleavage by tetrazines via the IEDDA reaction was studied. Due to the unstrained 
nature of the vinyl handle, the reaction with tetrazine proved to be slow (complete after > 11h). In 
addition, vinyl-protected ketoprofen proved unstable in biological media, limiting the application of 
this reaction. On the other hand, TCO-protected ketoprofen proved highly stable, likely due to the 
increased steric protection around the ester bond. In addition, the reaction with tetrazines proved 
rapid (complete within 2 minutes) showing that this reaction may be suitable for in vivo applications.  
During the synthesis, we also demonstrated that it is possible to use chiral HPLC to separate the 
desired axial trans-isomer from a mixture containing the less reactive cis- and equatorial trans-
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isomers. This strategy is important as, under many reaction conditions, the trans double bond readily 
isomerises to form a mixture of diastereomers.  
By extending the IEDDA reaction to the release of carboxylic acids and demonstrating the application 
on anti-inflammatory drugs, we have expanded the bioorthogonal prodrug activation strategy to 
encompass a wider range of drugs and diseases. A stable TCO-protected NSAID was successfully 
decaged in live macrophages, enabling the reinstatement of the anti-inflammatory activity. Near 
spontaneous release of the active drug after administration of the tetrazine trigger suggests that this 
strategy may hold in vivo potential.  
We anticipate that antibodies could be used to target the bioorthogonal handles to extracellular 
receptors expressed on macrophages (e.g. CD204).[16] For example, an antibody-tetrazine conjugate 
could be used as the targeting agent. However, this would still result in off-target drug release due to 
the high cell permeability and non-specific intracellular enzymatic cleavage of the prodrug. In addition, 
the TCO prodrug would likely be unstable in vivo due to isomerisation of the trans double bond by Cu 
ions.[17] On the other hand, these problems could be avoided by conjugating the antibody to the 
prodrug. An ADC containing a bifunctional TCO linker[18] would prevent isomerisation of TCO (due to 
increased steric hindrance around the double bond) and stop the prodrug from entering cells. In a 
pretargeting strategy, after administration and localisation of the ADC at the target site, injection of 
the tetrazine trigger would result in extracellular drug release, which could then be internalised by 
target cells (Scheme 74). This approach would allow the fast and local delivery of ketoprofen at sites 
of inflammation. 
 
Scheme 74. Localised drug release at sites of inflammation through a pretargeting strategy.  
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Chapter 3 
 
Development of a self-immolative linker for the release of 
alcohols 
This chapter is based on the following publication and all figures are adapted from the published 
manuscript:  
Development of a self-immolative linker for tetrazine-triggered release of alcohols in cells. Sarah 
Davies, Bruno L. Oliveira, and Gonçalo J. L. Bernardes. Org. Biomol. Chem., 2019, 17, 5725-5730.  
 
3.1 Introduction  
Despite the large number of drugs that contain a hydroxyl group,[1] few bioorthogonal decaging 
reactions for the release of alcohols have been reported. Therefore, methods for fast decaging of 
protected alcohols would greatly expand the scope of drugs that can be used for in vivo prodrug 
activation. The aim of this chapter was to develop rapid decaging methods to release alcohols through 
the use of the tetrazine-TCO reaction. Since TCO is a highly reactive, strained alkene, we envisaged 
that TCO-protected alcohols would exhibit faster alcohol release than the previously reported vinyl 
ethers and would, therefore, provide a more useful strategy for in vivo applications. Here we describe 
the design, synthesis and decaging studies of several TCO-based linkers for masking alcohol 
functionality: TCO-carbonates, TCO-ethers and TCO-carbamate benzyl ethers (Scheme 75). 
 
Scheme 75. Project aims: tetrazine-triggered release of alcohol-containing molecules from TCO-carbonates, 
TCO-ethers and TCO-carbamate benzyl ethers. 
In the course of this work, additional methods for alcohol release from isonitrile[2] and TCO[3] based 
protecting groups were reported. Robillard reported that the TCO handle could be cleaved from 
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carbonates and ethers to release alcohol-containing molecules (Scheme 76).[3] The reported approach 
requires synthesis of the cis-cyclooctene ether followed by photochemical isomerisation to the trans-
isomer. This final isomerisation step is very low yielding (3–12% after 1.3–7 days under flow) and 
requires a specialised flow set-up. Although this route is achievable on the reported model 
compounds, it is not always feasible to obtain such a large quantity of cis-product, particularly if this 
reaction is to gain more widespread use in the area of drug activation. In addition, the synthesis of the 
ether bond is challenging and attempts to form the ether bond from TCO-OH resulted in isomerisation 
to the cis-form.[3]  
 
Scheme 76. Tetrazine-triggered release of alcohols from TCO-ethers and TCO-carbonates that were reported by 
the group of Robillard in the course of this work.[3] 
 
 
3.2 Carbonate linker 
Initially, taking inspiration from the reported TCO-carbamate linker, we proposed an analogous 
carbonate linker for the release of alcohols. Fluorescent compound 7-hydroxycoumarin (122) was 
chosen as the molecule of interest to enable both the kinetics of release and the stability of the linker 
to be easily assessed by fluorescence. Model compound 123 was synthesised by activation of TCO-OH 
(119) with para-nitrochloroformate (120) followed by reaction with 7-hydroxycoumarin (7-HC, 122, 
Scheme 77).  
 
Scheme 77. Synthesis of carbonate 123. 
Next, the reaction of model compound 123 with tetrazine 58 in 50% DMSO/H2O at 30 °C was studied 
under second-order conditions by measuring the fluorescence intensity (FI, λex = 325 nm,                          
λem = 460 nm, Scheme 78). Tetrazine 58 was chosen for this study as it gave the fastest rate of decaging 
in cells with the analogous TCO-carbamate.[4] 
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Scheme 78. Tetrazine-triggered release of 7-hydroxycoumarin (122) from carbonate 123. 
The increase in coumarin fluorescence was complete within 90 minutes (t1/2 = 19 min, Figure 38). This 
rate of release is a similar order of magnitude to, but slower than, the release of doxorubicin from the 
carbamate linker (complete within 16 min).[5] Importantly it was significantly faster than the previously 
reported vinyl ether decaging [with 350-fold excess of vinyl ether, the fastest tetrazine had a pseudo 
first-order rate constant (kobs) of approximately 2 x 104 s1 that corresponds to a half-life of 58 min].[1]  
 
Figure 38. Release of 7-hydroxycoumarin (122) in 50% H2O/DMSO at 30 °C monitored by following the increase 
in fluorescence (λex = 325, λem = 460 nm).  
However, carbonate 123 proved to be highly unstable in 20% human plasma (t1/2 = 5 min) and cell 
media (DMEM + 10% FBS, t1/2 = 45 min) and presented moderate stability in PBS (t1/2 = 193 min, Figure 
39), which prevents its application in biological systems. This result was consistent with the work of 
Robillard who recently reported a TCO-carbonate linker and showed that it underwent 100% 
fragmentation after 5 h in 50% mouse serum at 37 °C.[3]  
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Figure 39. Stability of carbonate 123 in PBS, complete cell culture media (DMEM + 10% FBS) and 20% human 
plasma/PBS, followed by the increase in fluorescence (λex = 325, λem = 460 nm). Data points and error bars shown. 
Importantly, carbonate 123 was shown to be stable in 50% H2O/DMSO over the time period of the 
decaging reaction (Figure 40).  
 
Figure 40. Stability of carbonate 123 in 50% H2O/DMSO at 30 °C monitored by following the increase in 
fluorescence (λex = 325, λem = 460 nm) at the same time as the decaging reaction of 123 + 58. 
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3.3 Ether linker  
Due to the limited stability of the carbonate linker, a new TCO-ether linker was proposed that was 
expected to be more stable. The envisaged decaging mechanism for this reaction is depicted in 
Scheme 79.[6]  
 
Scheme 79. Proposed mechanism of decaging of the TCO-ether linker.  
We decided to use cis-cycloocten-1-ol (111) to establish a synthetic route to the TCO-ether linker. Not 
only does this avoid using the more expensive trans-isomer, it also allows us to assess whether late 
stage isomerisation to the trans-isomer is possible. Originally we planned to form the ether bond by 
converting cis-cyclooct-2-en-1-ol (111) into either mesylate 125 or tosylate 126 and reacting this with 
4-hydroxybenzaldehyde (Scheme 80). We envisaged that either an SN2 or SN2’ reaction could occur 
and both would result in desired product 127. However, both the mesylation and tosylation were 
unsuccessful and no reaction occurred after 24 h in either case.  
 
Scheme 80. Attempts to form the mesylate (125) or tosylate (126) of cis-cycloocten-1-ol (111) were 
unsuccessful. 
A second route was then proposed, in which we planned to introduce the ether bond via a mitsunobu 
reaction with 4-hydroxybenzaldehyde (128, Scheme 81). The desired ether product 127 was obtained 
in 44% yield (50 mg) on a 0.5 mmol scale. However, the reaction is not scalable as only 2% yield was 
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obtained when the reaction was repeated on a 1.9 mmol scale. This step was then followed by 
reduction of the aldehyde with NaBH4 which resulted in 129 in 50% yield. After this, attempts were 
made to convert the hydroxyl group into a suitable leaving group. However, attempts to form the 
tosylate and bromide proved unsuccessful. Formation of chloride 130 was achieved using 
methanesulfonyl chloride and this was then reacted with 7-hydroxycoumarin (122) to give 131 in 8% 
yield over 2 steps. Isomerisation of cis-compound 131 was then attempted, however this resulted in 
loss of alkene peaks in the 1H NMR spectrum, indicating that this compound is unstable to the UV 
radiation that is required for isomerisation. The final 3 steps of this synthesis were carried out by Dr 
Bruno Oliveira.  
 
Scheme 81. Synthetic route to ether linker 124.  
Since it was not possible to isomerise the double bond in the last step, we decided to try isomerisation 
of the different intermediates. The stability of both alcohol 129 and chloride 130 to UV radiation was 
assessed in deuterated chloroform in a quartz cuvette using 2 penray lamps. 1H NMR analysis showed 
that no alkene peaks were present after irradiation for 2 h (Table 4, Entries 1 and 2). Originally 
deuterated chloroform was chosen as the solvent in order to facilitate monitoring the reaction by 1H 
NMR. However, it is possible that irradiation of CDCl3 results in chloride radicals which can react with 
the double bond. Therefore, in a second attempt, alcohol 129 was irradiated in 50% ether/hexane and 
alkene peaks were still present by 1H NMR after 2 h (Table 4, Entry 3). Alcohol 129 was expected to 
be more stable to UV irradiation than 130 since chloride is a better leaving group than hydroxide. 
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Table 4. Assessing the stability of intermediates 129 and 130 after irradiation at 254 nm for 2 h by observing 
whether the alkene is still present by 1H NMR. 
Entry Compound Solvent Alkene peaks present by 1H NMR 
1 129 CDCl3 No 
2 130 CDCl3 No 
3 129 Et2O/hexane yes 
 
The promising stability of the alkene in 129 to UV radiation prompted us to attempt the isomerisation 
of 129. Alcohol 129 was irradiated for 6 h at 254 nm and every 30 min the reaction mixture was passed 
through a column of silver nitrate coated silica, which should selectively bind the trans-isomer[7] 
(Scheme 82). The silica was then dried and extracted with ammonium hydroxide, however, no trans-
product was isolated. 15% of the cis-starting material was recovered from the washings of the column.  
 
Scheme 82. Attempted isomerisation of 129. 
The isomerisation of cis-cyclooctenol (111) is low yielding and it seems it is even less efficient if the 
alcohol is functionalised. Indeed, Robillard required 5.5 grams of starting material 133 to give 144 mg 
(2.6%) of trans-product 134 after 7 days of isomerisation under flow (Scheme 83).[3]  
 
Scheme 83. Reported isomerisation of ether 133 required grams of starting material and resulted in very low 
yields of product 134.[3]  
Since the first step of this synthetic route is an unscalable mitsunobu reaction, it would be impractical 
to obtain gram quantities of the cis-ether. Therefore, we decided it was best to start with the trans-
isomer of TCO-OH. However, unfortunately the mitsunobu reaction with TCO-OH (119) only resulted 
in the cis-isomer of the product (127, Scheme 84).  
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Scheme 84. Repeating the mitsunobu reaction with TCO-OH (119) resulted in complete isomerisation to the cis-
product 127. 
Since the trans double bond in TCO is unstable to mitsunobu conditions and the late stage 
isomerisation of the cis double bond is not feasible, we decided not to pursue this route. An alternative 
linker was proposed which does not contain the synthetically challenging TCO-ether bond. 
 
 
3.4 Carbamate benzyl ether linker 
Next, we designed an alternative linker in which TCO is connected to a self-immolative benzyl ether 
linker through a carbamate (Scheme 85). This carbamate was expected to eliminate CO2 and the free 
amine of the self-immolative linker, which can then undergo 1,6-elimination to release the free 
alcohol. In addition, use of the proposed TCO-carbamate benzyl ether linker for decaging should 
address the instability of the carbonate linker.  
 
Scheme 85. Proposed mechanism of alcohol release from the TCO-carbamate benzyl ether linker. 
Initially, we proposed a synthetic route which involved attaching the molecule of interest in the final 
step (Scheme 86). This minimises the amount of payload required, which is an important consideration 
when the molecule of interest is an expensive drug. Another reason we chose to attach the payload 
in the final step is that drugs often contain other functional groups that are incompatible with further 
synthetic steps. First, 4-aminobenzyl alcohol (136) was reacted with tert-butyl dimethylsilyl chloride 
(TBSCl) to give 137 in 77% yield. This was followed by reaction with triphosgene to generate isocyanate 
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138 and then reaction with TCO-OH to give desired carbamate 139 (10% yield over 2 steps). This yield 
is comparable to the previously reported one-step reaction of TCO-OH with commercial benzyl 
isocyanate, which gave yields of 2137% with reaction times of  3 days.[5,8] 
After this, TBS deprotection resulted in 140 with no observable isomerisation of the double bond. 
However, in the following bromination step with PBr3, the double bond isomerised to give bromide 
141 as 70% cis-isomer. Isomerisation occurred after 5 min at 0 °C and no further isomerisation 
occurred after the reaction was left for 12 h. This highlights the difficulty of synthesis involving TCO 
because the double bond is highly unstable and readily isomerises. This behaviour interferes with the 
decaging kinetics because the cis-isomer is 7 orders of magnitude less reactive towards tetrazines than 
the trans-isomer.[9] It was not possible to separate the cis- and trans-isomers of the bromide (owing 
to its instability on silica), so the mixture of isomers was used in the subsequent step.  
 
Scheme 86. First synthetic route to the synthesis of TCO-coumarin (142), in which the molecule of interest is 
attached in the final step. The product was obtained as a 7:3 mixture of cis:trans-isomers.  
Reaction with 7-hydroxycoumarin (122) and caesium carbonate gave 3 mg of final product 142 as a 
7:3 mixture of cis:trans-isomers. This corresponds to a yield of 5% over 3 steps. It has been reported 
that the trans-isomer selectively binds to AgNO3-impregnated silica and this is used to separate the 
trans-isomer during the photochemical synthesis of TCO-OH.[10] However, attempts to separate the 
isomers of 142 by trapping onto AgNO3-coated silica were unsuccessful. Interestingly, the product 
mixture is stable to further isomerisation for 3 weeks in CDCl3 at room temperature (Figure 41).  
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Figure 41. Alkene region of the 1H NMR spectra of product 142 obtained as a 7:3 mixture of cis:trans-isomers. 
The NMR sample was left in CDCl3 in light at rt and no further isomerisation occurred after 3 weeks.  
With these results in hand we decided that this route was not synthetically useful since it required the 
use of a large amount of expensive TCO-OH to give the final compound in low yield, predominantly as 
the less active cis-isomer, which would then require separation by chiral HPLC.[11]  
Therefore, we next attempted to attach TCO-OH in the final step. In this route, 4-aminobenzyl alcohol 
(136) was first protected with a tert-butyloxycarbonyl (Boc) group to give 143 in 96% yield (Scheme 
87). Reaction with PBr3 resulted in bromide 144, which was subsequently reacted with 7-
hydroxycoumarin (122) and caesium carbonate to give 145 in 20% yield over 2 steps. Next, Boc 
deprotection was attempted using bromotrimethylsilane (TMSBr), which is known to be compatible 
with coumarins.[12] We were worried that stronger acidic conditions would hydrolyse the coumarin 
lactone bond. Unfortunately, after removal of the Boc group, the self-immolative linker can undergo 
1,6-elimination and although complete consumption of 145 occurred, no free aniline 146 was 
detected and coumarin 122 was observed by 1H NMR.  
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Scheme 87. Second synthetic route to the synthesis of TCO-coumarin (142), in which TCO is attached in the final 
step. Removal of the Boc protecting group resulted in an unstable aniline intermediate.  
Next, an attempt was made to generate isocyanate 147 directly from 145 without isolating the free 
aniline intermediate 146 (Scheme 88). However, reaction with 2-chloropyridine and trifluoromethane 
sulfonic anhydride following the method by Spyropoulos et al.[13] proved unsuccessful. In another 
attempt, 145 was heated in a solution of triphosgene. It was proposed that the Boc group was 
thermally unstable and that, due to the high reactivity of triphosgene, aniline 146 would react rapidly 
before elimination could occur. However, no reaction occurred.  
 
Scheme 88. Attempts to form isocyanate 147 directly from Boc protected 145. 
It was then found that isocyanates can be formed directly from anilinium chloride salts.[14] Therefore, 
the deprotection of 145 was then carried out using HCl (4 M in dioxane, Scheme 89). Upon completion 
of the reaction, removal of the solvent resulted in the anilinium chloride salt 148, which was then 
reacted with triphosgene to give isocyanate 147.[14] The formation of the anilinium chloride salt proved 
crucial to prevent elimination and generate the isocyanate from the Boc-protected amine, which may 
be a useful strategy in self-immolative linker synthesis.  
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Scheme 89. Final synthetic route to the synthesis of TCO-coumarin (142), in which TCO is attached in the final 
step. Formation of isocyanate 147 from Boc protected 145 via the anilinium chloride salt 148 proved crucial to 
prevent elimination.  
Finally, isocyanate 147 was reacted with TCO-OH. Dibutyltin dilaurate, a catalyst commonly used for 
isocyanate reactions, caused isomerisation of TCO (observed by TLC). However, by using 1,4-
diazabicyclo[2.2.2]octane (DABCO) as a catalyst, final compound 142 was obtained in 8% yield over 3 
steps. Again, although this yield is fairly low, it is similar to previous reactions of TCO-OH with 
isocyanates[5,8] and is an improvement on the one-step photochemical isomerisation (312% after 
1.3–7 days under flow).[3] In addition, it does not require the alcohol in gram-scale, which is essential 
when working with expensive drug payloads. Importantly, the product was obtained entirely as the 
axial, trans-isomer.  
 
 
3.5 Prodrug synthesis 
Next, the developed route was applied to the synthesis of prodrugs. As previously mentioned, drugs 
often contain several reactive functional groups and, for this reason, it is common to attach the drug 
in the final synthetic step. However, in our optimised synthetic route it was essential to attach TCO in 
the final step in order to avoid isomerisation. This meant that it was necessary to attach the drug at 
an earlier stage. Therefore, we selected alcohol-containing drugs with little other functionality, in 
order to minimise problems of functional group tolerance during the synthesis: triclosan (TCS, 149, an 
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antibacterial drug) and camptothecin (81, an anticancer, topoisomerase I inhibitor, Figure 42). 
Attempts to conjugate more structurally complex drugs to TCO were unsuccessful, as the presence of 
additional functional groups in the drug made it incompatible with the final steps of the synthesis.  
 
Figure 42. Alcohol-containing drugs triclosan (149) and camptothecin (81) were selected for prodrug synthesis 
due to their lack of other reactive functional groups.  
Prodrug 153 was synthesised according to the previously reported protocol (Scheme 90). Reaction of 
bromide 144 with triclosan (149) gave 150 in 56% yield and conversion of 150 to 153 in the final 3 
steps was achieved in 18% yield. Again, the product was obtained as 100% the axial, trans-isomer.  
 
Scheme 90. Synthesis of TCO-protected triclosan (153).  
Finally, the synthetic route was attempted using camptothecin. Reaction of camptothecin (81) with 
bromide 144 resulted in 49% of desired product 154 (Scheme 91). 
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Scheme 91. Conjugation of camptothecin (81) with bromide 144.  
However, 154 proved highly unstable and after storage at -20 °C overnight, a significant reduction in 
the intensity of peaks corresponding to the linker (4.65 ppm: CH2, 6.48 ppm: NH, 7.33 ppm: Ar-H) was 
observed by 1H NMR (Figure 43). Therefore, this route was not viable for this compound.  
 
Figure 43. Section of the 1H NMR spectra of 154 immediately after purification compared to after storage 
overnight at -20 °C. After storage, the peaks corresponding to the linker showed a significant reduction in 
intensity (4.65 ppm: CH2, 6.48 ppm: NH, 7.33 ppm: Ar-H) and the remaining peaks correspond to         
camptothecin (81).  
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3.6 Kinetic and stability studies 
The kinetics and stability of the TCO-carbamate benzyl ether linker were then assessed using model 
coumarin compound 142. The stability of 142 was evaluated by monitoring the fluorescence intensity 
(λex = 325 nm, λem = 460 nm) over 15 h. The compound proved to be stable for 15 h in PBS, complete 
cell culture media (DMEM + 10% FBS), Lysogeny broth (LB) media and 20% human plasma/H2O, with 
no increase in fluorescence observed (Figure 44).  
 
Figure 44. Stability of TCO-coumarin (142) in PBS, complete cell culture media (DMEM + 10% FBS), LB media and 
20% human plasma/H2O. Assessed by monitoring the fluorescence intensity (λex = 325 nm, λem = 460 nm) over 
15 h.  
Before studying the reaction of 142 with tetrazines, quantitative NMR (qNMR) with benzoic acid as an 
external standard was used to accurately determine the concentration of stock solutions of each 
reagent (Figure 45). Briefly, a sealed capillary tube containing 10 mM benzoic acid in DMSO-D6 was 
calibrated against stock solutions of 7-hydroxycoumarin (122) at known concentrations (26.55.4 mM 
prepared by accurate dilution based on solvent weight). The 1H NMR spectra was recorded twice for 
each sample and the integration ratio of coumarin:benzoic acid was plotted against concentration. 
Importantly the relationship between concentration and integration ratio was shown to be solvent 
dependent. After calibration of the external standard, the capillary was added to NMR tubes 
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containing stock solutions of compounds and the ratio of integration (compound:benzoic acid 
standard) was measured. This was then converted to concentration using the fitting on the 
appropriate graph. This method was essential as < 10 mg of model compound 142 was synthesised 
and therefore, the mass balance error would be high. It is important to know accurate reagent 
concentrations for the determination of reaction rates using second-order kinetics, in which the 
reagents must be equimolar. qNMR can also be used to determine the concentration of saturated 
solutions, which is useful for compounds of low solubility (eg. tetrazine 15).  
 
Figure 45. Quantitative NMR (qNMR) with benzoic acid as an external standard was used in order to accurately 
determine the concentration of stock solutions of each reagent. Calibration graphs of 1H NMR integration ratios 
of coumarin:benzoic acid peaks vs coumarin concentration were plotted in two different solvent systems.  
With exact concentrations of the stock solutions determined, we next studied the reaction of model 
compound 142 with tetrazines 15, 58, 89, 90, 91, 155 (Scheme 92). In addition to the tetrazines studied 
in chapter 2, tetrazine 155, bearing an amine group, was chosen (Figure 46). 
 
Scheme 92. Reaction of model compound 142 with tetrazines 15, 58, 89, 90, 91, 155.  
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Figure 46. Structures of tetrazines chosen for studies with TCO-coumarin (142). 
The reactants were mixed in a 1:1 ratio in 50% H2O/DMSO and the reaction mixture was analysed after 
24 h by HPLC. Concentration of the released coumarin was determined using a calibration curve with 
known concentrations of coumarin and internal standard (Figure 47). Briefly, mixtures of 122 at known 
concentrations (0.20.83 mM) and internal standard benzoic acid (0.67 mM) were analysed by 
HPLC/UV and the ratio of areas of the UV peaks at 220 nm were plotted against concentration of 122. 
 
Figure 47. Calibration curve for the detection of 7-hydroxycoumarin (122) by HPLC. 
The highest decaging yield (39%) was observed with tetrazine 90. 15 and 155 showed particularly low 
yields (< 10%) whereas 91, 89 and 58 resulted in yields of 22%, 25% and 32%, respectively (Figure 48). 
 
Figure 48. Decaging yield of the reaction of TCO-coumarin (142) with tetrazines after 24 h, assessed by HPLC/UV.  
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For this reason, along with its higher stability relative to other tetrazines (Figure 49), tetrazine 90 was 
chosen for subsequent studies.  
 
Figure 49. Stability of tetrazines 15, 58, 89, 90, 91, 155 in 50% H2O/DMSO assessed by monitoring the absorbance 
at 530 nm. Data for tetrazines 15, 58, 89, 90, 91 was previously shown in Chapter 2.  
It should be mentioned that decaging yields are often obtained from monitoring the fluorescence 
intensity and comparing it to the maximum obtained after complete decaging of the protected 
fluorophore.[4] However, in our case we found that the reaction mixture can quench the coumarin 
fluorescence and therefore obtaining a yield by this method is unreliable. Briefly, an aliquot of the 
reaction mixture of TCO-coumarin (142) + tetrazine 90 was added to a sample of 7-hydroxycoumarin 
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(122) at various time points and the fluorescence intensity was recorded and compared to the 
fluorescence intensity of 122 alone (Figure 50).  
 
Figure 50. Quenching effect of the reaction mixture on the fluorescence of 122 in 50% H2O/DMSO.  
The kinetics of the reaction of 142 with tetrazine 90 (addition step) were then assessed by monitoring 
the decrease of the tetrazine absorbance at 530 nm using stopped-flow spectrometry. A calibration 
graph was obtained by plotting the absorbance at 530 nm for known concentrations of tetrazine 90 
(0.151 mM) against concentration (Figure 51). 
 
Figure 51. Stopped-flow calibration curve of tetrazine 90. 
142 and tetrazine 90 were then mixed in a 1:1 ratio and the absorbance at 530 nm was monitored and 
converted into concentration using the calibration graph. The second-order rate constant was found 
to be 96.4 ± 12.3 M1 s1 (t1/2 = 7 s) in DMSO (Figure 52).  
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Figure 52. Rate of consumption of tetrazine upon reaction of 142 with 90, determined by following the decrease 
in absorbance (λ = 530 nm) by stopped-flow. 
In addition, the rate of decaging was determined by following the increase in fluorescence over time 
(Figure 53). These studies revealed that the release of coumarin 122 was complete within 120 minutes 
(t1/2 = 27 min), which is faster than the previously reported vinyl ether[1] and similar to the release from 
the TCO-ether reported by Robillard (initial release is complete within 30 min and an additional 10% 
release occurs after 20 h).[3]  
 
Figure 53. Rate of release of 122 upon reaction of 142 with 90 (final concentration 100 μM) in 50% H2O/DMSO, 
determined by following the increase in fluorescence (λex = 325, λem = 460 nm).  
Importantly, the reaction was also shown to be compatible with cell media. The fluorescence intensity 
was measured over 5 h at 37 °C and the release of coumarin 122 was observed in 50% DMSO/LB media 
(t1/2 = 120 min, Figure 54). 
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Figure 54. Rate of release of 122 upon reaction of 142 with 90 (final concentration 100 μM) in 50% DMSO/LB 
media determined by following the increase in fluorescence (λex = 325, λem = 460 nm).  
The release of coumarin 122 was also monitored by HPLC coupled to a fluorescence detector (Figure 
55). The reaction was analysed at the following times: 5 min, 1 h, 2 h, 3 h, 4 h, 24 h. 
 
Figure 55. Following the reaction of TCO-coumarin (142) with 90 by HPLC/FLD (λex = 325 nm, λem = 460 nm).  
Finally, the yield of the reaction after 24 h was assessed under different conditions by HPLC analysis. 
The yield was shown to be highest in 50% H2O/DMSO, although there was no clear correlation 
between water content and yield (Figure 56). It should be noted that it was not possible to study the 
reaction in > 50% H2O owing to the limited solubility of 142. The reaction was also shown to be pH 
dependent; similar yields (2530%) were obtained for pH 47.4, however no reaction occurs at pH 9, 
which is consistent with previous reports.[15] 
0 100 200 300
0
2.0
4.0
6.0
time (min)
t
1/2
 = 120 min
R2 = 0.989
F
I 
(x
1
0
7
)
0.0 2.0 4.0 6.0 8.0
-5,000,000
0
5,000,000
10,000,000
15,000,000
20,000,000
25,000,000
30,000,000
35,000,000 counts
min
24 h
4 h
3 h
2 h
1 h
5 min
325 nm /460 nm
Chapter 3: Development of a self-immolative linker for the release of alcohols 
 
108 
 
Figure 56. Decaging yield of the reaction of TCO-coumarin (142) with 90 determined by HPLC under different 
conditions after reaction for 24h. The conditions pH 9, 7.4, 6, 5.6, 4 refer to 50% DMSO/corresponding buffer 
(sodium phosphate (NaPi) pH 9, PBS pH 7.4, NaPi pH 6, acetate pH 5.6, acetate pH 4).  
After studying the reaction of model compound 142 with tetrazines, the reaction of prodrug 153 with 
tetrazine 90 was then studied by HPLC. First, a calibration graph was obtained. Mixtures of triclosan 
(149) at known concentrations (0.21.2 mM) and internal standard benzoic acid (0.67 mM) were 
analysed by HPLC/UV and the ratio of areas of the UV peaks at 220 nm were plotted against 
concentration of 149 (Figure 57).  
 
Figure 57. Calibration curve for detection of triclosan (149) by HPLC/UV 
Next, the reaction of 153 and 90 was monitored by HPLC/UV at various timepoints (10 min, 30 min,   
1 h, 2 h, 4 h, 24 h). The measured ratio of UV peaks was converted to concentration using the 
calibration graph and a decaging yield of 22% was observed (Figure 58). 
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Figure 58. Decaging yield for the reaction of TCO-triclosan (153) with tetrazine 90 by HPLC analysis with an 
internal standard (benzoic acid). 
In addition, detection of intermediate peaks by LC-MS analysis confirmed our proposed mechanism of 
decaging (Figure 59).  
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Figure 59. LC-MS analysis of reaction mixture of TCO-triclosan (153) and tetrazine 90 after 24 h.  
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3.7 Cell studies 
Finally, the decaging reaction was carried out in the presence of live bacteria (E. Coli BL21(DE3), 
Scheme 93). Triclosan is a biocide that is found in many commercial products, for example toothpaste, 
soap and detergents. Its mechanism of action is inhibition of the enol-acyl carrier protein reductase 
(ENR) which is an essential enzyme for fatty acid synthesis.[16] This causes cell membranes to weaken, 
leading to cell death.  
 
Scheme 93. Tetrazine-triggered prodrug activation in the presence of live cells.  
First, the bactericidal activities of triclosan (149), prodrug 153 and 153 + 90 were determined by 
assessing the cell viability at concentrations of 50 nM1 μM (Figure 60). The bioorthogonal reactant 
pair, TCO-triclosan (153) + tetrazine 90 (10 equiv.), was shown to be  3 times less active                           
(IC50 = 298 ± 20 nM) than triclosan (149) alone (IC50 = 122 ± 10 nM). This lower activity is due to the 
non-quantitative decaging yield. Importantly, both the prodrug TCO-triclosan (153) and tetrazine 90 
were shown to be non-toxic at all concentrations tested.  
 
Figure 60. Representative IC50 curves. Toxicity assessed by the CellTiter-Blue assay. Tetrazine 90 and TCO-
triclosan (153) proved to be non-toxic at all concentrations tested (0.051 μM for 153, 0.510 μM for 90). The 
experiment was performed in technical triplicates (3 wells), 3 independent times and similar results were 
obtained each time. Average IC50 values were found to be 122 ± 10 nM (149) and 298 ± 20 nM (153 + 90). 
tetrazine 90
E. Coli
12 h
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After the initial assessment of toxicity, the decaging reaction was then carried out at a concentration 
of 1 μM. Compounds were added to the cells and the viability was assessed after 12 h by the CellTiter-
Blue cell viability assay (Figure 61). Tetrazine 90 and prodrug 153 alone have no effect on the viability, 
but together they result in 100% cell death, as expected from release of an antibacterial drug. 
Complete cell death was also observed when cells were treated with the free drug 149. This confirms 
that the prodrug is activated in the presence of live cells.  
 
Figure 61. Representative cell viability data after treatment of E. Coli with either 149, 90, 153, 153 + 90 assessed 
by the CellTiter-Blue assay. Treatment with bioorthogonal reactant pair 153 + 90 resulted in complete cell killing. 
The experiment was performed in technical triplicates (3 wells), 3 independent times and similar results were 
obtained each time. *** (P ≤ 0.001). 
In addition, the viability was also assessed by measuring the optical density at 600 nm (OD600) (Figure 
62) and the results were consistent with those obtained from the CellTiter-Blue cell viability assay. 
Again, it was observed that the OD600 was significantly reduced when cells were treated with 153 + 90 
compared to 153 alone. Therefore, the reinstation of the bactericidal activity of triclosan (149) was 
achieved upon decaging of 153 in the presence of live cells. 
 
Figure 62. Representative cytotoxicity data of 149, 90, 153, 153 + 90 assessed by measuring the OD600. The 
experiment was performed in technical triplicates (3 wells), 3 independent times and similar results were 
obtained each time *** (P ≤ 0.001). 
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3.8 Conclusion and future directions 
We have explored TCO based protecting groups for masking alcohol functionality. Initially a TCO-
carbonate linker was proposed and alcohol release occurred rapidly upon reaction of the carbonate 
with a tetrazine. However, this handle was limited by the instability of the carbonate under biological 
conditions. Therefore, we next designed an ether linker which was predicted to be more stable than 
the carbonate. However, the synthesis of the TCO-ether bond proved to be synthetically challenging. 
Finally, we successfully developed a TCO-carbamate benzyl ether linker for the controlled release of 
alcohol-containing drugs and fluorophores upon reaction with a tetrazine trigger. 
A synthetic route was developed that enabled generation of TCO-carbamate benzyl ethers 142 and 
153 as 100% the axial, trans-isomer by direct modification of trans-cyclooct-2-en-1-ol. The synthesis 
does not require a late stage photochemical isomerisation under flow, which is typically very low 
yielding and requires a specialised setup. The benzyl ether linker proved to be highly stable and can 
rapidly liberate alcohols under physiological conditions upon reaction with tetrazines. The mechanism 
and decaging yield were systematically examined by fluorescence and HPLC analysis by using a 
fluorogenic TCO-benzyl ether-coumarin probe (142) and different 3,6‐substituted tetrazine 
derivatives. This study revealed that decaging occurs rapidly (t1/2 = 27 min) and the cycloaddition step 
happens within seconds (t1/2 = 7 secs) with reaction rates of  100 M–1s–1. In addition, observation of 
the intermediates confirmed the proposed 1,6-elimination mechanism from the aniline benzyl-ether 
derivative.  
Importantly, the reaction was shown to be compatible with living organisms as demonstrated by the 
decaging of a prodrug of the antibacterial compound triclosan in the presence of live E. Coli, that 
resulted in complete cell killing by action of the released “OH-active drug”. Overall, this work describes 
a new linker for masking alcohol functionality that can be rapidly reinstated through tetrazine-
triggered decaging. The significant improvement in kinetics from the previous vinyl ether handle[1] 
suggests this reaction may hold potential for in vivo prodrug activation.  
We envisage that this methodology could be used in a pretargeting strategy (as described in chapter 
2), to deliver the TCO prodrug to the target site. Site selective drug release could then be achieved 
upon administration of the tetrazine trigger (Scheme 94). One of the challenges of this approach is 
achieving a homogeneous distribution of the antibody in the tumour, which in necessary in order to 
kill all cancer cells and prevent tumour relapse.[7] This may be addressed by using antibody fragments, 
such as antigen-binding fragments (Fabs), single-chain variable fragments (scFvs) and nanobodies, 
which result in faster tumour accumulation and homogeneous distribution at the tumour due to their 
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smaller size. In addition, since they have shorter circulation half-lives than full IgG antibodies, they 
result in higher tumour-to-background ratios. 
 
Scheme 94. A pretargeting strategy to achieve tumour-specific drug release. The use of smaller antibody 
fragments instead of full IgGs can lead to increased tumour penetration of the therapeutic agent.  
 A drawback of this work is that the drug must be attached at an early stage in the synthesis, as it is 
necessary to attach TCO in the final step in order to avoid isomerisation. Therefore, this restricts the 
range of drugs that can be used to those containing little or no other functionality, as other functional 
groups may not be compatible with later synthetic steps. However, the previously reported 
methodology involving UV isomerisation to the trans-isomer in the final step is also only applicable to 
a limited scope of drugs. For example, the presence of aromatic rings may interfere with the UV 
absorption of the compound and hinder isomerisation. Therefore, further work is required in order to 
develop alternative linkers and robust synthetic routes that can be tolerated by a wide range of 
alcohol-containing drugs.  
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Chapter 4 
 
Experimental 
 
 
 
4.1 General experimental 
Solvents and reagents: All non-aqueous reactions were performed in oven-dried glassware under 
argon atmosphere unless otherwise stated. Argon gas was pre-dried via passage through calcium 
chloride. Reaction vessels were heated using thermostatically controlled dry-syn blocks with the liquid 
level of the flask below that of the heating block. Reaction temperatures refer to the thermostat set 
point. All reagents were purchased from commercial sources and used without further purification 
unless otherwise stated. Trans-cyclooct-2-en-1-ol (TCO-OH) was purchased as the axial isomer from 
Sirius Fine Chemicals. CH2Cl2, THF and Et2O were purified either according to the method of Grubbs 
and Pangborn[1] or by distillation under an inert atmosphere (CH2Cl2, MeOH, toluene and MeCN were 
distilled from calcium hydride. THF and Et2O were pre-dried over sodium wire then distilled from 
calcium hydride and lithium aluminium hydride). N,N-diisopropylethylamine (DIPEA) was purified by 
distillation over calcium hydride and stored over 4 Å molecular sieves. Petroleum ether and EtOAc 
were distilled on site. ‘Petrol’ refers to the distillate of petroleum ether collected between 4060 °C 
unless otherwise stated. Water used experimentally was deionised and prepared on site. Flash column 
chromatography was performed using silica gel 60 Å (4063 μm) from Material Harvest and 
preparative TLC was performed on Merck PLC 60 F254 plates. Analytical thin layer chromatography 
was performed using Merck Silica 42 gel 60 F254 1 mm glass plates and visualised by UV (254 nm) 
and/or by staining with potassium permanganate (KMnO4).  
 
Characterisation: NMR spectra were recorded on Bruker 400-Avance III HD, Avance DPX-400, 400-
QNP Cryoprobe or 500-DCH Cryoprobe spectrometers. Chemical shifts are reported in parts per 
million (ppm) and the residual solvent peaks were used as an internal reference for chemical shift (1H 
NMR CDCl3 δ 7.26 ppm, MeOD δ 3.31 ppm, DMSO-D6 δ 2.50 ppm; 13C NMR CDCl3 δ 77.2 ppm, MeOD 
δ 49.0 ppm, DMSO-D6 δ 39.5 ppm). Multiplicities are described as s (singlet), d (doublet), t (triplet), q 
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(quartet), m (multiplet), dd (double doublet) and so on. Coupling constants (J) are reported in hertz 
(Hz) to 1 decimal place using MestreNova for signal processing. The centre of each peak is reported 
except for multiplet signals where a range of ppm values is given. Structural assignments are made 
with the aid of COSY, HSQC, and HMBC experiments, performed by the NMR Spectrometry Service, 
University of Cambridge. High-resolution mass spectra were performed by the Mass Spectrometry 
Service, Department of Chemistry, University of Cambridge using a Waters LCT Premier or a Waters 
Xevo G2-S spectrometer and ionised by ESI or ASAP. 
 
4.2 Experimental procedures for Chapter 2 
4.2.1 Synthetic procedures 
bis(pyridin-2’-yl)-1,2,4,5-tetrazine (15) was purchased from Sigma-Aldrich. 
 
3-Methyl-6-(pyrimidin-2’-yl)-1,2,4,5-tetrazine (58)  
 
 
According to the procedure by Fan et al.,[2] 2-pyrimidinecarbonitrile (92, 0.53 g, 5.0 mmol, 1.0 equiv.), 
MeCN (1.30 mL, 25 mmol, 5.0 equiv.), zinc trifluoromethane sulfonate (91 mg, 0.25 mmol, 5 mol%) 
and hydrazine monohydrate (1.20 mL, 25 mmol, 5.0 equiv.) were added to a Schlenk tube under a 
positive argon gas stream. The reaction mixture was stirred at 60 °C for 24 h under argon. The reaction 
was cooled to rt then sodium nitrite (aq) (1 M, 50 mL) was added. HCl (1 M) was added until the reaction 
mixture was pH 3. The layers were separated and the aqueous phase was extracted with CH2Cl2 (3 x 
100 mL). The combined organic layers were washed with brine (20 mL), dried over anhydrous Na2SO4 
and concentrated in vacuo. Purification via flash column chromatography (24% MeOH/CH2Cl2) 
followed by another flash column chromatography (1016% acetone/CH2Cl2) yielded 58 as a pink solid 
(0.237 g, 1.36 mmol, 27%). The NMR data were in accordance with literature data.[2]  
 
Rf 0.25 (10% acetone/CH2Cl2). 
1H NMR (400 MHz, CDCl3) δ 9.10 (d, J = 4.9 Hz, 2H, H4’, H6’), 7.57 (td, J = 4.8, 1.0 Hz, 1H, H5’), 3.20 (d, 
J = 1.0 Hz, 3H, H7).  
13C NMR (101 MHz, CDCl3) δ 168.7 (C3), 163.3 (C6), 159.6 (C2’), 158.4 (C4’, C6’), 122.5 (C5’), 21.5 (C7). 
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Ethenyl 3-phenylpropanoate (87) 
 
According to the procedure by Krejzová et al.,[3] palladium (II) acetate (22 mg, 0.098 mmol, 1 mol%) 
and vinyl acetate (10.1 mL, 110 mmol, 11.0 equiv.) were added to a solution of 3-phenylpropionic acid 
(86, 1.5 g, 10.0 mmol, 1.0 equiv.) in anhydrous, degassed THF (1 mL). The mixture was stirred at 60 °C 
for 16 h and then cooled to rt. Silica was added and all volatiles were removed in vacuo. Purification 
via flash column chromatography (5% EtOAc/Petrol) yielded 87 as a pale yellow oil (0.80 g, 4.6 mmol, 
46%). The NMR data were in accordance with literature data.[3]  
 
Rf 0.58 (5% EtOAc/Petrol). 
1H NMR (400 MHz, CDCl3) δ 7.35 – 7.28 (m, 3H, H6, H8), 7.26 – 7.21 (m, 3H, H5, H7), 4.91 (dd, J = 14.0, 
1.7 Hz, 1H, H9Z), 4.60 (dd, J = 6.3, 1.6 Hz, 1H, H9E), 3.02 (t, J = 7.8 Hz, 2H, H3), 2.75 ( t, J = 7.8 Hz, 2H, 
H2). 
13C NMR (101 MHz, CDCl3) δ 169.9 (C1), 141.1 (C8), 140.1 (C4), 128.6 (C6), 128.3 (C5), 126.4 (C7), 97.8 
(C9), 35.6 (C2), 30.6 (C3). 
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3-Phenylpropionic acid (86) and 3,6-Bis(pyridin-2’-yl)pyridazine (88) 
 
 
Ethynyl-3-phenylpropanoate (87, 34 mg, 0.193 mmol, 1.0 equiv.) and 2,6-di-2-pyridyl-1,2,4,5-tetrazine 
(15, 91 mg, 0.386 mmol, 2.0 equiv.) were suspended in 25% H2O/DMF (16 mL) and stirred at 37 °C for 
3 days. The reaction was cooled to rt and H2O (40 mL) was added. The mixture was extracted with 
EtOAc (4 x 40 mL) and the combined organic layers were washed with 10% LiCl(aq) (4 x 40 mL) and brine 
(40 mL) then dried over anhydrous MgSO4, filtered and concentrated in vacuo. Purification via flash 
column chromatography (50% EtOAc/Petrol) yielded 3-phenylpropionic acid (86) as a white solid          
(8 mg, 0.05 mmol, 28%) and 3,6-bis(pyridine-2-yl)pyridazine (88) as a yellow solid (14 mg, 0.06 mmol, 
31%). The NMR data were in accordance with literature data.[4,5]  
 
3-phenylpropionic acid (86) 
Rf 0.23 (50% EtOAc/Petrol). 
1H NMR (400 MHz, CDCl3) δ 7.33 – 7.27 (m, 2H, H6), 7.24 – 7.16 (m, 3H, H5, H7), 2.97 (t, J = 7.8 Hz, 2H, 
H3), 2.69 (t, J = 7.8 Hz, 2H, H2). 
 
3,6-Bis(pyridin-2’-yl)pyridazine (88) 
Rf 0.35 (50% EtOAc/Petrol). 
1H NMR (400 MHz, CDCl3) δ 8.83 – 8.74 (m, 4H, H6’, H3’), 8.71 (s, 2H, H4, H5), 7.93 (td, J = 7.8, 1.9 Hz, 
2H, H4’), 7.43 (ddd, J = 7.5, 4.8, 1.2 Hz, 2H, H5’). 
13C NMR (101 MHz, CDCl3) δ 158.2 (C3, C6), 153.5 (C2’), 149.5 (C6’), 137.2 (C4’), 125.2 (C4, C5), 124.8 
(C5’), 121.7 (C3’). 
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3-Methyl-6-(pyridin-2’-yl)-1,2,4,5-tetrazine (89) 
 
According to the procedure by Fan et al.,[2] 2-pyridinecarbonitrile (93, 0.104 g, 1.0 mmol, 1.0 equiv.), 
MeCN (0.26 mL, 5.0 mmol, 5.0 equiv.), zinc trifluoromethane sulfonate (18 mg, 0.05 mmol, 5 mol%) 
and hydrazine monohydrate (0.24 mL, 5.0 mmol, 5.0 equiv.) were added to a Schlenk tube under a 
positive argon gas stream. The reaction mixture was stirred at 60 °C for 24 h under argon. The reaction 
was cooled to rt then sodium nitrite (aq) (1 M, 10 mL) was added. HCl (1 M) was added until the reaction 
mixture was pH 3. The layers were separated and the aqueous phase was extracted with CH2Cl2 (3 x 
50 mL). The combined organic layers were washed with brine (20 mL), dried over anhydrous Na2SO4 
and concentrated in vacuo. Purification via flash column chromatography (10% acetone/CH2Cl2) 
yielded 89 as a pink solid (31 mg, 0.177 mmol, 18%). The NMR data were in accordance with literature 
data.[2]  
 
Rf 0.41 (10% acetone/CH2Cl2). 
1H NMR (400 MHz, CDCl3) δ 8.95 (ddd, J = 4.8, 1.8, 0.9 Hz, 1H, H6’), 8.64 (dt, J = 7.9, 1.1 Hz, 1H, H3’), 
7.98 (td, J = 7.8, 1.7 Hz, 1H, H4’), 7.55 (ddd, J = 7.7, 4.8, 1.2 Hz, 1H, H5’), 3.16 (d, J = 0.8 Hz, 3H, H7). 
13C NMR (101 MHz, CDCl3) δ 168.1 (C3), 163.6 (C6), 150.9 (C6’), 150.3 (C2’), 137.4 (C4’), 126.3 (C5’), 
123.9 (C3'), 21.4 (C7). 
 
4’-(1,2,4,5-tetrazin-3-yl)benzoic acid (90) was prepared by Ester Jiménez-Moreno (Bernardes 
group).[5] 
 
dimethyl-1,2,4,5-tetrazine (91) was prepared by Russel Guo (Bernardes group) 
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Ethenyl 2-oxochromene-3-carboxylate (96) 
 
 
According to the procedure by Krejzová et al.,[3] palladium (II) acetate (3 mg, 0.013 mmol, 1 mol%) and 
vinyl acetate (1.07 mL, 11.6 mmol, 11 equiv.) were added to a solution of coumarin-3-carboxylic acid 
(95, 0.200 g, 1.05 mmol, 1.0 equiv.) in anhydrous, degassed THF (3 mL). The mixture was stirred at     
60 °C for 24 h and then cooled to rt. Further portions of palladium (II) acetate (3 mg, 0.013 mmol,          
1 mol%) were added after 16 h and 19 h. Silica was added and all volatiles were removed in vacuo. 
Purification of the dry residue directly via flash column chromatography (2050% EtOAc/Petrol) gave 
96 as a white solid (0.036 g, 0.167 mmol, 16%).  
 
Rf 0.29 (50% EtOAc/Petrol). 
Mp 124126 °C. 
1H NMR (400 MHz, CDCl3) δ 8.66 (s, 1H, H4), 7.76 – 7.64 (m, 2H, H5, H7), 7.50 (dd, J = 13.9, 6.2 Hz, 1H, 
H10), 7.44 – 7.34 (m, 2H, H6, H8), 5.16 (dd, J = 13.9, 1.9 Hz, 1H, H11Z), 4.79 (dd, J = 6.2, 1.9 Hz, 1H, 
H11E). 
13C NMR (101 MHz, CDCl3) δ 159.9 (C9), 156.2 (C8a), 155.4 (C2), 149.8 (C4), 141.1 (C10), 134.9 (C7), 
129.7 (C5), 125.0 (C6), 117.7 (C4a), 116.9 (C8), 116.8 (C3), 99.4 (C11). 
IR (thin film, νmax/cm) 3063w, 1760s, 1643w, 1609m, 1567m, 1488w, 1452m, 1377m, 1300m, 1241m, 
1211s, 1138s, 1012m, 963m. 
HRMS (ESI+): m/z calc. for C12H8O4 [M+H]+ 217.0501, found 217.0492, ∆ -4.1 ppm.  
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Ethyl 7-hydroxy-2-oxochromene-3-carboxylate (99) 
 
According to the procedure by Vieira et al.,[6] piperidine (0.12 mL, 1.21 mmol, 0.33 equiv.) was added 
to a solution of 2,4-dihydroxybenzaldehyde (97, 0.511 g, 3.70 mmol, 1.0 equiv.) in diethylmalonate 
(1.20 mL, 7.90 mmol, 2.1 equiv.). The reaction mixture was stirred at rt for 20 h then acidified using 
HCl (3M, 5 mL). The precipitate was filtered and washed with ice-cold water (10 mL). Purification via 
flash column chromatography (70% CH2Cl2/EtOAc) yielded 99 as a white solid (0.133 g, 0.568 mmol, 
15%). The NMR data were in accordance with literature data.[6] 
 
Rf 0.25 (70% CH2Cl2/EtOAc). 
1H NMR (400 MHz, DMSO-D6) δ 8.67 (s, 1H, H4), 7.75 (d, J = 8.6 Hz, 1H, H5), 6.84 (dd, J = 8.6, 2.3 Hz, 
1H, H6), 6.72 (d, J = 2.2 Hz, 1H, H8), 4.25 (q, J = 7.1 Hz, 2H, H10), 1.29 (t, J = 7.1 Hz, 3H, H11). 
13C NMR (101 MHz, DMSO-D6) 164.5 (C7), 163.4 (C9), 157.6 (C8a), 156.9 (C2), 149.9 (C4), 132.6 (C5), 
114.5 (C6), 112.5 (C3), 110.9 (C4a), 102.2 (C8), 61.3 (C10), 14.6 (C11). 
 
7-Hydroxy-2-oxochromene-3-carboxylic acid (100)  
 
According to the procedure by Zhang et al.,[7] ethyl 7-hydroxy-2-oxochromene-3-carboxylate (99, 
0.133 g, 0.568 mmol) was dissolved in NaOH(aq) (2M, 2.5 mL) and the reaction was stirred at rt for        
16 h. The reaction was acidified with HCl(aq) (2M) until pH 2. The precipitate was washed with water 
followed by acetonitrile and then dried in vacuo to give 100 as a white solid (0.033 g, 0.160 mmol, 
28%). The NMR data were in accordance with literature data.[7] 
 
1H NMR (400 MHz, DMSO-D6) δ 8.68 (d, J = 1.6 Hz, 1H, H4), 7.75 (dd, J = 8.6, 1.5 Hz, 1H, H5), 6.85 (dt, 
J = 8.5, 1.9 Hz, 1H, H6), 6.74 (d, J = 2.3 Hz, 1H, H8). 
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Ethenyl 7-(ethenyloxy)-2-oxochromene-3-carboxylate (101) 
 
According to the procedure by Krejzová et al.,[3] palladium (II) acetate (3 mg, 0.013 mmol, 1 mol%) and 
vinyl acetate (0.98 mL, 10.7 mmol, 11 equiv.) were added to a solution of 7-hydroxycoumarin-3-
carboxylic acid (100, 0.200 g, 0.970 mmol, 1.0 equiv.) in anhydrous, degassed THF (3 mL). The mixture 
was stirred at 60 °C for 24 h and then cooled to rt. Further portions of palladium (II) acetate (3 mg, 
0.013 mmol, 1 mol%) were added after 16 h and 19 h. Silica was added and all volatiles were removed 
in vacuo. Purification of the dry residue directly via flash column chromatography (25% EtOAc/Petrol) 
yielded 101 as a white solid (20 mg, 0.077 mmol, 8%). 
 
Rf 0.36 (25% EtOAc/Petrol). 
Mp 9497 °C. 
1H NMR (400 MHz, DMSO-D6) δ 8.94 (d, J = 0.6 Hz, 1H, H4), 7.98 (d, J = 8.7 Hz, 1H, H5), 7.40 (dd,                   
J = 13.9, 6.2 Hz, 1H, H10), 7.22 (d, J = 2.4 Hz, 1H, H8), 7.17 (dd, J = 8.7, 2.4 Hz, 1H, H6), 7.14 (dd,                     
J = 13.4, 5.9 Hz, 1H, H12), 5.09 (dd, J = 13.9, 1.7 Hz, 1H, H11Z), 4.99 (dd, J = 13.4, 1.9 Hz, 1H, H13Z), 4.83 
(dd, J = 6.2, 1.7 Hz, 1H, H11E), 4.73 (dd, J = 5.9, 1.8 Hz, 1H, H13E). 
13C NMR (101 MHz, DMSO-D6) δ 161.5 (C7), 159.9 (C9), 156.9 (C8a), 155.9 (C2), 150.5 (C4), 146.5 (C12), 
141.5 (C10), 132.6 (C5), 114.1 (C6), 113.2 (C4a), 112.9 (C3), 102.7 (C8), 99.5 (C11), 98.6 (C13). 
 IR (thin film, νmax/cm) 3045w, 1760s, 1715m, 1647m, 1608s, 1658m, 1498m, 1375m, 1292m, 1211m, 
1122s, 940s. 
HRMS (ASAP+): m/z calc. for C14H11O5 [M+H]+ 259.0606, found 259.0601, ∆ -1.9 ppm. 
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Ethenyl 7-hydroxy-2-oxochromene-3-carboxylate (102) 
 
Ethenyl 7-(ethenyloxy)-2-oxochromene-3-carboxylate (101, 12 mg, 0.0465 mmol, 1.0 equiv.) was 
dissolved in MeOH (0.6 mL). HCl (0.3 mL, 12M, 3.6 mmol, 77 equiv.) was added and the reaction was 
stirred at rt for 45 min then concentrated in vacuo. CH2Cl2 (5 mL) was added and the solution was 
neutralised with NaHCO3 (aq) (sat. soln.) at 0 °C. The layers were separated and the aqueous layer was 
extracted with CH2Cl2 (3 x 5 mL). The combined organic layers were washed with brine (10 mL), dried 
over anhydrous Na2SO4 and concentrated in vacuo. Purification via flash column chromatography 
(1050% EtOAc/Petrol) yielded 102 as a peach solid (3 mg, 0.0129 mmol, 28%).  
 
Rf 0.29 (50% EtOAc/Petrol). 
Mp 188192 °C. 
1H NMR (500 MHz, Methanol-d4) δ 8.78 (d, J = 0.6 Hz, 1H, H4), 7.67 (d, J = 8.7 Hz, 1H, H5), 7.45 (dd,       
J = 13.9, 6.3 Hz, 1H, H10), 6.86 (dd, J = 8.7, 2.3 Hz, 1H, H6), 6.73 (d, J = 2.5 Hz, 1H, H8), 5.09 (dd,                     
J = 14.0, 1.7 Hz, 1H, H11Z), 4.73 (dd, J = 6.3, 1.7 Hz, 1H, H11E). 
13C NMR (126 MHz, Methanol-d4) δ 165.5 (C7), 160.3 (C9), 157.9 (C8a/C2), 157.8 (C8a/C2), 150.9 (C4), 
140.9 (C10), 132.0 (C5), 114.3 (C6), 110.8 (C4a), 110.0 (C3), 101.7 (C8), 97.5 (C11). 
IR (thin film, νmax/cm) 3558w, 3475w, 3058w, 2924w, 1741s, 1686m, 1617s, 1604s, 1452m, 1389m, 
1214s, 1145s.  
HRMS (ESI+): m/z calc. for C12H8O5Na [M+Na]+ 255.0264, found 255.0258, ∆ -2.4 ppm. 
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2-(3-benzoylphenyl)propanoic acid (105) 
 
Esterase from porcine liver (0.125 units) and either the axial or equatorial isomer of TCO-ketoprofen 
(114, 0.5 μmol, 1.0 equiv.) were added to PBS buffer (1 mL, pH = 7.4) from a stock dissolved in DMSO 
(200 mM) and the mixture was shaken at 37 °C for 24 h. Analysis of the mixture by HPLC gave 
ketoprofen (105) in yields of 71% (axial isomer) and 14% (equatorial isomer). This experiment was 
performed by Luxi Qiao.  
 
Vinyl 2-(3’-benzoylphenyl)propanoate (106) 
 
According to the procedure by Krejzova et al.,[3] palladium (II) acetate (13 mg, 0.06 mmol, 3 mol%) and 
vinyl acetate (2.0 mL, 21.6 mmol, 11.0 equiv.) were added to a solution of ketoprofen (105, 500 mg, 
1.97 mmol, 1.0 equiv.) in anhydrous, degassed THF (5 mL). The mixture was stirred at 60 °C for 16 h, 
cooled to rt and then concentrated in vacuo. Purification via flash column chromatography (2025% 
EtOAc/petrol) yielded 106 as a red oil (292 mg, 1.04 mmol, 53%). This experiment was performed by 
Luxi Qiao.  
 
1H NMR (400 MHz, CDCl3) δ 7.81–7.73 (m, 3H, H2’,H6), 7.69 (dt, J = 7.6, 1.5 Hz, 1H, H4’), 7.62–7.53 (m, 
2H, H8, H6’), 7.50–7.42 (m, 3H, H5’, H7), 7.30–7.21 (m, 1H, H9), 4.87 (dd, J = 14.0, 1.7 Hz, 1H, H10Z), 
4.58 (dd, J = 6.3, 1.7 Hz, 1H, H10E), 3.86 (q, J = 7.2 Hz, 1H, H2), 1.57 (d, J = 7.2 Hz, 3H, H3).  
13C NMR (101 MHz, CDCl3) δ 196.5 (C4), 171.3 (C1), 141.4 (C9), 140.1(C3’), 138.0 (C5), 137.6 (C1’), 
132.7 (C6’), 131.6 (C8), 130.0 (C2’), 130.2 (C6), 129.4 (C4’), 128.8 (C5’), 128.5 (C7), 98.4 (C10), 45.3 
(C2), 18.5 (C3).  
IR (thin film, νmax/cm1) 2980w, 2917w, 1747s, 1658s, 1645s, 1597m, 1579m, 1447m, 1379w, 1318m, 
1281s, 1228w, 1201m, 1807br, 1076m, 947m, 876m, 821w, 789w, 768w, 704br. 
HRMS (ESI+): m/z calc. for C18H16O323Na [M+Na]+ 303.0992, found 303.0978, Δ -4.3 ppm.  
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(2Z)-Cyclooct-2-en-1-ol (111) 
 
According to the procedure by Becker et al.,[8] diphenyl diselenide (2.00 g, 6.41 mmol, 1.5 equiv.) was 
dissolved in CH2Cl2 (21 mL) and cooled to 0 °C under argon. Hydrogen peroxide solution (0.67 mL, 30% 
w/w in water, 6.51 mmol, 1.5 equiv.) was added dropwise and the reaction mixture was stirred 
vigorously for 30 min. Magnesium sulfate (1.07 g, 8.89 mmol, 2.1 equiv.) was added and the reaction 
was stirred for a further 30 min then allowed to warm to rt. Cyclooctene (110, 0.56 mL, 4.26 mmol, 
1.0 equiv.) was added and the reaction was stirred at rt under argon for 20 h then cooled to 0 °C.             
t-butylhydroperoxide solution (4.56 mL, 5-6 M in decane,  22.8 mmol,  5.4 equiv.) was added slowly, 
the ice bath was removed and the reaction was stirred at rt for 20 h. The precipitate was filtered off 
and washed with diethyl ether. The filtrate was concentrated in vacuo and then redissolved in diethyl 
ether (30 mL) and washed sequentially with 5% Na2CO3(aq) (17 mL, 9 mL), water (9 mL), 10% ferrous 
sulfate(aq) (17 mL, 9 mL), water (20 mL), NaHCO3 (aq) (sat. soln., 20 mL), water (20 mL) and brine                
(20 mL). The organic layer was dried over anhydrous MgSO4 for 24 h then concentrated in vacuo. 
Purification via flash column chromatography (20% Et2O/Petrol) yielded 111 as a pale yellow oil     
(0.273 g, 2.16 mmol, 51%). The NMR data were in accordance with literature data.[9]  
 
1H NMR (400 MHz, CDCl3) δ 5.63 (dddd, J = 10.4, 8.6, 7.0, 1.5 Hz, 1H, H3), 5.54 (ddd, J = 10.8, 6.6,         
1.0 Hz, 1H, H2), 4.67 (ddd, J = 10.3, 6.3, 4.6 Hz, 1H, H1), 2.26 – 2.00 (2H, m, H4), 1.93 (1H, m, H8a), 
1.75 – 1.34 (7H, m, H5-H7, H8b). 
 13C NMR (101 MHz, CDCl3) δ 135.0 (C2), 128.7 (C3), 69.5 (C1), 38.7 (C8), 29.1 (C5), 26.3 (C4), 25.9 
(C6/C7), 23.7 (C6/C7). 
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(Z)-Cyclooct-2-en-1-yl 2’-(3’’-benzoylphenyl)propanoate (113) 
 
According to the procedure by Schlegel et al.,[10] a solution of ketoprofen (105, 40 mg, 0.157 mmol,    
1.0 equiv.) and thionyl chloride (0.1 mL, 1.37 mmol, 8.7 equiv.) in toluene was stirred at 85 °C for 2 h. 
The reaction was cooled to rt then concentrated in vacuo to give acyl chloride 112 which was used 
directly in the subsequent step, assuming quantitative yield. 
 
Triethylamine (0.1 mL, 0.72 mmol, 4.6 equiv.) was added to a solution of 112 (quantitative,                
0.157 mmol) and cis-cycloocten-1-ol (111, 13 mg, 0.10 mmol, 0.6 equiv.) in CH2Cl2 (5 mL) and the 
mixture was stirred at rt for 18 h. The mixture was then concentrated in vacuo. Purification via flash 
column chromatography (20% EtOAc/petrol) yielded 113 as a yellow oil (28.1 mg, 0.08 mmol, 75%) as 
a mixture of diastereoisomers. This experiment was performed by Luxi Qiao.  
 
1H NMR (500 MHz, CDCl3) δ 7.82–7.78 (m, 2H, H11), 7.75 (dt, J = 3.5, 1.9 Hz, 1H, H2”), 7.68 (dd, J = 7.6, 
1.5 Hz, 1H, H4”), 7.61–7.57 (m, 1H, H13), 7.55 (ddt, J = 7.7, 4.5, 1.5 Hz, 1H, H6”), 7.50–7.41(m, 3H, H12, 
H5”), 5.69-5.58 (m, 2H, H2, H3), 5.45 (ddd, J = 10.8, 7.1, 1.3 Hz, 0.3 H, H1), 5.32 (ddd, J = 10.8, 7.0,      
1.4 Hz, 0.7H, H1), 3.78 (q, J = 7.2 Hz, 1H, H2’), 2.27–2.17 (m, 1H, H4a), 2.13–2.02 (m, 1H, H4b),           
1.92–1.83 (m, 0.7H, H8a), 1.81–1.72 (m, 0.3H, H8a), 1.67 (ddq, J = 12.8, 8.3, 4.1 Hz, 1H, H8b),              
1.61–1.45 (m, 7H, H3’, H5, H6), 1.44–1.36 (m, 1H, H7), 0.87 (qt, J = 8.6, 6.0 Hz, 1H, H7).  
13C NMR (126 MHz, CDCl3) δ 196.7 (C9), 173.5 (C1’), 141.1 (C3”), 138.0 (C10), 137.7 (C1”), 132.6 (C6”), 
131.7 (C2), 130.4(C13), 130.2 (C2”), 130.0 (C11), 129.4 (C3), 129.0 (C4”), 128.7 (C5”), 128.4 (C12), 73.0 
(C1), 45.7 (C2’), 35.1 (C8), 28.9 (C4), 26.4 (C6), 25.9 (C5), 23.4 (C7), 18.6 (C3’).  
IR (thin film, νmax /cm1) 2927s, 2855m, 1730s, 1660s, 1598w, 1448br, 1377w, 1318m, 1282s, 1205s, 
1175br, 1077w, 1024br, 945br, 899br, 820w, 755m. 
HRMS (ESI+): m/z calc. for C24H26O323Na [M+Na]+ 385.1774, found 385.1765, Δ -2.4 ppm.  
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(E)-Cyclooct-2-en-1-yl 2-(3-benzoylphenyl)propanoate (114) 
 
According to the procedure by Schlegel et al,[10] a solution of ketoprofen (105, 40 mg, 0.157 mmol,    
1.0 equiv.) and thionyl chloride (0.1 mL, 1.37 mmol, 8.7 equiv.) in toluene was stirred at 85 °C for 2 h. 
The reaction was cooled to rt then concentrated in vacuo to give acyl chloride 112 which was used 
directly in the subsequent step, assuming quantitative yield. 
 
Triethylamine (0.1 mL, 0.717 mmol, 4.6 equiv.) was added to a solution of 112 (quantitative,             
0.157 mmol) and trans-cyclooct-2-en-1-ol (119, 13 mg, 0.10 mmol, 0.6 equiv.) in CH2Cl2 (5 mL) and the 
mixture was stirred at rt for 18 h. The mixture was then concentrated in vacuo. Purification via flash 
column chromatography (20% EtOAc/petrol) yielded 114 as a yellow oil as a mixture of 8 
diastereomers (4 corresponding to the cis-isomer 113) (33 mg, 0.09 mmol, 84%). This experiment was 
performed by Luxi Qiao.  
 
Separation of chiral isomers using HPLC: The crude mixture was dissolved in 1% 2-propanol/hexane to 
a concentration of 5 mg/100 μL. 30 μL was injected each time, and the different peaks were collected 
in separate vials and concentrated in vacuo. The separation was performed on an Agilent 1100 series 
instrument with a YMC Chiralart Cellulose-SC column (250 x 4.6 mmI.D. s-3 μm). The mobile phase 
consisted of hexane and 2-propanol. The peaks were eluted with a step gradient (035 min 0.8%             
2-propanol, 3570 min 4% 2-propanol, 1 mL/min). This experiment was performed by Luxi Qiao.  
 
IR (thin film, νmax /cm1) 2924s, 2852m, 1733s, 1661s, 1598w, 1449m, 1378w, 1282s, 1205m, 1176br, 
1122m, 1071m, 1023w, 989w, 952w, 932w, 907w, 818w, 719s. 
HRMS (ESI+): m/z calc. for C24H26O323Na [M+Na]+ 385.1774, found 385.1760, Δ -3.7 ppm.  
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(R/S)-Axial: 
1H NMR (500 MHz, CDCl3) δ 7.82–7.77 (m, 3H, H2”, H11), 7.68 (dt, J = 7.7, 1.4 Hz, 1H, H4”), 7.62–7.55 
(m, 2H, H6”, H13), 7.51–7.42 (m, 3H, H5”, H12), 5.67 (dddd, J = 16.1, 11.1, 3.8, 1.0 Hz, 1H, H3), 5.49 
(dd, J = 16.5, 2.4 Hz, 1H, H2), 5.39 (qq, J = 2.2, 1.1 Hz, 1H, H1), 3.86 (q, J = 7.2 Hz, 1H, H2’), 2.46–2.38 
(m, 1H, H4a), 2.03–1.89 (m, 3H, H4b, H8), 1.86–1.77 (m, 1H, H7a), 1.64 (ddd, J = 13.0, 3.3, 1.7 Hz, 1H, 
H5a), 1.57 (d, J = 7.2 Hz, 3H, H3’), 1.53–1.47 (m, 1H, H5b), 1.41–1.36 (m, 1H, H6a), 0.85–0.80 (m, 1H, 
H6b), 0.79–0.68 (m, 1H, H7b).  
13C NMR (126 MHz, CDCl3) δ 196.5 (C9), 173.0 (C1’), 141.0 (C3”), 137.9 (C10), 137.5 (C1”), 132.5 (C6”), 
132.3 (C2), 131.6 (C13), 130.4 (C2”), 130.0 (C11), 129.3 (C3), 128.9 (C4”), 128.5 (C5”), 128.3 (C12), 73.9 
(C1), 45.7 (C2’), 40.4 (C8), 35.9 (C4), 35.9 (C6), 29.0 (C5), 23.9 (C7), 18.2 (C3’). 
 
(R/S)-Equatorial: 
1H NMR (500 MHz, CDCl3) δ 7.82–7.76 (m, 3H, H2”, H11), 7.69 (dt, J = 7.7, 1.4 Hz, 1H, H4”), 7.62–7.55 
(m, 2H, H6”, H13), 7.51–7.43 (m, 3H, H5”, H12), 5.46 (dd, J = 16.5, 2.3 Hz, 1H, H3), 5.40–5.33 (m, 2H, 
H1, H2), 3.85 (q, J = 7.2 Hz, 1H, H2’), 2.31 (dddd, J = 9.6, 4.9, 3.6, 1.5 Hz, 1H, H4a), 2.07–1.87 (m, 3H, 
H4b, H8), 1.82 (dddt, J = 14.9, 11.3, 5.1, 1.7 Hz, 1H, H7a), 1.70–1.51 (m, 2H, H5), 1.57 (d, J = 7.2 Hz, 3H, 
H3’), 1.39–1.32 (m, 1H, H6a), 1.00–0.92 (m, 1H, H6b), 0.79–0.69 (m, 1H, H7b).  
13C NMR (126 MHz, CDCl3) δ 196.5 (C9), 172.9 (C1’), 140.9 (C3”), 137.9 (C10), 137.5 (C1”), 132.5 (C6”), 
132.0 (C2), 131.6 (C13), 130.4 (C2”), 130.1 (C11), 129.4 (C3), 128.9 (C4”), 128.5 (C5”), 128.3 (C12), 73.9 
(C1), 45.7 (C2’), 40.5 (C8), 35.9 (C4), 35.8 (C6), 29.0 (C5), 24.1 (C7), 18.1 (C3’). 
 
 
 
  
130 
Chapter 4: Experimental   
4.2.2 Stability studies 
Vinyl-protected ketoprofen (106): Stock solutions of 106 in MeCN (50 mM) were diluted in PBS, DMEM 
+ 10% FBS or 10% human plasma in PBS to a final concentration of 1 mM. Acetophenone was used as 
an internal standard. A stock solution of acetophenone in MeCN (60 mM) was added to the samples 
to give a final concentration of 2.5 mM. The sample mixture was incubated at 37 °C and analysed at 
different times by HPLC/UV analysis (1 h, 2h, 4 h, 24 h). The HPLC/UV analysis was performed on a 
Dionex UltiMate 3000 UHPLC+ system (Thermo Scientific) with a Phenomenex Luna NH2 Column (100 
Å 5 μm, 250 mm x 4.6 mm). The mobile phase consisted of A: H2O with 0.1% formic acid, and B: MeCN 
with 0.1% formic acid. The samples were eluted with a linear gradient (315 min 0100% B, and 1523 
min 100% B, 0.50 mL/min. This experiment was performed by Luxi Qiao. 
Cis-cyclooctene-protected ketoprofen (113): Stock solutions of 113 in MeCN (20 mM) were diluted in 
PBS, DMEM + 10% FBS or 10% human plasma in PBS to give a final concentration of 800 μM. Benzoic 
acid was used as an internal standard, and a stock solution of benzoic acid in MeCN (200 mM) was 
added to the samples to give a final concentration of 2 mM. The sample mixture was incubated at 37 
°C and analysed at different times (1 h, 2 h, 4 h, 24 h, and 48 h) by HPLC/UV analysis. The HPLC/UV 
analysis was performed on an Agilent 1100 series instrument with a Phenomenex Luna NH2 Column 
(100 Å 5 μm, 250 mm x 4.6 mm). The mobile phase consisted of A: H2O with 0.1% TFA, and B: MeCN 
with 0.1% TFA. The samples were eluted with a linear gradient (320 min 0100% B and 2027 min 
100% B, 0.50 mL/min). This experiment was performed by Luxi Qiao. 
Tetrazines 15, 58, 89, 90, 91: 60 μL of tetrazines 15, 58, 89, 90, 91 (2 mM, 50% DMSO/H2O) was added 
to a 96 well plate (Greiner, black, clear bottomed) in technical triplicates and the absorbance was 
monitored over 24 h at 37 °C. For tetrazine 15, which was not completely soluble at this concentration, 
the stock solution was centrifuged and the supernatant was used for the experiment. Readings were 
taken every minute using a SpectraMax i3x plate reader (λmax = 530 nm). This assay was performed 3 
independent times. Data were processed using GraphPad Prism (GraphPad Software, La Jolla, CA, 
USA). 
Biological stability of tetrazine 90: A stock solution of tetrazine 90 in DMSO (400 mM) was diluted in 
PBS, DMEM + 10% FBS or 10% human plasma in PBS to give a final concentration of 10 mM. The sample 
mixtures were then filtered and the decay of the UV absorbance of the tetrazine at 530 nm was 
followed over 24 h at 37 °C with measurements taken at every 5 min with a Cary 100 instrument from 
Varian. This experiment was performed by Luxi Qiao. 
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4.2.3 Decaging studies 
Kinetics of vinyl ester decaging: Rate constants were determined under pseudo-first order conditions. 
Stocks solutions in 30% H2O/DMF were prepared for each tetrazine 15, 58, 89, 90, 91 (4 mM) and vinyl 
propionate (103, 300 to 700 mM). Mixing equal volumes of the stock solutions resulted in final 
concentrations of 2 mM for the tetrazine and 150350 mM for vinyl propionate (103). The decay of 
the UV absorbance of the tetrazine at the corresponding wavelength was followed over time at 37 °C 
with a Cary 100 instrument from Varian and the data were fitted to an exponential one-phase decay 
equation Y = (Y0 – Plateau)e(kX) + Plateau. Each measurement was repeated three different times. The 
resulting values for kobs were then plotted against the concentration of vinyl propionate and fitted to 
a linear equation to obtain the second-order rate constant k2 from the slope. Data were processed 
using GraphPad Prism (GraphPad Software, La Jolla, CA, USA). This experiment was performed by Luxi 
Qiao. 
Decaging of vinyl-protected ketoprofen (106): The caged compound 106 (1.25 mM) was mixed with 
tetrazine 90 (37.5 mM) in 43% MeOH in H2O. The sample mixtures were incubated at 37 °C and 
analysed at different times (0 h, 24 h). The HPLC/UV analysis was performed on a Dionex UltiMate 
3000 UHPLC+ system (Thermo Scientific) with a Phenomenex Luna NH2 Column (100 Å 5 μm, 250 mm 
x 4.6 mm). The mobile phase consisted of A: H2O with 0.1% formic acid, and B: MeCN with 0.1% formic 
acid. The samples were eluted with a linear gradient (310 min 0100% B, and 1017 min 100% B, 
0.50 mL/min). This experiment was performed by Luxi Qiao. 
Decaging of TCO-protected ketoprofen (114): TCO-ketoprofen (114) in DMF (23 μL, 11.4 mM), 
tetrazine 15, 89, 90 or 91 in DMF (23 μL, 11.4 mM) and the internal standard benzoic acid in MeCN 
(80 μL, 2 mM) were mixed to give final reactant concentrations of 2.1 mM (114 and tetrazine 15, 89, 
90 or 91) and 1.3 mM (benzoic acid standard). For reactions in 25%, 50%, 75% water and 1% formic 
acid, the benzoic acid stock solution (and for 75% water, the tetrazine) was prepared in an appropriate 
solvent system (MeCN/H2O) to ensure the correct final percentage of water in the reaction mixture. 
25 μL of reactant mixture was quenched at different time points (10 s, 30 s, 2 min, 1 h, and 3 h) with 
an excess of TCO-OH (3.3 μL, 400 mM in MeCN). The sample was then diluted with 6.5 μL 50% 
MeCN/H2O and injected into the LC-MS. The LC-MS analysis was performed on Waters SQD2 with 
Waters H-Class UPLC system with a Waters Acquity UPLC BEH C18 column (1.7µm, 2.1 x 50 mm). The 
mobile phase consisted of A: 10mM ammonium acetate with 0.1% formic acid, and B: 95% aqueous 
MeCN with 0.05% formic acid. The samples were eluted with a linear gradient (0.252 min 0100% B, 
and 22.5 min 100% B, 0.80 mL/min).  
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4.2.4 Live cells studies 
Cell Culture: RAW264.7 (ATCC TIB-71) cells were routinely grown in a humidified incubator at 37 °C 
under 5% CO2, and split before reaching confluence using a cell scraper. The cell line was grown on 
DMEM medium (catalogue number: 21063029) supplemented with 10% heat-inactivated FBS 
(Endotoxin level: ≤5 EU/mL, catalogue number: 10082147), 4 mM L-glutamine, 4500 mg/L glucose,      
1 mM sodium pyruvate, 1500 mg/L sodium bicarbonate, and 100 units/mL penicillin. All reagents were 
bought from Gibco, Life Technologies (Thermo Fisher Scientific, UK), unless otherwise stated. Pipette 
tips were Pyrogen free and purchased from STARLAB, UK (catalogue number: S1126-7810). 
Cytotoxicity in RAW264.7 cells: Cytotoxicity of axial-TCO-ketoprofen (114ax), equatorial-TCO-
ketoprofen (114eq), tetrazine 90, ketoprofen (105) and LPS was assessed using a CellTiter-Blue Cell 
Viability Assay (ThermoFisher Scientific, USA). Briefly, cells were seeded at a concentration of           
5,000 cells/well (200 μL) in flat-bottom 96-well plates and allowed to adhere and adapt to the plates 
for 24 h. At this point, increasing concentrations of each compound (dissolved in DMSO) were added 
in technical triplicates (for tetrazines: 440 μM, 148 μM, 49 μM, 16 μM, and 5.0 μM; for LPS: 15 μg/mL, 
10 μg/mL, 5 μg/mL, 2.5 μg/mL, 1 μg/mL, 500 ng/mL, 100 ng/mL and 50 ng/mL); for other compounds: 
133 μM, 44.4 μM, 14.8 μM, 4.9 μM, 1.6 μM, and 0.5 μM). Final concentration of DMSO in each well 
was < 0.5%. Plates were incubated for 3 days, at which time cell viability was assessed by the addition 
of CellTiter-Blue Reagent (dilution 1:10 from commercial stock) and incubation for a further 3 h, before 
analysis of fluorescence on a SpectraMax i3x plate reader (λex = 570 nm, λem = 590 nm).  
Inhibition of nitric oxide production in LPS-stimulated RAW264.7 Cells: The anti-inflammatory effect 
of axial-TCO-ketoprofen (114ax), equatorial-TCO-ketoprofen (114eq), tetrazine 90, ketoprofen (105), 
axial-TCO-ketoprofen (114ax) with tetrazine 90, and equatorial-TCO-ketoprofen (114eq) with 90 was 
assessed using the Griess test, which detects nitric oxide (NO) levels by the production of a UV-active 
coloured azo compound. RAW264.7 cells were seeded at a density of 4 x 104 cells/well in 96-well plates 
and incubated for 24 h at 37 °C and 5% CO2. At this point, the media was replaced with phenol red-
free complete media (200 μL). Tetrazine 90 was added in technical triplicates by replacing the media 
with 200 μl of a 50 μM solution of tetrazine in phenol red-free complete media. Other compounds 
(dissolved in DMSO) were added in technical triplicates to give a concentration of 10 μM. LPS was then 
added to each well to give a concentration of 500 ng/mL. Final concentration of DMSO in each well 
was ≤ 0.125%. Plates were incubated for 11 h (5 h, 11 h, 24 h in optimisation experiments), at which 
time 100 μL of the supernatent was extracted and added to 100 μL of Griess reagent (Sigma-Aldrich) 
for 15 min before measurement of the absorbance on a SpectraMax i3x plate reader, (λmax = 540 nm). 
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This assay was performed 3 independent times. Statistical analysis was performed on GraphPad Prism 
using a one-way analysis of variance (ANOVA). 
Cell permeability of TCO-ketoprofen and ketoprofen in RAW264.7 cells: The cell permeability of axial-
TCO-ketoprofen (114ax), equatorial-TCO-ketoprofen (114eq), and ketoprofen (105) were evaluated 
by HPLC. Cells were seeded at a concentration of 125,000 cells/well (500 μL) in flat-bottom 24 well-
plates and allowed to adhere and adapt to the plates for 24 h. At this point, media was replaced and 
LPS was added to each well in the concentration of 5 μg/mL and each compound was added (200 mM 
stock dissolved in DMSO) in technical triplicates for a final concentration of 1 mM. Final concentration 
of DMSO in each well was 0.5%. Plates were incubated for 24 h, at which time the media was collected, 
centrifuged, and the supernatant analyzed using HPLC. The HPLC/UV analysis was performed on a 
Dionex UltiMate 3000 UHPLC+ system (Thermo Scientific) with a Phenomenex Luna NH2 Column      
(100 Å 5 μm, 250 mm x 4.6 mm). The mobile phase consisted of A: H2O with 0.1% formic acid, and B: 
MeCN with 0.1% formic acid. The samples were eluted with a linear gradient (315 min 0100% B, 
and 1523 min 100% B, 0.50 mL/min). 
Inhibition of PGE2 expression in LPS-stimulated RAW264.7 Cells: The anti-inflammatory effect of 
axial-TCO-ketoprofen (114ax), equatorial-TCO-ketoprofen (114eq), tetrazine 90, ketoprofen (105), 
axial-TCO-ketoprofen (114ax) with tetrazine 90 and equatorial-TCO-ketoprofen (114eq) with tetrazine 
90 was assessed using a competitive ELISA assay, which detects PGE2 levels. RAW264.7 cells were 
seeded at a density of 4 x 104 cells/well in 96-well plates and incubated for 24 h at 37 °C and 5% CO2. 
At this point, the media was replaced with phenol red-free complete media (200 μL). Tetrazine was 
added in technical triplicates by replacing the media with 200 μl of a 50 μM solution of tetrazine in 
phenol red-free complete media. Other compounds (dissolved in DMSO) were added in technical 
triplicates to give a concentration of 10 μM. LPS was then added to each well to give a concentration 
of 500 ng/mL. Final concentration of DMSO in each well was ≤ 0.125%. Plates were incubated for           
11 h, at which time 100 μL of the content of each well was extracted. PGE2 (R&D Systems, Minneapolis, 
USA) was measured according the manufacturer's directions. Statistical analysis was performed on 
GraphPad Prism using a one-way ANOVA. 
 Computational Studies were performed by Claudio Navo and Gonzalo Jiménez‐Osés from the 
Universidad de la Rioja, Spain.[11]  
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4.3 Experimental procedures for Chapter 3 
4.3.1 Synthetic procedures 
(2E)-Cyclooct-2’-en-1’-yl 4-nitrophenyl carbonate (121) 
 
According to the procedure by Lemke et al.,[12] (2E)-cyclooct-2-en-1-ol (axial isomer) (119, 35 mg,  
0.277 mmol, 1.0 equiv.) and pyridine (0.06 mL, 0.693 mmol, 2.5 equiv.) were dissolved in CH2Cl2               
(3 mL). A solution of 4-nitrophenyl chloroformate (120, 84 mg, 0.416 mmol, 1.5 equiv.) in CH2Cl2              
(3 mL) was added and the reaction was stirred at rt for 5 h. The reaction was stopped by addition of 
NH4Cl (aq) (sat. soln., 5 mL) and the phases were separated. The aqueous phase was extracted with 
CH2Cl2 (2 x 10 mL) and the combined organic extracts were washed with brine (10 mL), dried over 
anhydrous Na2SO4 and concentrated in vacuo. Purification via flash column chromatography (5% 
EtOAc/Petrol) yielded 121 as a white solid (49 mg, 0.168 mmol, 61%). The NMR data were in 
accordance with the previously reported literature data.[12]  
 
Rf 0.17 (5% EtOAc/Petrol).  
1H NMR (400 MHz, CDCl3) δ 8.48 – 8.19 (m, 2H, H3), 7.42 (d, J = 9.2 Hz, 2H, H2), 6.00 (ddd, J = 16.2, 
11.1, 3.8 Hz, 1H, H3’), 5.58 (dd, J = 16.2, 2.3 Hz, 1H, H2’), 5.51 – 5.35 (m, 1H, H1’), 2.55 (dd, J = 10.8, 
4.3 Hz, 1H, H4a’), 2.30 – 2.17 (m, 1H, H8a’), 2.17 – 2.01 (m, 2H, H4b’, H5a’), 1.99 – 1.87 (m, 1H, H6a’), 
1.88 – 1.68 (m, 2H, H7a’, H8b’), 1.63 – 1.50 (m, 1H, H5b’), 1.31 – 1.12 (m, 1H, H7b’), 0.86 (tdd, J = 12.9, 
5.4, 3.2 Hz, 1H, H6b’).  
13C NMR (101 MHz, CDCl3) δ 155.6 (C1), 151.6 (C5), 145.3 (C4), 133.1 (C3’), 129.4 (C2’), 125.3 (C3), 
121.8 (C2), 78.8 (C1’), 40.4 (C8’), 36.0 (C4’), 35.9 (C5’), 28.9 (C6’), 24.0 (C7’). 
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(2E)-Cyclooct-2’-en-1’-yl 2-oxochromen-7-yl carbonate (123) 
 
According to the modified procedure by Renslo et al.,[13] 7-hydroxycoumarin (122, 71 mg, 0.437 mmol, 
2.6 equiv.), DIPEA (0.09 mL, 0.505 mmol, 3.0 equiv.) and 4-(N,N-dimethylamino)pyridine (DMAP, 8 mg, 
0.067 mmol, 0.4 equiv.) were added to a solution of (2E)-cyclooct-2-en-1-yl 4-nitrophenyl carbonate 
(121, 49 mg, 0.168 mmol, 1.0 equiv.) in DMF (3 mL). The reaction mixture was stirred at rt for 24 h 
then an additional portion of 7-hydroxycoumarin (122, 30 mg, 0.185 mmol, 1.1 equiv.) and DIPEA   
(0.03 mL, 0.185 mmol, 1.1 equiv.) was added. The reaction was stirred for a further 3 h then diluted 
with Et2O (30 mL), washed with HCl (1M, 10 mL), NaOH (1M, 5 x 10 mL), brine (20 mL), dried over 
anhydrous MgSO4, filtered and concentrated in vacuo. Purification via flash column chromatography 
(2025% EtOAc/Petrol) yielded 123 as a white solid (32 mg, 0.102 mmol, 61%). 
 
Rf 0.30 (25% EtOAc/Petrol).  
Mp 105107 °C.  
1H NMR (400 MHz, CDCl3) δ 7.69 (d, J = 9.5 Hz, 1H, H4), 7.49 (d, J = 8.5 Hz, 1H, H5), 7.23 (d, J = 2.3 Hz, 
1H, H8), 7.16 (dd, J = 8.5, 2.3 Hz, 1H, H6), 6.40 (d, J = 9.5 Hz, 1H, H3), 5.98 (ddd, J = 16.2, 11.2, 3.8 Hz, 
1H, H3’), 5.56 (dd, J = 16.2, 2.3 Hz, 1H, H2’), 5.46 – 5.40 (m, 1H, H1’), 2.53 (dd, J = 10.7, 4.3 Hz, 1H, 
H4a’), 2.27 – 2.16 (m, 1H, H8a’), 2.13 – 1.97 (m, 2H, H4b’, H5a’), 1.92 (dddd, J = 15.1, 7.2, 3.5, 1.7 Hz, 
1H, H6a’), 1.85 – 1.65 (m, 2H, H7a’, H8b’), 1.65 – 1.46 (m, 1H, H5b’), 1.19 (dddd, J = 19.1, 15.0, 9.7,     
1.7 Hz, 1H, H7b’), 0.92 – 0.72 (m, 1H, H6b’).  
13C NMR (101 MHz, CDCl3) δ 160.3 (C2), 154.7 (C8a), 153.5 (C7), 151.9 (C9), 142.8 (C4) , 133.1 (C3’), 
129.5 (C2’), 128.6 (C5), 117.8 (C6), 116.7 (C4a), 116.2 (C3), 109.9 (C8), 78.6 (C1’), 40.5 (C8’), 36.0 (C4’), 
35.9 (C5’), 29.0 (C6’), 24.0 (C7’).  
IR (thin film, νmax/cm1) 2929m, 2852w, 1759s, 1726s, 1706m, 1619m, 1567w, 1503w, 1453w, 1401m, 
1277m.  
HRMS (ESI+): m/z calc. for C18H18O5 [M+H]+ 315.1227, found 315.1220, ∆ -2.1 ppm.  
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4-[(2’Z)-cyclooct-2’-en-1’-yloxy]benzaldehyde (127) 
 
According to the modified procedure by Versteegen et al.[14] 4-hydrobenzaldehyde (128, 90 mg,     
0.737 mmol, 1.5 equiv.) and triphenylphosphine (193 mg, 0.737 mmol, 1.5 equiv.) were added to a 
solution of cis-cyclooct-2-en-1-ol (111, 62 mg, 0.491 mmol, 1.0 equiv.) in THF (4 mL). The reaction 
mixture was cooled to 0 °C and diisopropyl azodicarboxylate (DIAD, 0.15 mL, 0.737 mmol, 1.5 equiv.) 
was added dropwise. The reaction was stirred in the dark at rt for 20 h. Silica was added and all 
volatiles were removed in vacuo. Purification of the dry residue directly via flash column 
chromatography (17% EtOAc/Petrol) gave 127 as a pale yellow oil (40 mg, 0.174 mmol, 35%). 
 
Rf 0.34 (7% EtOAc/Petrol). 
1H NMR (500 MHz, CDCl3) δ 9.86 (s, 1H, H5), 7.84 – 7.75 (m, 2H, H2), 6.99 – 6.92 (m, 2H, H3), 5.80 
(dddd, J = 10.9, 9.1, 7.4, 1.6 Hz, 1H, H3’), 5.49 (ddd, J = 10.8, 7.1, 1.3 Hz, 1H, H2’), 5.17 (dddd, J = 8.6, 
6.6, 4.6, 1.5 Hz, 1H, H1’), 2.38 – 2.19 (m, 2H, H4’), 2.11 (ddt, J = 13.0, 8.7, 4.4 Hz, 1H, H8a’), 1.87 – 1.36 
(m, 6H, H5a’, H6’, H7’, H8b’), 0.98 – 0.75 (m, 1H, H5b’). 
13C NMR (126 MHz, CDCl3) δ 190.8 (C5), 163.5 (C4), 132.0 (C3’), 131.9 (C2), 130.8 (C2’), 129.6 (C1), 
115.7 (C3), 75.8 (C1’), 35.7 (C8’), 29.0 (C5’), 26.8 (C6’), 26.1 (C4’), 23.3(C7’). 
IR (thin film, νmax/cm) 2926m, 2854w, 1689s, 1597s, 1575m, 1506m, 1306m, 1246s, 1214m, 1157s.  
HRMS (ASAP+): m/z calc. for C15H18O2 [M]+ 230.1307, found 230.1302, ∆  2.2 ppm.  
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{4-[(2Z)-cyclooct-2’-en-1’-yloxy]phenyl}methanol (129) 
 
Aldehyde 127 (36 mg, 0.156 mmol, 1.0 equiv.) was dissolved in MeOH (2 mL) and cooled to 0 °C. 
Sodium borohydride (59 mg, 1.56 mmol, 10 equiv.) was added and the reaction was stirred at rt for    
2 h. NH4Cl (aq) (sat. soln., 2 mL) was added slowly and the reaction was stirred for 10 min. MeOH was 
removed in vacuo and the aqueous solution was extracted with EtOAc (3 x 5 mL). The organic layers 
were washed with brine (10 mL), dried over anhydrous Na2SO4 and concentrated in vacuo. Purification 
via flash column chromatography (20% EtOAc/PE) yielded 129 as a colourless oil (18 mg, 0.077 mmol, 
50%).  
 
Rf 0.20 (20% EtOAc/Petrol). 
1H NMR (500 MHz, MeOD) δ 7.26 – 7.16 (m, 2H, H2), 6.87 – 6.76 (m, 2H, H3), 5.74 (dddd, J = 10.8, 9.0, 
7.2, 1.6 Hz, 1H, H3’), 5.45 (ddd, J = 10.9, 7.1, 1.4 Hz, 1H, H2’), 5.16 – 5.07 (m, 1H, H1’), 4.51 (s, 2H, H5), 
2.41 – 2.29 (m, 1H, H4a’), 2.24 – 2.15 (m, 1H, H4b’), 2.11 – 2.00 (m, 1H, H8a’), 1.82 – 1.52 (m, 6H, H5a’, 
H6’, H7’, H8b’), 1.46 (tdt, J = 12.6, 6.6, 3.4 Hz, 1H, H5b’). 
13C NMR (126 MHz, MeOD) δ 157.5 (C4), 133.2 (C2’), 132.9 (C1), 129.6 (C3’), 128.1 (C2), 115.1 (C3), 
74.8 (C1’), 63.6 (C5), 35.5 (C8’), 28.7 (C5’), 26.2 (C4’), 25.9 (C6’), 23.1(C7’).  
IR (thin film, νmax/cm) 3375m, 2927s, 2853m, 1611m, 1584w, 1509s, 1455w, 1241s, 1038m. 
HRMS (ESI+): m/z calc. for C15H20O2Na [M+Na]+ 255.1356, found 255.1361, ∆ 2.3 ppm.   
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(1’Z)-3’-[4-(chloromethyl)phenoxy]cyclooct-1’-ene (130) 
 
 
 
Triethylamine (78 µL, 0.516 mmol, 3.0 equiv.) was added to a solution of alcohol 129 (40 mg,             
0.172 mmol, 1.0 equiv.) in CH2Cl2 (2 mL) and the solution was cooled to 0 °C. A solution of 
methanesulfonyl chloride (26 µL, 0.344 mmol, 2.0 equiv.) in CH2Cl2 (2 mL) was added dropwise and 
the reaction mixture was warmed to rt and stirred at rt for 18 h. The reaction mixture was 
concentrated in vacuo and filtered through silica (3% EtOAc/Petrol). This experiment was performed 
by Dr. Bruno Oliveira. 
 
1H NMR (400 MHz, CDCl3) δ 7.29 (d, J = 5.7 Hz, 2H, H2), 6.93 – 6.77 (m, 2H, H3), 5.77 (dddd, J = 10.8, 
9.0, 7.3, 1.6 Hz, 1H, H1’), 5.52 (ddd, J = 10.8, 7.1, 1.3 Hz, 1H, H2’), 5.10 (dddd, J = 11.5, 6.8, 4.7, 1.5 Hz, 
1H, H3’), 4.57 (s, 2H, H5), 2.40 – 2.16 (m, 2H, H8’), 2.11 (ddt, J = 13.0, 8.9, 4.6 Hz, 1H, H4a’), 1.84 – 1.39 
(m, 6H, H7a’, H6’, H5’, H4b’), 0.96 – 0.79 (m, 1H, H7b’). 
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7-({4’’-[(2’Z)-cyclooct-2’-en-1’-yloxy]phenyl}methoxy)chromen-2-one (131) 
 
To a solution of chloride 130 (30 mg, 0.098 mmol, 1.0 equiv.) in MeCN (2 mL) was added a solution of 
7-hydroxycoumarin (122, 31 mg, 0.193 mmol, 2.0 equiv.) and DIPEA (34 µL, 0.193 mmol, 2.0 equiv.) in 
MeCN (2 mL). The reaction mixture was refluxed for 24 h, then cooled to rt and concentrated in vacuo. 
Purification via flash column chromatography (0.5% MeOH/CH2Cl2) yielded 131 as a colourless oil          
(5 mg, 0.013 mmol, 8% over 2 steps). This experiment was performed by Dr. Bruno Oliveira. 
 
1H NMR (400 MHz, CDCl3) δ 7.65 (d, J = 9.5 Hz, 1H, H4), 7.42 – 7.36 (m, 1H, H5), 7.36 – 7.30 (m, 2H, 
H6, H8), 6.97 – 6.88 (m, 4H, H2’’, H3’’), 6.27 (d, J = 9.5 Hz, 1H, H3), 5.78 (dddd, J = 10.8, 9.0, 7.2,               
1.6 Hz, 1H, H3’), 5.53 (ddd, J = 10.9, 7.1, 1.3 Hz, 1H, H2’), 5.12 (dd, J = 11.4, 5.6 Hz, 1H, H1’), 5.06 (s, 
2H, H9), 2.40 – 2.17 (m, 2H, H4’), 2.11 (ddt, J = 13.0, 8.8, 4.7 Hz, 1H, H8a’), 1.82 – 1.61 (m, 4H), 1.58 – 
1.40 (m, 2H), 0.88 – 0.80 (m, 1H, H6’). 
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4-{[(tert-butyldimethylsilyl)oxy]methyl}aniline (137) 
 
According to the procedure by Haynes et al.,[15] 4-aminobenzyl alcohol (136, 0.250 g, 2.03 mmol,          
1.0 equiv.) and imidazole (0.152 g, 2.23 mmol, 1.1 equiv.) were dissolved in CH2Cl2 (5 mL). TBSCl     
(0.336 g, 2.23 mmol, 1.1 equiv.) was added and the reaction was stirred at rt for 24 h. The reaction 
was quenched with water (10 mL) and extracted with CH2Cl2 (4 x 10 mL). The combined organic layers 
were washed with brine (20 mL), dried over anhydrous Na2SO4 and concentrated in vacuo. Purification 
via flash column chromatography (40% EtOAc/Petrol) yielded 137 as a yellow liquid (0.373 g,                
1.57 mmol, 77%). The NMR data were in accordance with reported data.[16] 
 
Rf 0.76 (40% EtOAc/Petrol).  
1H NMR (400 MHz, CDCl3) δ 7.18 – 7.06 (m, 2H, H3), 6.66 (d, J = 8.4 Hz, 2H, H2), 4.62 (s, 2H, H5), 3.61 
(br s, 2H, NH2), 0.92 (s, 9H, OSi(CH3)2C(CH3)3), 0.08 (s, 6H, OSi(CH3)2C(CH3)3).  
 
tert-butyl[(4-isocyanatophenyl)methoxy]dimethylsilane (138) 
 
According to the procedure by Alaoui et al.,[17] amine 137 (50 mg, 0.211 mmol, 1.0 equiv.) was 
dissolved in toluene (5 mL). Triethylamine (0.03 mL, 0.232 mmol, 1.1 equiv.) and triphosgene (25 mg, 
0.084 mmol, 0.4 equiv.) were added and the reaction mixture was heated to 70 °C for 3 h. The mixture 
was filtered, washed with toluene and concentrated in vacuo to give 138 as a colourless oil which was 
used directly in the next step assuming quantitative yield. The NMR data were in accordance with 
reported data.[17]  
 
1H NMR (400 MHz, CDCl3) δ 7.31 – 7.24 (m, 2H, H2/3), 7.05 (dd, J = 8.5, 2.0 Hz, 2H, H2/3), 4.71 (s, 2H, 
H5), 0.95 (d, J = 1.6 Hz, 9H, OSi(CH3)2C(CH3)3), 0.10 (d, J = 1.6 Hz, 6H, OSi(CH3)2C(CH3)3).  
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(2E)-cyclooct-2-en-1-yl N-(4-{[(tert-butyldimethylsilyl)oxy]methyl}phenyl)carbamate (139) 
 
(2E)-Cyclooct-2-en-1-ol (119, axial isomer) (60 mg, 0.486 mmol, 1.0 equiv.) was dissolved in toluene   
(3 mL) and cooled to 0 °C. Triethylamine (0.07 mL, 0.535 mmol, 1.1 equiv.) was added followed by a 
solution of isocyanate 138 (166 mg, 0.632 mmol, 1.3 equiv.) in toluene (2 mL). The reaction was stirred 
at rt for 16 h then silica was added and all volatiles were removed in vacuo. Purification of the dry 
residue directly via flash column chromatography (210% EtOAc/Petrol) yielded 139 as a colourless 
oil (60 mg, 0.154 mmol, 24%). 
 
Rf 0.26 (10% EtOAc/Petrol). 
1H NMR (500 MHz, CDCl3) δ 7.36 (d, J = 8.2 Hz, 2H, H2), 7.25 (s, 1H, H3 (masked by CDCl3 peak)), 5.88 
(td, J = 13.2, 11.1, 3.6 Hz, 1H, H3’), 5.57 (dd, J = 16.4, 2.5 Hz, 1H, H2’), 5.44 (s, 1H, H1’), 4.69 (s, 2H, H5), 
2.52 – 2.42 (m, 1H, H4a’), 2.20 – 2.10 (m, 1H, H8a’), 2.09 – 1.95 (m, 2H, H4b’, H5a’), 1.89 (dddt,                     
J = 12.8, 8.9, 5.2, 1.7 Hz, 1H, H6a’), 1.80 – 1.63 (m, 2H, H7a’, H8b’), 1.53 – 1.43 (m, 1H, H5b’), 1.12 (ddt, 
J = 14.7, 12.7, 8.0 Hz, 1H, H7b’), 0.93 (s, 9H, OSi(CH3)2C(CH3)3), 0.89 – 0.77 (m, 1H, H6b’), 0.09 (s, 6H, 
OSi(CH3)2C(CH3)3).  
13C NMR (126 MHz, CDCl3) δ 152.7 (C6), 136.7 (C4), 136.4 (C1), 132.1 (C3’), 131.0 (C2’), 126.9 (C3), 
118.3 (C2), 74.4 (C1’), 64.7 (C5), 40.7 (C8’), 36.0 (C4’), 35.9 (C5’), 29.1 (C6’), 26.0 (OSi(CH3)2C(CH3)3), 
24.2 (C7’), 18.4 (OSi(CH3)2C(CH3)3), -5.2 (OSi(CH3)2C(CH3)3).  
HRMS (ESI+): m/z calc. for C22H35O3NSiNa [M+Na]+ 412.2278, found 412.2262, ∆ 3.9 ppm.  
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(2’’E)-cyclooct-2’’-en-1’’-yl N-(4-{[(2’-oxochromen-7’-yl)oxy]methyl}phenyl)carbamate (142) from 
route 1 
 
According to the procedure by Hay et al.,[18] 139 (60 mg, 0.154 mmol) was dissolved in MeOH (2 mL). 
HCl (1 M, 1 mL) was added and the reaction was stirred at rt for 1 h, until TLC showed complete 
consumption of the starting material. The reaction mixture was then poured into brine (5 mL) and 
extracted with EtOAc (3 x 10 mL). The combined organic layers were washed with water (10 mL), dried 
over anhydrous MgSO4 and concentrated in vacuo. 1H NMR showed that the reaction was not 
complete, so the crude mixture was redissolved in MeOH (2 mL) and HCl (1 M, 1 mL), stirred at rt for 
1 h and then worked up as described above to give 140, which was used crude in the following step 
assuming quantitative yield.  
 
(2’E)-cyclooct-2’-en-1’-yl N-[4-(hydroxymethyl)phenyl]carbamate (140)  
Rf 0.11 (20% EtOAc/Petrol).  
1H NMR (400 MHz, CDCl3) δ 7.40 (d, J = 8.0 Hz, 2H, H2), 7.33 – 7.28 (m, 2H, H3), 6.67 (s, 1H, NH), 5.88 
(ddd, J = 15.8, 11.1, 3.7 Hz, 1H, H3’), 5.57 (dd, J = 16.4, 2.4 Hz, 1H, H2’), 5.44 (s, 1H, H1’), 4.64 (s, 2H, 
H5), 2.49 (dd, J = 10.5, 4.8 Hz, 1H, H4a’), 2.14 (dd, J = 14.3, 5.2 Hz, 1H, H8a’), 2.08 – 1.95 (m, 2H, H4b’, 
H5a’), 1.95 – 1.83 (m, 1H, H6a’), 1.81 – 1.63 (m, 2H, H7a’, H8b’), 1.58 (d, J = 4.8 Hz, 1H, H5b’), 1.10 (dd, 
J = 14.1, 6.1 Hz, 1H, H7b’), 0.83 (ddd, J = 16.6, 9.8, 4.3 Hz, 1H, H6b’). 
 
According to the procedure by Behnam et al.,[19] crude compound 140 was dissolved in Et2O (5 mL) 
and cooled to 0 °C. PBr3 (0.1 M in CH2Cl2, 0.12 mL, 0.8 equiv.) was added dropwise and the reaction 
was stirred at 0 °C for 18 h. The reaction mixture was then poured into NaHCO3 (aq) (sat. soln., 10 mL) 
and extracted with Et2O (3 x 10 mL). The combined organic layers were washed with water (20 mL), 
dried over anhydrous Na2SO4 and concentrated in vacuo. 2 products were observed by TLC and               
1H NMR which correspond to the cis- and trans-isomers. Compound 141 was used crude in the next 
step assuming quantitative yield. 
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(2’E)-cyclooct-2’-en-1’-yl N-[4-(bromomethyl)phenyl]carbamate (141) 
Rf 0.61, 0.7 (20% EtOAc/Petrol). 
 1H NMR (400 MHz, CDCl3) δ 7.42 – 7.30 (m, 4H), 6.69 (s, 0.4H, NH trans), 6.61 (s, 0.6H, NH cis), 5.93 – 
5.82 (m, 0.3H), 5.74 – 5.61 (m, 0.6H), 5.62 – 5.57 (m, 0.2H), 5.57 – 5.48 (m, 0.6H), 5.44 (s, 0.3H), 4.48 
(d, J = 1.6 Hz, 2H), 2.52 – 2.41 (m, 1H), 2.34 – 2.21 (m, 1H), 2.19 – 2.09 (m, 1H), 2.08 – 1.96 (m, 1H), 
1.94 – 1.82 (m, 0.3H), 1.81 – 1.47 (m, 4H), 1.19 – 1.02 (m, 0.5H), 0.94 – 0.73 (m, 1H). NMR not assigned 
due to mixture of isomers. 
 
141 was dissolved in MeCN (2 mL) and added to a solution of 7-hydroxycoumarin (122, 19 mg,                  
0.116 mmol, 1.5 equiv.) and caesium carbonate (50 mg, 0.154 mmol, 2.0 equiv.) in MeCN (3 mL). The 
reaction mixture was stirred at rt for 10 min then the solvent was removed in vacuo. The residue was 
re-dissolved in CH2Cl2 (10 mL) and washed with water (5 mL), NaHCO3 (aq) (sat. soln., 2 x 5 mL), water 
(5 mL), dried over anhydrous MgSO4 and concentrated in vacuo. Purification via flash column 
chromatography (1% MeOH/CH2Cl2) yielded impure product 142 as a white powder (3 mg) as a 3:7 
mixture of trans:cis. The product was not pure and 1H NMR is only shown to confirm the mixture of 
isomers. Full characterisation was obtained on the pure trans-isomer of 142 that was obtained during 
route 2 (see below). 
 
(2’’E)-cyclooct-2’’-en-1’’-yl N-(4-{[(2’-oxochromen-7’-yl)oxy]methyl}phenyl)carbamate (142) 
Rf 0.43 (1% MeOH/CH2Cl2).  
1H NMR (400 MHz, CDCl3) δ 7.63 (d, J = 9.5 Hz, 1H, H4’), 7.44 (dd, J = 8.5, 6.8 Hz, 2H, H2), 7.36 (dt,            
J = 6.4, 2.3 Hz, 3H, H3, H5’), 6.92 – 6.84 (m, 2H, H6’, H8’), 6.75 (s, 0.3H, NH trans), 6.65 (s, 0.7H,                
NH cis), 6.25 (d, J = 9.5 Hz, 1H, H3’), 5.88 (ddd, J = 15.8, 11.1, 3.7 Hz, 0.4H, H3’’ trans), 5.71 (ddd,                 
J = 10.9, 7.3, 1.8 Hz, 1.1H), 5.59 (t, J = 2.7 Hz, 0.2H), 5.53 (ddd, J = 10.9, 7.0, 1.3 Hz, 0.7H, H2’’ or H3’’ 
cis), 5.44 (s, 0.3H), 5.07 (d, J = 2.8 Hz, 2H, H5), 2.56 – 2.39 (m, 1H), 2.34 – 2.23 (m, 1H), 2.14 (ddt,                
J = 18.0, 7.7, 3.3 Hz, 1H), 2.02 (ddt, J = 14.6, 9.9, 4.8 Hz, 1H), 1.95 – 1.82 (m, 0.2H), 1.80 – 1.62 (m, 1H), 
1.56 (q, J = 13.1, 11.8 Hz, 3H), 1.11 (td, J = 14.2, 6.0 Hz, 0.4H), 0.92 – 0.77 (m, 1H). 
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(2’’E)-cyclooct-2’’-en-1’’-yl N-(4-{[(2’-oxochromen-7’-yl)oxy]methyl}phenyl)carbamate (142) from 
route 2 
 
Boc protected aniline 145 (183 mg, 0.499 mmol, 1.0 equiv.) was dissolved in 4 M HCl in dioxane (8 mL) 
and the reaction was stirred at rt for 1 h. The solvent was evaporated, then the residue was redissolved 
in dioxane (8 mL). Triphosgene (74 mg, 0.249 mmol, 0.5 equiv.) was added and the reaction was 
heated to 60 °C for 4 h before the mixture was concentrated in vacuo. The residue was dissolved in 
toluene (20 mL) before the addition of DABCO (168 mg, 1.50 mmol, 3.0 equiv.) followed by TCO-OH 
(119, 31 mg, 0.250 mmol, 0.5 equiv.). The reaction was stirred at 100 °C for 16 h then cooled to rt. 
Purification via flash column chromatography (40% EtOAc/Petrol) then flash column chromatography 
(3% MeOH/CH2Cl2) yielded 142 as a white solid (8 mg, 0.019 mmol, 8%). 
 
Rf 0.40 (40% EtOAc/Petrol).  
Tdecomp. 139.7 °C.  
1H NMR (500 MHz, CDCl3) δ 7.63 (dd, J = 9.5, 0.6 Hz, 1H, H4’), 7.45 (d, J = 8.3 Hz, 2H, H2), 7.39 – 7.34 
(m, 3H, H3, H5’), 6.92 – 6.86 (m, 2H, H6’, H8’), 6.75 – 6.70 (m, 1H, NH), 6.25 (d, J = 9.5 Hz, 1H, H3’), 
5.88 (ddd, J = 15.8, 11.0, 3.6 Hz, 1H, H3’’), 5.58 (dd, J = 16.4, 2.5 Hz, 1H, H2’’), 5.44 (s, 1H, H1’’), 5.07 
(d, J = 3.5 Hz, 2H, H5), 2.49 (dd, J = 10.5, 5.1 Hz, 1H, H4a’’), 2.22 – 2.10 (m, 1H, H8a’’), 2.09 – 1.95 (m, 
2H, H4b’’, H5a’’), 1.94 – 1.83 (m, 1H, H6a’’), 1.80 – 1.64 (m, 2H, H7a’’, H8b’’), 1.56 – 1.42 (m, 1H, H5b’’), 
1.17 – 1.03 (m, 1H, H7b’’), 0.91 – 0.75 (m, 1H, H6b’’).  
13C NMR (126 MHz, CDCl3) δ 162.0 (C7’), 161.3 (C2’), 156.0 (C8a’), 152.8 (C6), 143.5 (C4’), 138.3 (C1), 
132.3 (C3’’), 131.0 (C2’’), 130.6 (C3), 128.9 (C5’), 128.8 (C4), 118.8 (C2), 113.4 (C6’), 113.4 (C3’), 112.9 
(C4a’), 102.1 (C8’), 74.7 (C1’’), 70.3 (C5), 40.8 (C8’’), 36.2 (C4’’), 36.1 (C5’’), 29.2 (C6’’), 24.4 (C7’’).  
IR (thin film, νmax/cm1) 2981w, 2924w, 2855w, 1723m, 1612m, 1528m, 1463w, 1350w, 1277m, 
1227m, 1059m, 801m, 734m, 618s.  
HRMS (ESI+): m/z calc. for C25H25NO5Na [M+Na]+ 442.1625, found 442.1613, ∆ 2.6 ppm.  
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tert-butyl N-[4-(hydroxymethyl)phenyl]carbamate (143) 
 
According to the procedure by Zhao et al.,[20] a solution of 4-aminobenzyl alcohol (136, 50 mg,          
0.406 mmol, 1.0 equiv.), DIPEA (0.07 mL, 0.406 mmol, 1.0 equiv.) and Boc anhydride (89 mg,             
0.408 mmol, 1.0 equiv.) in THF (4 mL) was heated to 75 °C for 20 h. The reaction was cooled to rt and 
the solvent was removed in vacuo. The residue was re-dissolved in EtOAc (10 mL), washed with HCl           
(0.1 M, 5 mL), dried over anhydrous MgSO4 and concentrated in vacuo. Purification via flash column 
chromatography (50% EtOAc/Petrol) yielded 143 as white crystalline solid (87 mg, 0.390 mmol, 96%). 
The NMR data were in accordance with reported data.[20]  
 
Rf 0.48 (50% EtOAc/Petrol).  
Tdecomp. 81.682.4 °C.  
1H NMR (400 MHz, CDCl3) δ 7.35 (d, J = 8.3 Hz, 2H, H2/3), 7.29 (d, J = 8.6 Hz, 2H, H2/3), 6.47 (s, 1H, 
NH), 4.63 (d, J = 5.2 Hz, 2H, H5), 1.52 (s, 7H, C(CH3)3). 
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tert-butyl N-[4-(bromomethyl)phenyl]carbamate (144) 
 
According to the procedure by Behnam et al.,[19] alcohol 143 (67 mg, 0.30 mmol, 1.0 equiv.) was 
dissolved in Et2O (8 mL) and the solution was cooled to 0 °C. PBr3 (1 M in CH2Cl2, 0.24 mL, 0.8 equiv.) 
was added dropwise and the reaction was stirred for 20 h at 0 °C. The reaction was poured into 
NaHCO3 (aq) (sat. soln., 5 mL) and extracted with Et2O (3 x 5 mL). The organic layers were washed with 
water (5 mL), dried over anhydrous Na2SO4 and concentrated in vacuo. This gave 144 as a white solid 
which was sufficiently pure by 1H NMR to proceed to the next step. The NMR data were in accordance 
with reported data.[19] 
 
Rf 0.85 (30% EtOAc/Petrol).  
1H NMR (400 MHz, CDCl3) δ 7.33 (d, J = 2.2 Hz, 4H, H2, H3), 6.49 (s, 1H, NH), 4.48 (d, J = 1.9 Hz, 2H, 
H5), 1.52 (d, J = 1.9 Hz, 9H, C(CH3)3).  
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tert-butyl N-(4-{[(2’-oxochromen-7’-yl)oxy]methyl}phenyl)carbamate (145) 
 
A solution of bromide 144 (0.30 mmol, 1.0 equiv., assuming quantitative yield) in MeCN (3 mL) was 
added to a solution of 7-hydroxycoumarin (122, 73 mg, 0.45 mmol, 1.5 equiv.) and caesium carbonate 
(195 mg, 0.60 mmol, 2.0 equiv.) in MeCN (5 mL). The reaction was stirred at rt for 30 min then the 
solvent was removed in vacuo. The residue was re-dissolved in CH2Cl2 (10 mL), washed with water        
(3 x 10 mL), dried over anhydrous MgSO4 and concentrated in vacuo. Purification via flash column 
chromatography (30% EtOAc/Petrol) yielded 145 as a white solid (22 mg, 0.06 mmol, 20% over 2 
steps). 
 
Rf 0.28 (30% EtOAc/Petrol).  
Mp 188 °C.  
1H NMR (500 MHz, CDCl3) 7.63 (d, J = 9.5 Hz, 1H, H4’), 7.42 – 7.33 (m, 5H, H2, H3, H5’), 6.93 – 6.82 (m, 
2H, H6’, H8’), 6.50 (s, 1H, NH), 6.25 (d, J = 9.5 Hz, 1H, H3’), 5.07 (s, 2H, H5), 1.52 (s, 9H, C(CH3)3).  
13C NMR (126 MHz, CDCl3) δ 161.9 (C7’), 161.2 (C2’), 155.8 (C8a’), 152.6 (C=O), 143.4 (C4’), 138.6 (C1), 
130.1 (C4), 128.7 (C5’), 128.6 (C3), 118.6 (C2), 113.3 (C6’), 113.2 (C3’), 112.7 (C4a’), 101.9 (C8’), 80.8 
(C(CH3)3), 70.2 (C5), 28.3 (C(CH3)3).  
IR (thin film, νmax/cm1) 3336m, 2987w, 1731m, 1699s, 1614s, 1598m, 1527s, 1453w, 1402m, 1385m, 
1348m, 1315m, 1273m, 1228s, 1153s, 1002s, 815s.  
HRMS (ESI+): m/z calc. for C21H21NO5Na [M+Na]+ 390.1312, found 390.1302, ∆ 2.7 ppm. 
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tert-butyl N-{4’’-[5-chloro-2-(2’,4’-dichlorophenoxy)phenoxymethyl]phenyl}carbamate (150) 
 
A solution of bromide 144 (0.560 mmol, 1.0 equiv., assuming quantitative yield) in MeCN (3 mL) was 
added to a solution of triclosan (149, 178 mg, 0.616 mmol, 1.1 equiv.) and caesium carbonate              
(365 mg, 1.12 mmol, 2.0 equiv.) in MeCN (2 mL). The reaction was stirred at rt for 24 h then the solvent 
was removed in vacuo. The residue was re-dissolved in CH2Cl2 (10 mL), washed with water (3 x 10 mL), 
dried over anhydrous MgSO4 and concentrated in vacuo. Purification via flash column chromatography 
(10% EtOAc/Petrol) yielded 150 as a white solid (176 mg, 0.356 mmol, 63%). 
 
Rf 0.18 (10% EtOAc/Petrol).  
Mp 142144 °C.  
1H NMR (400 MHz, CDCl3) δ 7.40 (d, J = 2.5 Hz, 1H, H3’), 7.30 (d, J = 8.4 Hz, 2H, H3’’), 7.11 (d,                             
J = 8.5 Hz, 2H, H2’’), 7.09 – 7.06 (m, 1H, H5’), 7.01 (d, J = 1.8 Hz, 1H, H6), 6.94 – 6.92 (m, 2H, H3, H4), 
6.64 (d, J = 8.8 Hz, 1H, H6’), 6.51 (s, 1H, NH), 4.98 (s, 2H, H7), 1.52 (s, 9H, C(CH3)3). 
 13C NMR (101 MHz, CDCl3) δ 152.8 (C=O), 152.5 (C1’), 150.5 (C1), 143.6 (C2), 138.4 (C4’’), 130.6 (C5), 
130.4 (C4’), 130.3 (C3’), 128.2 (C2’’), 128.1 (C1’’), 127.7 (C5’), 124.7 (C2’), 122.2 (C3), 121.6 (C4), 118.5 
(C3’’), 118.2 (C6’), 115.9 (C6), 80.8 (C(CH3)3), 70.9 (C7), 28.5 (C(CH3)3).  
IR (thin film, νmax/cm1) 3360m, 1695s, 1599m, 1528s, 1498s, 1471s, 1406m, 1308m, 1366m, 1312m, 
1270m, 1227s, 1163s, 1056s, 910m, 841s.  
HRMS (ESI+): m/z calc. for C24H22NO435Cl3Na [M+Na]+ 516.0507, found 516.0507, ∆ 0.1 ppm.  
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(2’’’E)-cyclooct-2’’’-en-1-yl N-{4’’-[5-chloro-2-(2,4’dichlorophenoxy)phenoxymethyl]phenyl} 
carbamate (153)  
 
Boc protected aniline 150 (150 mg, 0.303 mmol, 1.0 equiv.) was dissolved in 4 M HCl in dioxane (5 mL) 
and the reaction was stirred at rt for 15 h. The solvent was evaporated then the residue was 
redissolved in dioxane (4 mL). Triphosgene (45 mg, 0.152 mmol, 0.5 equiv.) was added and the 
reaction was heated to 60 °C for 5 h. The mixture was concentrated in vacuo. The residue was 
dissolved in toluene (5 mL) then DABCO (102 mg, 0.909 mmol, 3.0 equiv.) was added followed by     
TCO-OH (119, 42 mg, 0.333 mmol, 1.1 equiv.) and the reaction was stirred at 100 °C for 19 h then 
cooled to rt. Purification via flash column chromatography (5% EtOAc/Petrol) then preparative TLC 
(70% CH2Cl2/petrol) yielded 153 as a white solid (9.7 mg, 0.0177 mmol, 18%). 
 
Rf 0.45 (70% CH2Cl2/Petrol).  
1H NMR (400 MHz, CDCl3) δ 7.41 (dd, J = 2.6, 0.6 Hz, 1H, H3’), 7.35 (d, J = 8.2 Hz, 2H, H3’’), 7.12 (d,          
J = 8.4 Hz, 2H, H2’’), 7.08 (ddd, J = 8.8, 2.5, 0.6 Hz, 1H, H5’), 7.01 (dd, J = 1.9, 0.9 Hz, 1H, H6), 6.94 (dd, 
J = 2.6, 0.7 Hz, 2H, H3, H4), 6.72 – 6.61 (m, 2H, H6’, NH), 5.87 (ddd, J = 15.7, 11.0, 3.7 Hz, 1H, H3’’’), 
5.57 (dd, J = 16.4, 2.4 Hz, 1H, H2’’’), 5.43 (s, 1H, H1’’’), 4.99 (s, 2H, H7), 2.48 (td, J = 8.8, 7.3, 4.0 Hz, 1H, 
H4a’’’), 2.19 – 2.10 (m, 1H, H8a’’’), 2.07 – 1.94 (m, 2H, H4b’’’, H5a’’’), 1.94 – 1.83 (m, 1H, H6a’’’), 1.80 
– 1.62 (m, 2H, H7a’’’, H8b’’’), 1.48 (td, J = 12.6, 4.3 Hz, 1H, H5b’’’), 1.17 – 1.04 (m, 1H, H7b’’’), 0.91 – 
0.76 (m, 1H, H6b’’’).  
13C NMR (101 MHz, CDCl3) δ 152.6 (C8), 152.4 (C1’), 150.4 (C1), 143.5 (C2), 137.9 (C4’’), 132.1 (C3’’’), 
130.9 (C2’’’), 130.6 (C5), 130.4 (C4’), 130.2 (C3’), 128.1 (C2’’), 128.0 (C1’’), 127.6 (C5’), 124.6 (C2’), 
122.0 (C3), 121.5 (C4), 118.5 (C3’’), 118.0 (C6’), 115.8 (C6), 74.6 (C1’’’), 70.8 (C7), 40.7 (C8’’’), 36.0 
(C4’’’), 35.9 (C5’’’), 29.1 (C6’’’), 24.2 (C7’’’).  
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IR (thin film, νmax/cm1) 2922m, 2853w, 1711m, 1599m, 1527m, 1494s, 1474s, 1407m, 1317m, 1227s, 
1204m, 1075m.  
HRMS (ESI): m/z calc. for C28H26N1O435Cl3Na [M+Na]+ 568.0820, found 568.0810, ∆ -1.7 ppm.  
 
tert-butyl N-{4-[({19-ethyl-14,18-dioxo-17-oxa-3,13-diazapentacyclo [11.8.0.0²,¹¹.0⁴,⁹.0¹⁵,²⁰] 
henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-19-yl} oxy)methyl]phenyl}carbamate (154) 
 
A solution of bromide 144 (0.403 mmol, 3.4 equiv., assuming quantitative yield) in CH2Cl2 (3 mL) was 
added to a solution of camptothecin (81, 41 mg, 0.118 mmol, 1 equiv.) and 1,8-
diazabicyclo[5.4.0]undec-7-ene (DBU, 0.02 mL, 0.129 mmol, 1.1 equiv.) in CH2Cl2 (2 mL) at 0 °C. The 
reaction was stirred at 0 °C for 10 min and then rt for 24 h. The solvent was removed in vacuo. 
Purification of the dry residue directly via flash column chromatography (510% MeOH/CH2Cl2) 
yielded 154 as a white solid (32 mg, 0.058 mmol, 49%). The product decomposed after storage 
overnight at -20 °C, before full characterisation could be obtained. 
 
Rf 0.15 (5% MeOH/CH2Cl2).  
1H NMR (400 MHz, CDCl3) δ 8.41 (s, 1H, H11), 8.26 (d, J = 8.1 Hz, 1H, H7), 7.95 (d, J = 8.4 Hz, 1H, H10), 
7.85 (s, 1H, H9), 7.69 (d, J = 8.7 Hz, 2H, H6, H8), 7.33 (d, J = 16.6 Hz, 4H, H1, H2), 6.48 (s, 1H, NH), 5.77 
(d, J = 15.8 Hz, 1H, H13), 5.33 (d, J = 11.9 Hz, 3H, H12, H13), 4.65 (s, 2H, H3), 3.74 (s, 1H, OH), 1.97 (d, 
J = 43.5 Hz, 2H, H4), 1.27 (s, 8H, C(CH3)3), 1.07 (d, J = 7.5 Hz, 3H, H5). 
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4.3.2 Stability studies 
TCO-carbonate (123) in 50% H2O/DMSO: A solution of 123 (100 μM, 50% H2O/DMSO) was added to a 
96 well plate (Greiner, black, clear bottomed) in technical triplets. The fluorescence intensity was 
measured over 2 h at 37 °C, at the same time as measuring the fluorescence intensity of the reaction 
of 123 with tetrazine 58. Readings were taken at 8 second intervals using a SpectraMax i3x plate 
reader (λex = 325 nm, λem = 460 nm). This assay was performed 3 independent times. Data were 
processed using GraphPad Prism (GraphPad Software, La Jolla, CA, USA). 
TCO-carbonate (123) in PBS, DMEM + 10% FBS and human plasma: 5 μL of 123 in DMSO (1 mM) was 
added to 95 μL PBS, DMEM + 10% FBS or 20% human plasma in PBS in a 96 well plate (Greiner, black, 
clear bottomed) in technical triplets. The fluorescence intensity was measured over 2 h at 37 °C. 
Readings were taken at 8 second intervals using a SpectraMax i3x plate reader (λex = 325 nm, λem = 460 
nm). This assay was performed 3 independent times. Data were processed and fitted to a one phase 
association using GraphPad Prism (GraphPad Software, La Jolla, CA, USA). 
TCO-carbamate benzyl ether (142) in PBS, DMEM + 10% FBS and human plasma: 10 μL of 142 in 
DMSO (0.5 mM) was added to 90 μL PBS, DMEM + 10% FBS or 20% human plasma in H2O or LB media 
in a 96 well plate (Greiner, black, clear bottomed) in technical triplets. The fluorescence intensity was 
measured over 15 h at 37 °C. Readings were taken at 30 second intervals using a SpectraMax i3x plate 
reader (λex = 325 nm, λem = 460 nm). This assay was performed 3 independent times. Data were 
processed using GraphPad Prism (GraphPad Software, La Jolla, CA, USA). 
Tetrazines 15, 58, 89, 90, 91, 155: 60 μL of tetrazines 15, 58, 89, 90, 91, 155 (2 mM, 50% DMSO/H2O) 
was added to a 96 well plate (Greiner, black, clear bottomed) in technical triplicates and the 
absorbance was monitored over 24 h at 37 °C. For tetrazine 15, which was not completely soluble at 
this concentration, the stock solution was centrifuged and the supernatant was used for the 
experiment. Readings were taken every minute using a SpectraMax i3x plate reader (λmax = 530 nm). 
This assay was performed 3 independent times. Data were processed and fitted to a one phase decay 
using GraphPad Prism (GraphPad Software, La Jolla, CA, USA). 
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4.3.3 Decaging studies 
Preparation and use of external NMR standard to determine accurate concentrations of stock 
solutions: A 100 mM solution of benzoic acid in DMSO was prepared in a volumetric flask. A sample 
of this solution was diluted in DMSO-D6 to give a 10 mM solution which was then sealed inside a 
capillary tube. This external standard was then calibrated against stock solutions of 7-
hydroxycoumarin at known concentrations (26.55.4 mM prepared by accurate dilution based on 
solvent weight). 7-hydroxycoumarin was chosen as the second reference compound as it contains 
peaks in the aromatic region of the 1H NMR spectrum that do not overlap with the peaks from benzoic 
acid. Briefly, the coumarin sample and the capillary containing the external standard were placed in a 
medium-walled NMR tube (Wilmad, Precision, 400 MHz). The 1H NMR spectra was recorded twice for 
each sample and the integration ratio of 7-hydroxycoumarin:benzoic acid was plotted against 
concentration.  
The capillary was then added to NMR tubes containing stock solutions of compounds and the exact 
concentration of these stock solutions was determined by measuring the ratio of integration 
(compound:benzoic acid standard) and converting it to concentration using the fitting on the 
appropriate graph.  
Decaging of 123 by monitoring the increase in fluorescence: Rate constants were determined under 
second order conditions. Stock solutions of 123 and 58 were prepared and the exact concentrations 
were determined by qNMR. Working solutions (200 μM in 50% H2O/DMSO) were prepared by dilution. 
40 μL these solutions were mixed together in a 96 well plate (Greiner, black, clear bottomed) in 
technical triplets to give a final reactant concentration of 100 μM. The fluorescence intensity was 
measured over 2 h at 37 °C with readings taken at 8 second intervals using a SpectraMax i3x plate 
reader (λex = 325 nm, λem = 460 nm). An adhesive film (Bio-Rad) was used to prevent solvent 
evaporation. This assay was performed 3 independent times. Data were processed and fitted to a one 
phase association using GraphPad Prism (GraphPad Software, La Jolla, CA, USA). 
Decaging of 142 by monitoring the increase in fluorescence: Rate constants were determined under 
second order conditions. Stock solutions of 142 and 90 were prepared and the exact concentrations 
were determined by qNMR. Working solutions (200 μM in 50% H2O/DMSO) were prepared by dilution. 
40 μL these solutions were mixed together in a 96 well plate (Greiner, black, clear bottomed) in 
technical triplets to give a final reactant concentration of 100 μM. The fluorescence intensity was 
measured over 5 h at 37 °C with readings taken at 8 second intervals using a SpectraMax i3x plate 
reader (λex = 325 nm, λem = 460 nm). An adhesive film (Bio-Rad) was used to prevent solvent 
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evaporation. This assay was performed 3 independent times. Data were processed and fitted to a one 
phase association using GraphPad Prism (GraphPad Software, La Jolla, CA, USA). 
Quenching effect of the reaction mixture on the coumarin fluorescence: TCO-coumarin (142) and 
tetrazine 90 were mixed to give a final concentration of 100 μM in 50% H2O/DMSO for both reagents. 
The reaction was incubated at 37 °C for 6 h. At various timepoints (0.5, 1, 2, 4, 6 h) an aliquot was 
taken and added to a solution of 7-hydroxycoumarin (122) to give a final concentration of 50 μM in 
50% H2O/DMSO for 7-hydroxycoumarin (122), TCO-coumarin (142) and tetrazine 90. The fluorescent 
intensity was measured and compared to that of a sample containing only coumarin 122 (50 μM, 50% 
H2O/DMSO). Readings were taken using a SpectraMax i3x plate reader (λex = 325 nm, λem = 460 nm) 
and the assay was performed 3 independent times. Data were processed using GraphPad Prism 
(GraphPad Software, La Jolla, CA, USA). 
Yield of reaction of TCO-coumarin (142) with tetrazines 15, 58, 89, 91 by HPLC: TCO-coumarin (142), 
tetrazines 15, 58, 89, 91 and the internal standard benzoic acid were mixed to give final reactant 
concentrations of 0.83 mM (142 and 15, 58, 89, 91) and 0.67 mM (benzoic acid standard) in 50% 
H2O/DMSO. The sample mixtures were incubated at 37 °C and analysed after 24 h. The HPLC/UV 
analysis was performed on a Dionex UltiMate 3000 UHPLC+ system (Thermo Scientific) with a 
Phenomenex Kinetex C18 Column (100 Å 5 μm, 50 mm x 4.6 mm). The mobile phase consisted of A: 
H2O with 0.1% formic acid, and B: MeCN with 0.1% formic acid. The samples were eluted with a linear 
gradient (110 min 050% B, and 1014 min 50100% B, 0.50 mL/min) and detected at 220 nm. 
Yield of reaction of TCO-coumarin (142) with tetrazine 90 by HPLC: TCO-coumarin (142), tetrazine 90 
and the internal standard benzoic acid were mixed to give final reactant concentrations of 0.83 mM 
(142 and 90) and 0.67 mM (benzoic acid standard) in the appropriate solvent system. The conditions 
pH 9, 7.4, 6, 5.6, 4 refer to 50% DMSO/corresponding buffer (NaPi pH 9, PBS pH 7.4, NaPi pH 6, acetate 
pH 5.6, acetate pH 4). A minimum of 50% DMSO was required for solubility of the reactants. The 
sample mixtures were incubated at 37 °C and analysed after 24 h. The HPLC/UV analysis was 
performed on a Dionex UltiMate 3000 UHPLC+ system (Thermo Scientific) with a Phenomenex Kinetex 
C18 Column (100 Å 5 μm, 50 mm x 4.6 mm). The mobile phase consisted of A: H2O with 0.1% formic 
acid, and B: MeCN with 0.1% formic acid. The samples were eluted with a linear gradient (15 min 
050% B and 58 min 50100% B, 0.80 mL/min) and detected at 220 nm. 
Yield of reaction of TCO-coumarin (142) with tetrazine 155 by HPLC: TCO-coumarin (142), tetrazine 
155 and the internal standard benzoic acid were mixed to give final reactant concentrations of            
0.83 mM (142 and 155) and 0.67 mM (benzoic acid standard) in 50% H2O/DMSO. The sample mixtures 
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were incubated at 37 °C and analysed after 24 h. The HPLC/UV analysis was performed on a Dionex 
UltiMate 3000 UHPLC+ system (Thermo Scientific) with a Phenomenex Kinetex C18 Column (100 Å        
5 μm, 50 mm x 4.6 mm). The mobile phase consisted of A: H2O with 0.1% formic acid, and B: MeCN 
with 0.1% formic acid. The samples were eluted with a linear gradient (15 min 0100% B,                     
0.80 mL/min) and detected at 220 nm. 
Following reaction of TCO-coumarin (142) with tetrazine 90 by HPLC/FLD: TCO-coumarin (142) in 
DMSO (23 μL, 11.4 mM), tetrazine 90 in DMSO (23 μL, 11.4 mM) and the internal standard benzoic 
acid in MeCN (80 μL, 2 mM) were mixed to give final reactant concentrations of 0.83 mM (142 and 90) 
and 0.67 mM (benzoic acid standard). The reaction mixture was incubated at 37 °C and an aliquot was 
taken for analysis at 5 min, 1, 2, 3, 4 and 24 h. The HPLC/UV-FLD analysis was performed on a Dionex 
UltiMate 3000 UHPLC+ system (Thermo Scientific) coupled to a Dionex UltiMate 3000 fluorescence 
detector with a Phenomenex Kinetex C18 Column (100 Å 5 μm, 50 mm x 4.6 mm). The mobile phase 
consisted of A: H2O with 0.1% formic acid, and B: MeCN with 0.1% formic acid. The samples were 
eluted with a linear gradient (15 min 050% B and 58 min 50100% B, 0.80 mL/min) and detected 
at λex = 325 nm, λem = 460 nm. 
Second order rate constant of reaction of TCO-coumarin (142) with tetrazine 90: The second order 
rate constant was determined under second order conditions using stopped-flow spectrometry. Stock 
solutions of 142 and 90 were prepared and the exact concentrations were determined by qNMR. 
Working solutions (1 mM in DMSO) were prepared by dilution. The rate was calculated in 100% DMSO 
due to the poor solubility of 142 at this concentration. Both reactant solutions were injected 
simultaneously in a 1:1 ratio into the reaction vessel to give a final concentration of 0.5 mM. The 
decrease in absorbance at 530 nm was monitored for 6 minutes at 25 °C. A calibration curve was 
prepared for concentrations of tetrazine 90 of 0.151 mM and the absorbance values were converted 
into concentrations. The curve of concentration vs time was fitted to a two phase exponential decay 
using GraphPad Prism (GraphPad Software, La Jolla, CA, USA). This experiment was performed 3 
independent times.  
Decaging yield of TCO-triclosan (153) by HPLC: TCO-triclosan (153), tetrazine 90 and the internal 
standard benzoic acid were mixed to give final reactant concentrations of 0.83 mM (153 and 90) and 
0.67 mM (benzoic acid standard) in 20% DMSO/MeCN. The reaction mixture was incubated at 37 °C 
and an aliquot was taken for analysis at 0.5, 1, 2, 4 and 24 h. The HPLC/UV analysis was performed on 
a Dionex UltiMate 3000 UHPLC+ system (Thermo Scientific) with a Phenomenex Kinetex C18 Column 
(100 Å 5 μm, 50 mm x 4.6 mm). The mobile phase consisted of A: H2O with 0.1% formic acid, and B: 
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MeCN with 0.1% formic acid. The samples were eluted with a linear gradient (126 min 050% B, 
2629 min 5070% B and 2932 min 70100% B, 0.80 mL/min) and detected at 220 nm. 
Decaging of 153 by LC-MS: TCO-triclosan (153) and tetrazine 90 were mixed to give final reactant 
concentrations of 0.83 mM in 20% DMSO/MeCN. The reaction mixture was incubated at 37 °C and 
analysed after 24 h. The LC-MS analysis was performed on a Waters SQ Detector 2 with a Waters 
Acquity UPLC H-Class system and a Waters Acquity UPLC BEH C18 column (1.7µm, 2.1 x 50 mm). The 
mobile phase consisted of A: H2O with 0.1% formic acid, and B: MeCN with 0.1% formic acid. The 
samples were eluted with a linear gradient (020 min 0100% B, 0.20 mL/min).  
 
4.3.4 Live cell studies 
Cell Culture: E. Coli BL21(DE3) cells (ThermoFisher Scientific, USA) were cultured in Luria Bertani (LB) 
broth (MP Biomedicals). Overnight cultures were prepared by inoculating 20 mL of LB broth and 
incubating at 37 °C, shaken at 180 rpm.  
Cytotoxicity in E. Coli BL21(DE3) cells: Cytotoxicity of triclosan (149), TCO-triclosan (153), tetrazine 90, 
TCO-triclosan (153) + 90 was assessed using a CellTiter-Blue Cell Viability Assay (ThermoFisher 
Scientific, USA). Overnight cultures were diluted and added to flat-bottom 96-well plates to give a 
density of 0.002 OD600 units (200 μL). Compounds (dissolved in DMSO) were added to wells in 6 
replicates to give final concentrations of 0.05 μM, 0.1 μM, 0.2 μM, 0.4 μM, 0.6 μM, 1.0 μM for 149 
and 153 and 0.5 μM, 1 μM, 2 μM, 4 μM, 6 μM, 10 μM for tetrazine 90. Final concentration of DMSO 
in each well was ≤ 1%. The plates were incubated at 37 °C for 12 h. 100 μL from each well was 
transferred to a new plate, for use in the cell density assay. Cell viability was assessed by the addition 
of 20 μL CellTiter-Blue Reagent to the remaining 100 μL in the initial plate. After incubation for a 
further 2 h without shaking, the fluorescence was measured on a SpectraMax i3x plate reader (λex = 
570 nm, λem = 590 nm). Statistical analysis was performed on GraphPad Prism using a one-way ANOVA. 
Cell density assay in E. Coli BL21(DE3) cells: Cytotoxicity of triclosan (149), TCO-triclosan (153), 
tetrazine 90, TCO-triclosan (153) + 90 was assessed by measuring the OD600. Overnight cultures were 
diluted and added to flat-bottom 96-well plates to give a density of 0.002 OD600 units (200 μL). 
Compounds (dissolved in DMSO) were added to wells in 6 replicates to give a final concentration of    
1 μM for 149 and 153 and 10 μM for tetrazine 90. Final concentration of DMSO in each well was ≤ 1%. 
The plates were incubated at 37 °C for 12 h. 100 μL from each well was transferred to a new plate and 
the absorbance was measured on a SpectraMax i3x plate reader (λ. = 600 nm). Statistical analysis was 
performed on GraphPad Prism using a one-way ANOVA. 
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Appendix (NMR spectra) 
1H NMR (400 MHz, CDCl3) of 3-Methyl-6-(pyrimidin-2’-yl)-1,2,4,5-tetrazine (58) 
 
13C NMR (101 MHz, CDCl3) of 3-Methyl-6-(pyrimidin-2’-yl)-1,2,4,5-tetrazine (58) 
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1H NMR (400 MHz, CDCl3) of 3-phenylpropionic acid (86) 
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Appendix (NMR spectra)   
1H NMR (400 MHz, CDCl3) of Ethenyl 3-phenylpropanoate (87) 
 
 
13C NMR (101 MHz, CDCl3) of Ethenyl 3-phenylpropanoate (87)  
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Appendix (NMR spectra)   
1H NMR (400 MHz, CDCl3) of 3,6-Bis(pyridin-2’-yl)pyridazine (88)  
 
 
 
 
13C NMR (101 MHz, CDCl3) of 3,6-Bis(pyridin-2’-yl)pyridazine (88) 
 
  
161 
Appendix (NMR spectra)   
1H NMR (400 MHz, CDCl3) of 3-Methyl-6-(pyridin-2’-yl)-1,2,4,5-tetrazine (89) 
 
13C NMR (101 MHz, CDCl3) of 3-Methyl-6-(pyridin-2’-yl)-1,2,4,5-tetrazine (89) 
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Appendix (NMR spectra)   
1H NMR (400 MHz, CDCl3) of Ethenyl 2-oxochromene-3-carboxylate (96)  
 
 
13C NMR (101 MHz, CDCl3) of Ethenyl 2-oxochromene-3-carboxylate (96)  
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1H NMR (400 MHz, DMSO-D6) of Ethyl 7-hydroxy-2-oxochromene-3-carboxylate (99)  
 
 
13C NMR (101 MHz, DMSO-D6) of Ethyl 7-hydroxy-2-oxochromene-3-carboxylate (99) 
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1H NMR (400 MHz, DMSO-D6) of 7-Hydroxy-2-oxochromene-3-carboxylic acid (100)  
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1H NMR (400 MHz, DMSO-D6) of Ethenyl 7-(ethenyloxy)-2-oxochromene-3-carboxylate (101)  
 
 
13C NMR (101 MHz, DMSO-D6) of Ethenyl 7-(ethenyloxy)-2-oxochromene-3-carboxylate (101)  
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1H NMR (500 MHz, Methanol-d4) of Ethenyl 7-hydroxy-2-oxochromene-3-carboxylate (102)  
 
13C NMR (126 MHz, Methanol-d4) of Ethenyl 7-hydroxy-2-oxochromene-3-carboxylate (102)  
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1H NMR (400 MHz, CDCl3) of vinyl 2-(3-benzoylphenyl)propanoate (106) 
 
13C NMR (101 MHz, CDCl3) of vinyl 2-(3-benzoylphenyl)propanoate (106) 
  
168 
Appendix (NMR spectra)   
1H NMR (400 MHz, CDCl3) of (2Z)-Cyclooct-2-en-1-ol (111) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR (101 MHz, CDCl3) of (2Z)-Cyclooct-2-en-1-ol (111) 
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1H NMR (500 MHz, CDCl3) of (Z)-Cyclooct-2-en-1-yl 2-(3-benzoylphenyl)propanoate (113) 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR (126 MHz, CDCl3) of (Z)-Cyclooct-2-en-1-yl 2-(3-benzoylphenyl)propanoate (113) 
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1H NMR (500 MHz, CDCl3) of (E)-Cyclooct-2-en-1-yl 2-(3-benzoylphenyl)propanoate (114) 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR (126 MHz, CDCl3) of (E)-Cyclooct-2-en-1-yl 2-(3-benzoylphenyl)propanoate (114) 
  
Axial isomer 
Axial isomer 
171 
Appendix (NMR spectra)   
1H NMR (500 MHz, CDCl3) of (E)-Cyclooct-2-en-1-yl 2-(3-benzoylphenyl)propanoate (114) 
 
13C NMR (126 MHz, CDCl3) of (E)-Cyclooct-2-en-1-yl 2-(3-benzoylphenyl)propanoate (114) 
 
  
Equatorial isomer 
Equatorial isomer 
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1H NMR (400 MHz, CDCl3) of (2E)-Cyclooct-2’-en-1’-yl 4-nitrophenyl carbonate (121) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR (101 MHz, CDCl3) of (2E)-Cyclooct-2’-en-1’-yl 4-nitrophenyl carbonate (121) 
 
  
173 
Appendix (NMR spectra)   
1H NMR (400 MHz, CDCl3) of (2E)-Cyclooct-2’-en-1’-yl 2-oxochromen-7-yl carbonate (123) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR (101 MHz, CDCl3) of (2E)-Cyclooct-2’-en-1’-yl 2-oxochromen-7-yl carbonate (123) 
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1H NMR (500 MHz, CDCl3) of 4-[(2’Z)-cyclooct-2’-en-1’-yloxy]benzaldehyde (127) 
 
  
13C NMR (126 MHz, CDCl3) of 4-[(2’Z)-cyclooct-2’-en-1’-yloxy]benzaldehyde (127) 
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1H NMR (500 MHz, Methanol-d4) of {4-[(2Z)-cyclooct-2-en-1-yloxy]phenyl}methanol (129) 
 
  
13C NMR (126 MHz, Methanol-d4) of {4-[(2Z)-cyclooct-2-en-1-yloxy]phenyl}methanol (129) 
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1H NMR (400 MHz, CDCl3) of (1’Z)-3’-[4-(chloromethyl)phenoxy]cyclooct-1’-ene (130) 
 
 
 
1H NMR (400MHz, CDCl3) of 7-({4’’-[(2’Z)-cyclooct-2’-en-1’-yloxy]phenyl}methoxy)chromen-2-one (131) 
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Appendix (NMR spectra)   
1H NMR (400 MHz, CDCl3) of 4-{[(tert-butyldimethylsilyl)oxy]methyl}aniline (137) 
 
1H NMR (400 MHz, CDCl3) of tert-butyl[(4-isocyanatophenyl)methoxy]dimethylsilane (138) 
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Appendix (NMR spectra)   
1H NMR (500 MHz, CDCl3) of (2E)-cyclooct-2-en-1-yl N-(4-{[(tert-butyldimethylsilyl)oxy]methyl}phenyl)carbamate (139) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR (126 MHz, CDCl3) of (2E)-cyclooct-2-en-1-yl N-(4-{[(tert-butyldimethylsilyl)oxy]methyl}phenyl)carbamate (139)  
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Crude 1H NMR (400 MHz, CDCl3) of (2’E)-cyclooct-2’-en-1’-yl N-[4-(hydroxymethyl)phenyl]carbamate (140) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR (400 MHz, CDCl3) of (2’E)-cyclooct-2’-en-1’-yl N-[4-(bromomethyl)phenyl]carbamate (141) 
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Appendix (NMR spectra)   
Crude 1H NMR (400 MHz, CDCl3) of (2’’E)-cyclooct-2’’-en-1’’-yl N-(4-{[(2’-oxochromen-7’-yl)oxy]methyl}phenyl)carbamate (142) 
from route 1 
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Appendix (NMR spectra)   
1H NMR (500 MHz, CDCl3) of (2’’E)-cyclooct-2’’-en-1’’-yl N-(4-{[(2’-oxochromen-7’-yl)oxy]methyl}phenyl)carbamate (142) from 
route 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR (126 MHz, CDCl3) of (2’’E)-cyclooct-2’’-en-1’’-yl N-(4-{[(2’-oxochromen-7’-yl)oxy]methyl}phenyl)carbamate (142) from 
route 2 
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1H NMR (400 MHz, CDCl3) of tert-butyl N-[4-(hydroxymethyl)phenyl]carbamate (143) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR (400 MHz, CDCl3) of tert-butyl N-[4-(bromomethyl)phenyl]carbamate (144) 
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1H NMR (500 MHz, CDCl3) of tert-butyl N-(4-{[(2’-oxochromen-7’-yl)oxy]methyl}phenyl)carbamate (145) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR (126 MHz, CDCl3) of tert-butyl N-(4-{[(2’-oxochromen-7’-yl)oxy]methyl}phenyl)carbamate (145) 
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1H NMR (400 MHz, CDCl3) of tert-butyl N-{4’’-[5-chloro-2-(2’,4’-dichlorophenoxy)phenoxymethyl]phenyl}carbamate (150) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR (101 MHz, CDCl3) of tert-butyl N-{4’’-[5-chloro-2-(2’,4’-dichlorophenoxy)phenoxymethyl]phenyl}carbamate (150)  
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1H NMR (400 MHz, CDCl3) of  
(2’’’E)-cyclooct-2’’’-en-1-yl N-{4’’-[5-chloro-2-(2’,4’-dichlorophenoxy)phenoxymethyl]phenyl}carbamate (153) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C NMR (101 MHz, CDCl3) of 
(2’’’E)-cyclooct-2’’’-en-1-yl N-{4’’-[5-chloro-2-(2’,4’-dichlorophenoxy)phenoxymethyl]phenyl}carbamate (153) 
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1H NMR (400 MHz, CDCl3) of tert-butyl N-{4-[({19-ethyl-14,18-dioxo-17-oxa-3,13-diazapentacyclo [11.8.0.0²,¹¹.0⁴,⁹.0¹⁵,²⁰] henicosa-
1(21),2,4(9),5,7,10,15(20)-heptaen-19-yl} oxy)methyl]phenyl}carbamate (154) 
 
 
 
